Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16840188,overall response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,85,284,DB00025,Antihemophilic Factor
,16840188,complete response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,38,285,DB00025,Antihemophilic Factor
≥,33086400,trough concentrations,Emicizumab trough concentrations ≥ 50 µg/mL were maintained throughout the study.,Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33086400/),[μg] / [ml],50,1988,DB00025,Antihemophilic Factor
,11372672,clearance,"The increase in clearance and the decrease in THL were significantly more pronounced in the group of MGUS patients (57.93 +/- 25.6 ml/h/kg, and 1.39 +/- 0.5 h, respectively) as compared to these parameters in the AMM (8.06 ml/h/kg, and 6.96 h, respectively) or the lymphoma (4.76 ml/h/kg, and 6.76 h. respectively) patients (p = 0.03 for clearance and 0.001 for THL).",Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372672/),[ml] / [h·kg],57.93,3438,DB00025,Antihemophilic Factor
,11372672,clearance,"The increase in clearance and the decrease in THL were significantly more pronounced in the group of MGUS patients (57.93 +/- 25.6 ml/h/kg, and 1.39 +/- 0.5 h, respectively) as compared to these parameters in the AMM (8.06 ml/h/kg, and 6.96 h, respectively) or the lymphoma (4.76 ml/h/kg, and 6.76 h. respectively) patients (p = 0.03 for clearance and 0.001 for THL).",Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372672/),h,1.39,3439,DB00025,Antihemophilic Factor
,11372672,clearance,"The increase in clearance and the decrease in THL were significantly more pronounced in the group of MGUS patients (57.93 +/- 25.6 ml/h/kg, and 1.39 +/- 0.5 h, respectively) as compared to these parameters in the AMM (8.06 ml/h/kg, and 6.96 h, respectively) or the lymphoma (4.76 ml/h/kg, and 6.76 h. respectively) patients (p = 0.03 for clearance and 0.001 for THL).",Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372672/),[ml] / [h·kg],8.06,3440,DB00025,Antihemophilic Factor
,11372672,clearance,"The increase in clearance and the decrease in THL were significantly more pronounced in the group of MGUS patients (57.93 +/- 25.6 ml/h/kg, and 1.39 +/- 0.5 h, respectively) as compared to these parameters in the AMM (8.06 ml/h/kg, and 6.96 h, respectively) or the lymphoma (4.76 ml/h/kg, and 6.76 h. respectively) patients (p = 0.03 for clearance and 0.001 for THL).",Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372672/),h,6.96,3441,DB00025,Antihemophilic Factor
,11372672,clearance,"The increase in clearance and the decrease in THL were significantly more pronounced in the group of MGUS patients (57.93 +/- 25.6 ml/h/kg, and 1.39 +/- 0.5 h, respectively) as compared to these parameters in the AMM (8.06 ml/h/kg, and 6.96 h, respectively) or the lymphoma (4.76 ml/h/kg, and 6.76 h. respectively) patients (p = 0.03 for clearance and 0.001 for THL).",Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372672/),[ml] / [h·kg],4.76,3442,DB00025,Antihemophilic Factor
,11372672,clearance,"The increase in clearance and the decrease in THL were significantly more pronounced in the group of MGUS patients (57.93 +/- 25.6 ml/h/kg, and 1.39 +/- 0.5 h, respectively) as compared to these parameters in the AMM (8.06 ml/h/kg, and 6.96 h, respectively) or the lymphoma (4.76 ml/h/kg, and 6.76 h. respectively) patients (p = 0.03 for clearance and 0.001 for THL).",Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372672/),h,6.76,3443,DB00025,Antihemophilic Factor
,11449335,elimination half-life,The mean elimination half-life was 10.5 +/- 2.6 hours at baseline and 10.4 +/- 3.3 hours at month 12.,Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11449335/),h,10.5,4284,DB00025,Antihemophilic Factor
,11449335,elimination half-life,The mean elimination half-life was 10.5 +/- 2.6 hours at baseline and 10.4 +/- 3.3 hours at month 12.,Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11449335/),h,10.4,4285,DB00025,Antihemophilic Factor
,28005225,AUClast,"Using both assays, geometric mean (coefficient of variation [%CV]) AUClast was significantly higher, and t ½ was significantly longer, for BAY 81-8973 versus rAHF-PFM (one-stage, AUClast: 1660 IU·h/dL [29.4] vs. 1310 IU·h/dL [29.0], p < 0.0001; one-stage, t ½: 14.5 [25.7] vs. 11.7 h [27.3], p < 0.0001).",Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28005225/),[h·iu] / [dl],1660,4868,DB00025,Antihemophilic Factor
,28005225,AUClast,"Using both assays, geometric mean (coefficient of variation [%CV]) AUClast was significantly higher, and t ½ was significantly longer, for BAY 81-8973 versus rAHF-PFM (one-stage, AUClast: 1660 IU·h/dL [29.4] vs. 1310 IU·h/dL [29.0], p < 0.0001; one-stage, t ½: 14.5 [25.7] vs. 11.7 h [27.3], p < 0.0001).",Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28005225/),[h·iu] / [dl],1310,4869,DB00025,Antihemophilic Factor
,28005225,t ½,"Using both assays, geometric mean (coefficient of variation [%CV]) AUClast was significantly higher, and t ½ was significantly longer, for BAY 81-8973 versus rAHF-PFM (one-stage, AUClast: 1660 IU·h/dL [29.4] vs. 1310 IU·h/dL [29.0], p < 0.0001; one-stage, t ½: 14.5 [25.7] vs. 11.7 h [27.3], p < 0.0001).",Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28005225/),h,14.5,4870,DB00025,Antihemophilic Factor
,28005225,t ½,"Using both assays, geometric mean (coefficient of variation [%CV]) AUClast was significantly higher, and t ½ was significantly longer, for BAY 81-8973 versus rAHF-PFM (one-stage, AUClast: 1660 IU·h/dL [29.4] vs. 1310 IU·h/dL [29.0], p < 0.0001; one-stage, t ½: 14.5 [25.7] vs. 11.7 h [27.3], p < 0.0001).",Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28005225/),h,11.7,4871,DB00025,Antihemophilic Factor
,3379594,bioavailability,"The bioavailability of desmopressin from the 2 x 50-microL dose was 20%, which was significantly greater than the 11% after the 1 x 50-microL (p less than 0.01) and 9% after the 1 x 100-microL (p less than 0.001) doses.",Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379594/),%,20,6006,DB00025,Antihemophilic Factor
,3379594,bioavailability,"The bioavailability of desmopressin from the 2 x 50-microL dose was 20%, which was significantly greater than the 11% after the 1 x 50-microL (p less than 0.01) and 9% after the 1 x 100-microL (p less than 0.001) doses.",Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379594/),%,11,6007,DB00025,Antihemophilic Factor
,3379594,bioavailability,"The bioavailability of desmopressin from the 2 x 50-microL dose was 20%, which was significantly greater than the 11% after the 1 x 50-microL (p less than 0.01) and 9% after the 1 x 100-microL (p less than 0.001) doses.",Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379594/),%,9,6008,DB00025,Antihemophilic Factor
,21725579,average,"The reported VWF:RCo average and terminal t1/2 of 10.4 and 15.8 hours (h), respectively, for Wilate and 9.3 h and 12.8 h for Humate-P, were not statistically different.","The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21725579/),(h)·h,10.4,8958,DB00025,Antihemophilic Factor
,21725579,average,"The reported VWF:RCo average and terminal t1/2 of 10.4 and 15.8 hours (h), respectively, for Wilate and 9.3 h and 12.8 h for Humate-P, were not statistically different.","The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21725579/),h,9.3,8959,DB00025,Antihemophilic Factor
,21725579,terminal t1/2,"The reported VWF:RCo average and terminal t1/2 of 10.4 and 15.8 hours (h), respectively, for Wilate and 9.3 h and 12.8 h for Humate-P, were not statistically different.","The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21725579/),(h)·h,15.8,8960,DB00025,Antihemophilic Factor
,21725579,terminal t1/2,"The reported VWF:RCo average and terminal t1/2 of 10.4 and 15.8 hours (h), respectively, for Wilate and 9.3 h and 12.8 h for Humate-P, were not statistically different.","The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21725579/),h,9.3,8961,DB00025,Antihemophilic Factor
,21725579,terminal t1/2,"The reported VWF:RCo average and terminal t1/2 of 10.4 and 15.8 hours (h), respectively, for Wilate and 9.3 h and 12.8 h for Humate-P, were not statistically different.","The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21725579/),h,12.8,8962,DB00025,Antihemophilic Factor
,27390359,clearance,"Typical values for clearance, intercompartment clearance, central and peripheral volume were 0.15 L/h/68 kg, 0.16 L/h/68 kg, 2.81 L/68 kg and 1.90 L/68 kg.",A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390359/),[l] / [68·h·kg],0.15,9362,DB00025,Antihemophilic Factor
,27390359,intercompartment clearance,"Typical values for clearance, intercompartment clearance, central and peripheral volume were 0.15 L/h/68 kg, 0.16 L/h/68 kg, 2.81 L/68 kg and 1.90 L/68 kg.",A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390359/),[l] / [68·h·kg],0.16,9363,DB00025,Antihemophilic Factor
,27390359,intercompartment clearance,"Typical values for clearance, intercompartment clearance, central and peripheral volume were 0.15 L/h/68 kg, 0.16 L/h/68 kg, 2.81 L/68 kg and 1.90 L/68 kg.",A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390359/),[l] / [68·kg],2.81,9364,DB00025,Antihemophilic Factor
,27390359,central,"Typical values for clearance, intercompartment clearance, central and peripheral volume were 0.15 L/h/68 kg, 0.16 L/h/68 kg, 2.81 L/68 kg and 1.90 L/68 kg.",A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390359/),[l] / [68·h·kg],0.16,9365,DB00025,Antihemophilic Factor
,27390359,central,"Typical values for clearance, intercompartment clearance, central and peripheral volume were 0.15 L/h/68 kg, 0.16 L/h/68 kg, 2.81 L/68 kg and 1.90 L/68 kg.",A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390359/),[l] / [68·kg],2.81,9366,DB00025,Antihemophilic Factor
,27390359,peripheral volume,"Typical values for clearance, intercompartment clearance, central and peripheral volume were 0.15 L/h/68 kg, 0.16 L/h/68 kg, 2.81 L/68 kg and 1.90 L/68 kg.",A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390359/),[l] / [68·kg],1.90,9367,DB00025,Antihemophilic Factor
<,15569163,trough level,Some patients did not bleed in spite of a trough level of <1% and others did in spite of trough levels >3%.,"A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15569163/),,1,10167,DB00025,Antihemophilic Factor
>,15569163,trough levels,Some patients did not bleed in spite of a trough level of <1% and others did in spite of trough levels >3%.,"A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15569163/),,3,10168,DB00025,Antihemophilic Factor
,31366602,mean residence time,The significantly improved PK profile versus rFVIII was confirmed in cynomolgus monkeys [mean residence time: 23.4 vs.,Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31366602/),,23.4,11488,DB00025,Antihemophilic Factor
,31366602,area under the curve from time 0 to infinity),10.1 hours; exposure (area under the curve from time 0 to infinity): 206 vs. 48.2 IU/ml⋅h] and is in line with results from rodent studies.,Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31366602/),[iu] / [h·ml],206,11489,DB00025,Antihemophilic Factor
,31366602,area under the curve from time 0 to infinity),10.1 hours; exposure (area under the curve from time 0 to infinity): 206 vs. 48.2 IU/ml⋅h] and is in line with results from rodent studies.,Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31366602/),[iu] / [h·ml],48.2,11490,DB00025,Antihemophilic Factor
,33884664,CL,"Population PK modelling provided estimates for CL, V1, V2, and Q: 171 mL h-1 68 kg-1 , 2930 mL 68 kg-1 , 1810 mL 68 kg-1 , and 172 mL h-1 68 kg-1 , respectively.",Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33884664/),[68·ml] / [h·kg],171,11651,DB00025,Antihemophilic Factor
,33884664,V1,"Population PK modelling provided estimates for CL, V1, V2, and Q: 171 mL h-1 68 kg-1 , 2930 mL 68 kg-1 , 1810 mL 68 kg-1 , and 172 mL h-1 68 kg-1 , respectively.",Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33884664/),[68·ml] / [kg],2930,11652,DB00025,Antihemophilic Factor
,33884664,V1,"Population PK modelling provided estimates for CL, V1, V2, and Q: 171 mL h-1 68 kg-1 , 2930 mL 68 kg-1 , 1810 mL 68 kg-1 , and 172 mL h-1 68 kg-1 , respectively.",Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33884664/),[68·ml] / [kg],1810,11653,DB00025,Antihemophilic Factor
,33884664,V2,"Population PK modelling provided estimates for CL, V1, V2, and Q: 171 mL h-1 68 kg-1 , 2930 mL 68 kg-1 , 1810 mL 68 kg-1 , and 172 mL h-1 68 kg-1 , respectively.",Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33884664/),[68·ml] / [kg],1810,11654,DB00025,Antihemophilic Factor
,33884664,Q,"Population PK modelling provided estimates for CL, V1, V2, and Q: 171 mL h-1 68 kg-1 , 2930 mL 68 kg-1 , 1810 mL 68 kg-1 , and 172 mL h-1 68 kg-1 , respectively.",Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33884664/),[68·ml] / [h·kg],172,11655,DB00025,Antihemophilic Factor
,31236667,AUClast,"In the analysis set excluding one outlier, geometric mean (coefficient of variation [%CV, 95% confidence interval {CI}]) AUClast was significantly higher for BAY 94-9027 versus rFVIIIFc (2940 [37.8, 2440-3550] IU h/dL versus 2360 [31.8, 2010-2770] IU h/dL, p = 0.0001).","Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236667/),[h·iu] / [dl],2940,15151,DB00025,Antihemophilic Factor
,31236667,AUClast,"In the analysis set excluding one outlier, geometric mean (coefficient of variation [%CV, 95% confidence interval {CI}]) AUClast was significantly higher for BAY 94-9027 versus rFVIIIFc (2940 [37.8, 2440-3550] IU h/dL versus 2360 [31.8, 2010-2770] IU h/dL, p = 0.0001).","Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236667/),[h·iu] / [dl],2360,15152,DB00025,Antihemophilic Factor
,31236667,time to 1 I,A population PK model was developed to simulate time to reach FVIII threshold levels; median time to 1 IU/dL was approximately 13 h longer for BAY 94-9027 versus rFVIIIFc after a single infusion of 60 IU/kg.,"Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236667/),h,13,15153,DB00025,Antihemophilic Factor
,25643824,trough levels,These FVIII levels were chosen based on the observation that trough levels of 1 IU dL(-1) may not be sufficient in all patients.,Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25643824/),[iu] / [dl],1,15612,DB00025,Antihemophilic Factor
,8646294,peak level,Both products achieved a peak level close to that predicted (100 IU/dl for Liberate and 103 IU/dl for Z8) and there were no significant differences in the recoveries achieved nor of any of the other pharmacokinetic parameters.,A pharmacokinetic study of an ion-exchange solvent-detergent-treated high-purity factor VIII concentrate. Haemophilia Directors for Scotland and Northern Ireland. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646294/),[iu] / [dl],100,16399,DB00025,Antihemophilic Factor
,8646294,peak level,Both products achieved a peak level close to that predicted (100 IU/dl for Liberate and 103 IU/dl for Z8) and there were no significant differences in the recoveries achieved nor of any of the other pharmacokinetic parameters.,A pharmacokinetic study of an ion-exchange solvent-detergent-treated high-purity factor VIII concentrate. Haemophilia Directors for Scotland and Northern Ireland. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646294/),[iu] / [dl],103,16400,DB00025,Antihemophilic Factor
,10028316,half-life,"In a pharmacokinetic study with Humate-P including six patients with various types of von Willebrand disease, a median half-life of 11.3 h for vWF:RCoF and of 15.2 h for vWF:Ag was found.","Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028316/),h,11.3,18391,DB00025,Antihemophilic Factor
,10028316,half-life,"In a pharmacokinetic study with Humate-P including six patients with various types of von Willebrand disease, a median half-life of 11.3 h for vWF:RCoF and of 15.2 h for vWF:Ag was found.","Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028316/),h,15.2,18392,DB00025,Antihemophilic Factor
,10028316,in vivo recovery (IVR),"The median value of in vivo recovery (IVR) was estimated for vWF:RCoF as 2.10 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 73%), for vWF:Ag as 1.88 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 69%); and for FVIII:C as 2.69 IU dL-1 plasma per 1 IU kg-1 b.w. (or 99%).","Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028316/),[iu·plasma] / [1·dl],2.10,18393,DB00025,Antihemophilic Factor
,10028316,in vivo recovery (IVR),"The median value of in vivo recovery (IVR) was estimated for vWF:RCoF as 2.10 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 73%), for vWF:Ag as 1.88 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 69%); and for FVIII:C as 2.69 IU dL-1 plasma per 1 IU kg-1 b.w. (or 99%).","Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028316/),%,73,18394,DB00025,Antihemophilic Factor
,10028316,in vivo recovery (IVR),"The median value of in vivo recovery (IVR) was estimated for vWF:RCoF as 2.10 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 73%), for vWF:Ag as 1.88 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 69%); and for FVIII:C as 2.69 IU dL-1 plasma per 1 IU kg-1 b.w. (or 99%).","Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028316/),[iu·plasma] / [1·dl],1.88,18395,DB00025,Antihemophilic Factor
,10028316,in vivo recovery (IVR),"The median value of in vivo recovery (IVR) was estimated for vWF:RCoF as 2.10 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 73%), for vWF:Ag as 1.88 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 69%); and for FVIII:C as 2.69 IU dL-1 plasma per 1 IU kg-1 b.w. (or 99%).","Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028316/),%,69,18396,DB00025,Antihemophilic Factor
,10028316,in vivo recovery (IVR),"The median value of in vivo recovery (IVR) was estimated for vWF:RCoF as 2.10 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 73%), for vWF:Ag as 1.88 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 69%); and for FVIII:C as 2.69 IU dL-1 plasma per 1 IU kg-1 b.w. (or 99%).","Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028316/),[-1·iu·plasma] / [dl],2.69,18397,DB00025,Antihemophilic Factor
,10028316,in vivo recovery (IVR),"The median value of in vivo recovery (IVR) was estimated for vWF:RCoF as 2.10 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 73%), for vWF:Ag as 1.88 IU dL-1 plasma per 1 substituted IU kg-1 b.w. (or 69%); and for FVIII:C as 2.69 IU dL-1 plasma per 1 IU kg-1 b.w. (or 99%).","Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028316/),%,99,18398,DB00025,Antihemophilic Factor
,29194866,t1/2,The mean t1/2 of FVIII was 10.20 ± 2.72 hours and the mean time of FVIII <1 IU/dL in 1 week was 44.7 hours (-38.56 to 102.33 hours).,Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194866/),h,10.20,19959,DB00025,Antihemophilic Factor
,29194866,time,The mean t1/2 of FVIII was 10.20 ± 2.72 hours and the mean time of FVIII <1 IU/dL in 1 week was 44.7 hours (-38.56 to 102.33 hours).,Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194866/),h,44.7,19960,DB00025,Antihemophilic Factor
,21682818,t(½),"N8 and Advate® exhibited similar PK parameters, with t(½) 7.7-11 h and MRT 11-14 h.",Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21682818/),h,7.7-11,20711,DB00025,Antihemophilic Factor
,21682818,MRT,"N8 and Advate® exhibited similar PK parameters, with t(½) 7.7-11 h and MRT 11-14 h.",Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21682818/),h,11-14,20712,DB00025,Antihemophilic Factor
,26863900,trough levels,"rFVIII dosed 3x30 IU kg(-1) weekly gave trough levels of 2.7, 2.8 and 0.7 IU dL(-1) , and time spent below 1, 3 and 5 IU dL(-1) of 0.2/1.2/2.3 days week(-1) .","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],2.7,23338,DB00025,Antihemophilic Factor
,26863900,trough levels,"rFVIII dosed 3x30 IU kg(-1) weekly gave trough levels of 2.7, 2.8 and 0.7 IU dL(-1) , and time spent below 1, 3 and 5 IU dL(-1) of 0.2/1.2/2.3 days week(-1) .","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],2.8,23339,DB00025,Antihemophilic Factor
,26863900,trough levels,"rFVIII dosed 3x30 IU kg(-1) weekly gave trough levels of 2.7, 2.8 and 0.7 IU dL(-1) , and time spent below 1, 3 and 5 IU dL(-1) of 0.2/1.2/2.3 days week(-1) .","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],0.7,23340,DB00025,Antihemophilic Factor
,26863900,time spent,"rFVIII dosed 3x30 IU kg(-1) weekly gave trough levels of 2.7, 2.8 and 0.7 IU dL(-1) , and time spent below 1, 3 and 5 IU dL(-1) of 0.2/1.2/2.3 days week(-1) .","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[d] / [week],0.2,23341,DB00025,Antihemophilic Factor
,26863900,time spent,"rFVIII dosed 3x30 IU kg(-1) weekly gave trough levels of 2.7, 2.8 and 0.7 IU dL(-1) , and time spent below 1, 3 and 5 IU dL(-1) of 0.2/1.2/2.3 days week(-1) .","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[d] / [week],1.2,23342,DB00025,Antihemophilic Factor
,26863900,time spent,"rFVIII dosed 3x30 IU kg(-1) weekly gave trough levels of 2.7, 2.8 and 0.7 IU dL(-1) , and time spent below 1, 3 and 5 IU dL(-1) of 0.2/1.2/2.3 days week(-1) .","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[d] / [week],2.3,23343,DB00025,Antihemophilic Factor
,26863900,troughs,"rFVIIIFc 2 x 45 IU kg(-1) gave higher troughs (4.4 and 1.7 IU dL(-1) ) and shorter time spent below 1, 3 and 5 IU dL(-1) (0/0.6/1.3 days week(-1) ), with same total factor consumption.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],4.4,23344,DB00025,Antihemophilic Factor
,26863900,troughs,"rFVIIIFc 2 x 45 IU kg(-1) gave higher troughs (4.4 and 1.7 IU dL(-1) ) and shorter time spent below 1, 3 and 5 IU dL(-1) (0/0.6/1.3 days week(-1) ), with same total factor consumption.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],1.7,23345,DB00025,Antihemophilic Factor
,26863900,troughs,"rFVIIIFc 2 x 30 IU kg(-1) gave similar troughs (3.0 and 1.2 IU kg(-1) ) and time spent below 1, 3 and 5 IU dL(-1) (0/1.0/2.1 days week(-1) ), despite total factor consumption being reduced by one-third.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [kg],3.0,23346,DB00025,Antihemophilic Factor
,26863900,troughs,"rFVIIIFc 2 x 30 IU kg(-1) gave similar troughs (3.0 and 1.2 IU kg(-1) ) and time spent below 1, 3 and 5 IU dL(-1) (0/1.0/2.1 days week(-1) ), despite total factor consumption being reduced by one-third.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [kg],1.2,23347,DB00025,Antihemophilic Factor
below,26863900,time spent,"rFVIIIFc 2 x 30 IU kg(-1) gave similar troughs (3.0 and 1.2 IU kg(-1) ) and time spent below 1, 3 and 5 IU dL(-1) (0/1.0/2.1 days week(-1) ), despite total factor consumption being reduced by one-third.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],1,23348,DB00025,Antihemophilic Factor
below,26863900,time spent,"rFVIIIFc 2 x 30 IU kg(-1) gave similar troughs (3.0 and 1.2 IU kg(-1) ) and time spent below 1, 3 and 5 IU dL(-1) (0/1.0/2.1 days week(-1) ), despite total factor consumption being reduced by one-third.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],3,23349,DB00025,Antihemophilic Factor
below,26863900,time spent,"rFVIIIFc 2 x 30 IU kg(-1) gave similar troughs (3.0 and 1.2 IU kg(-1) ) and time spent below 1, 3 and 5 IU dL(-1) (0/1.0/2.1 days week(-1) ), despite total factor consumption being reduced by one-third.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],5,23350,DB00025,Antihemophilic Factor
,26863900,time spent,"rFVIIIFc 2 x 30 IU kg(-1) gave similar troughs (3.0 and 1.2 IU kg(-1) ) and time spent below 1, 3 and 5 IU dL(-1) (0/1.0/2.1 days week(-1) ), despite total factor consumption being reduced by one-third.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[d] / [week],0,23351,DB00025,Antihemophilic Factor
,26863900,time spent,"rFVIIIFc 2 x 30 IU kg(-1) gave similar troughs (3.0 and 1.2 IU kg(-1) ) and time spent below 1, 3 and 5 IU dL(-1) (0/1.0/2.1 days week(-1) ), despite total factor consumption being reduced by one-third.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[d] / [week],1.0,23352,DB00025,Antihemophilic Factor
,26863900,time spent,"rFVIIIFc 2 x 30 IU kg(-1) gave similar troughs (3.0 and 1.2 IU kg(-1) ) and time spent below 1, 3 and 5 IU dL(-1) (0/1.0/2.1 days week(-1) ), despite total factor consumption being reduced by one-third.","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[d] / [week],2.1,23353,DB00025,Antihemophilic Factor
,26863900,troughs,"The same dose and interval of rFVIIIFc (3 x 30 IU kg(-1) ) gave substantially higher troughs (7.8, 8.5 and 3.3 IU dL(-1) ) and markedly shorter time spent below 1, 3 and 5 IU dL(-1) (0/0/0.4 days week(-1) ).","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],7.8,23354,DB00025,Antihemophilic Factor
,26863900,troughs,"The same dose and interval of rFVIIIFc (3 x 30 IU kg(-1) ) gave substantially higher troughs (7.8, 8.5 and 3.3 IU dL(-1) ) and markedly shorter time spent below 1, 3 and 5 IU dL(-1) (0/0/0.4 days week(-1) ).","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],8.5,23355,DB00025,Antihemophilic Factor
,26863900,troughs,"The same dose and interval of rFVIIIFc (3 x 30 IU kg(-1) ) gave substantially higher troughs (7.8, 8.5 and 3.3 IU dL(-1) ) and markedly shorter time spent below 1, 3 and 5 IU dL(-1) (0/0/0.4 days week(-1) ).","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[iu] / [dl],3.3,23356,DB00025,Antihemophilic Factor
,26863900,time,"The same dose and interval of rFVIIIFc (3 x 30 IU kg(-1) ) gave substantially higher troughs (7.8, 8.5 and 3.3 IU dL(-1) ) and markedly shorter time spent below 1, 3 and 5 IU dL(-1) (0/0/0.4 days week(-1) ).","Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863900/),[d] / [week],0,23357,DB00025,Antihemophilic Factor
less,12098087,secondary,Both ReFacto and Octonativ-M7 treatment reduced secondary bleeding time to less than 6 minutes.,Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12098087/),min,6,23979,DB00025,Antihemophilic Factor
,2493694,half-life,"The intravascular survival kinetics in these six patients showed a biphasic decay curve with an initial mean half-life of 5.1 +/- 1.2 hours probably representing early redistribution, and a late half-life of 13.3 +/- 4.9 hours.",The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493694/),h,5.1,27822,DB00025,Antihemophilic Factor
,2493694,late half-life,"The intravascular survival kinetics in these six patients showed a biphasic decay curve with an initial mean half-life of 5.1 +/- 1.2 hours probably representing early redistribution, and a late half-life of 13.3 +/- 4.9 hours.",The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493694/),h,13.3,27823,DB00025,Antihemophilic Factor
,19641914,clearance (CL),"One-compartment base-model population PK parameters were [mean parameter (interpatient variability %)] for CHS: clearance (CL) = 2.56 dl h(-1) (33.2%); volume of distribution (V) = 34.8 dl (12.8%); and for OSC: CL = 3.83 dl h(-1) (47.8%), V = 53.7 dl (22.4%).",Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641914/),[dl] / [h],2.56,27826,DB00025,Antihemophilic Factor
,19641914,volume of distribution (V),"One-compartment base-model population PK parameters were [mean parameter (interpatient variability %)] for CHS: clearance (CL) = 2.56 dl h(-1) (33.2%); volume of distribution (V) = 34.8 dl (12.8%); and for OSC: CL = 3.83 dl h(-1) (47.8%), V = 53.7 dl (22.4%).",Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641914/),dl,34.8,27827,DB00025,Antihemophilic Factor
,19641914,CL,"One-compartment base-model population PK parameters were [mean parameter (interpatient variability %)] for CHS: clearance (CL) = 2.56 dl h(-1) (33.2%); volume of distribution (V) = 34.8 dl (12.8%); and for OSC: CL = 3.83 dl h(-1) (47.8%), V = 53.7 dl (22.4%).",Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641914/),[dl] / [h],3.83,27828,DB00025,Antihemophilic Factor
,19641914,V,"One-compartment base-model population PK parameters were [mean parameter (interpatient variability %)] for CHS: clearance (CL) = 2.56 dl h(-1) (33.2%); volume of distribution (V) = 34.8 dl (12.8%); and for OSC: CL = 3.83 dl h(-1) (47.8%), V = 53.7 dl (22.4%).",Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641914/),dl,53.7,27829,DB00025,Antihemophilic Factor
,19641914,half-lives (t(1/2),"Nevertheless, the empirical half-lives (t(1/2) = l n (2) x V/CL) were similar for CHS and OSC, [(mean +/- standard deviation (SD)], 9.5 +/- 3 h and 10.2 +/- 4 h, respectively.",Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641914/),h,9.5,27830,DB00025,Antihemophilic Factor
,19641914,half-lives (t(1/2),"Nevertheless, the empirical half-lives (t(1/2) = l n (2) x V/CL) were similar for CHS and OSC, [(mean +/- standard deviation (SD)], 9.5 +/- 3 h and 10.2 +/- 4 h, respectively.",Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641914/),h,10.2,27831,DB00025,Antihemophilic Factor
,25382764,bleeding rate,The bleeding rate decreased from 14 (2012) to 1 (during the study period of 8.5 months).,Climbing therapy under PK-tailored prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25382764/),,14,29308,DB00025,Antihemophilic Factor
,25382764,bleeding rate,The bleeding rate decreased from 14 (2012) to 1 (during the study period of 8.5 months).,Climbing therapy under PK-tailored prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25382764/),,1,29309,DB00025,Antihemophilic Factor
,25382764,elimination half-life,The elimination half-life using Bayesian statistics was determined to be 16h.,Climbing therapy under PK-tailored prophylaxis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25382764/),h,16,29310,DB00025,Antihemophilic Factor
,10028318,volume of distribution,"Results in von Willebrand disease type 3 patients (nine patients; 10 infusions) indicated a volume of distribution of 39.9 and 39.8 mL kg-1 for RCoF and vWF:Ag, respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),[ml] / [kg],39.9,30220,DB00025,Antihemophilic Factor
,10028318,volume of distribution,"Results in von Willebrand disease type 3 patients (nine patients; 10 infusions) indicated a volume of distribution of 39.9 and 39.8 mL kg-1 for RCoF and vWF:Ag, respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),[ml] / [kg],39.8,30221,DB00025,Antihemophilic Factor
,10028318,rate of synthesis,The FVIII:C rate of synthesis was 6.4 U dL-1 h-1 (range: 4.4-8.8).,Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),[u] / [dl·h],6.4,30222,DB00025,Antihemophilic Factor
,10028318,decay rates,"The decay rates for FVIII:C, RCoF, and vWF:Ag were 0.041 (h-1) [t1/2: 16.9 h]; 0.061 (h-1) [t1/2: 11.3 h] and 0.006 (h-1) [t1/2: 12.4 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),1/[h],0.041,30223,DB00025,Antihemophilic Factor
,10028318,t1/2,"The decay rates for FVIII:C, RCoF, and vWF:Ag were 0.041 (h-1) [t1/2: 16.9 h]; 0.061 (h-1) [t1/2: 11.3 h] and 0.006 (h-1) [t1/2: 12.4 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),h,16.9,30224,DB00025,Antihemophilic Factor
,10028318,t1/2,"The decay rates for FVIII:C, RCoF, and vWF:Ag were 0.041 (h-1) [t1/2: 16.9 h]; 0.061 (h-1) [t1/2: 11.3 h] and 0.006 (h-1) [t1/2: 12.4 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),1/[h],0.061,30225,DB00025,Antihemophilic Factor
,10028318,t1/2,"The decay rates for FVIII:C, RCoF, and vWF:Ag were 0.041 (h-1) [t1/2: 16.9 h]; 0.061 (h-1) [t1/2: 11.3 h] and 0.006 (h-1) [t1/2: 12.4 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),h,11.3,30226,DB00025,Antihemophilic Factor
,10028318,t1/2,"The decay rates for FVIII:C, RCoF, and vWF:Ag were 0.041 (h-1) [t1/2: 16.9 h]; 0.061 (h-1) [t1/2: 11.3 h] and 0.006 (h-1) [t1/2: 12.4 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),1/[h],0.006,30227,DB00025,Antihemophilic Factor
,10028318,t1/2,"The decay rates for FVIII:C, RCoF, and vWF:Ag were 0.041 (h-1) [t1/2: 16.9 h]; 0.061 (h-1) [t1/2: 11.3 h] and 0.006 (h-1) [t1/2: 12.4 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),h,12.4,30228,DB00025,Antihemophilic Factor
,10028318,volume of distribution,In patients with von Willebrand disease type 2 (n = 8) the RCoF mean volume of distribution was 46 mL kg-1.,Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),[ml] / [kg],46,30229,DB00025,Antihemophilic Factor
,10028318,rate of synthesis,The factor VIIIC mean rate of synthesis was 5.5 U dL-1 h-1 and the decay rate 0.043 (h-1) [t1/2: 16.1 h].,Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),[u] / [dl·h],5.5,30230,DB00025,Antihemophilic Factor
,10028318,decay rate,The factor VIIIC mean rate of synthesis was 5.5 U dL-1 h-1 and the decay rate 0.043 (h-1) [t1/2: 16.1 h].,Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),1/[h],0.043,30231,DB00025,Antihemophilic Factor
,10028318,t1/2,The factor VIIIC mean rate of synthesis was 5.5 U dL-1 h-1 and the decay rate 0.043 (h-1) [t1/2: 16.1 h].,Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),h,16.1,30232,DB00025,Antihemophilic Factor
,10028318,rate of decay,"The rate of decay for RCoF and vWF:Ag were 0.050 (h-1) [t1/2: 13.9 h] and 0.044 (h-1) [t1/2: 15.7 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),,0.050,30233,DB00025,Antihemophilic Factor
,10028318,t1/2,"The rate of decay for RCoF and vWF:Ag were 0.050 (h-1) [t1/2: 13.9 h] and 0.044 (h-1) [t1/2: 15.7 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),h,13.9,30234,DB00025,Antihemophilic Factor
,10028318,t1/2,"The rate of decay for RCoF and vWF:Ag were 0.050 (h-1) [t1/2: 13.9 h] and 0.044 (h-1) [t1/2: 15.7 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),,0.044,30235,DB00025,Antihemophilic Factor
,10028318,t1/2,"The rate of decay for RCoF and vWF:Ag were 0.050 (h-1) [t1/2: 13.9 h] and 0.044 (h-1) [t1/2: 15.7 h], respectively.",Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028318/),h,15.7,30236,DB00025,Antihemophilic Factor
,3141199,plasma half-life,There was no effect of the route on the plasma half-life of DDAVP which ranged from 2.7 to 4.6 h.,Pharmacokinetics and haematological effects of desmopressin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),h,2.7 to 4.6,30448,DB00025,Antihemophilic Factor
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,112,30449,DB00025,Antihemophilic Factor
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,94,30450,DB00025,Antihemophilic Factor
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,2,30451,DB00025,Antihemophilic Factor
,34013558,THL,THL of FVIII-EHL was longer than of FVIII standard half-life (SHL; median 15.1 vs. 11.1 h).,"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34013558/),h,15.1,32474,DB00025,Antihemophilic Factor
,34013558,THL,THL of FVIII-EHL was longer than of FVIII standard half-life (SHL; median 15.1 vs. 11.1 h).,"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34013558/),h,11.1,32475,DB00025,Antihemophilic Factor
,34013558,THL,THL of FIX-EHL was longer than of FIX-SHL (median 106.9 vs. 36.5 h).,"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34013558/),h,106.9,32476,DB00025,Antihemophilic Factor
,34013558,THL,THL of FIX-EHL was longer than of FIX-SHL (median 106.9 vs. 36.5 h).,"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34013558/),h,36.5,32477,DB00025,Antihemophilic Factor
,34407556,MRT,"Compared to the other ASGR2 genotypes, the c.-95TT homozygotes (n=9), showed three-fold longer Alpha HL (3.60 h, 95% CI 1.44-5.76, p=0.006), and the c.-95TC heterozygotes (n=17) showed 25% shorter MRT (18.5 h, 15.0-22.0, p=0.038) and 32% shorter Beta HL (13.5 h, 10.9-16.0, p=0.016).",The asialoglycoprotein receptor minor subunit gene (ASGR2) contributes to pharmacokinetics of factor VIII concentrates in Hemophilia A. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34407556/),h,18.5,36180,DB00025,Antihemophilic Factor
,8903006,half-life,"From the studies on the clearance rate and immunohistochemical staining of injected h-rTFPI into normal rats, we found that most of the intravenously-injected h-rTFPI was localized on the central vein and sinusoids in the liver and catabolized via the proteoglycan-mediated pathway with a half-life of 48 min.",Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903006/),min,48,36701,DB00025,Antihemophilic Factor
,8826903,decay rates,"The average decay rates for FVIIIC, VWF:RiCoF and VWF:Ag were 0.041, 0.061 and 0.056 respectively.",Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826903/),,0.041,38591,DB00025,Antihemophilic Factor
,8826903,decay rates,"The average decay rates for FVIIIC, VWF:RiCoF and VWF:Ag were 0.041, 0.061 and 0.056 respectively.",Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826903/),,0.061,38592,DB00025,Antihemophilic Factor
,8826903,decay rates,"The average decay rates for FVIIIC, VWF:RiCoF and VWF:Ag were 0.041, 0.061 and 0.056 respectively.",Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826903/),,0.056,38593,DB00025,Antihemophilic Factor
,8826903,'synthesis' rate,The average calculated 'synthesis' rate for FVIIIC was 6.4 u/dl/h.,Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826903/),[u] / [dl·h],6.4,38594,DB00025,Antihemophilic Factor
,8826903,bleeding time,At 4 h post infusion the median bleeding time was 9 min following a dose of 50 iu VWF:RiCoF/kg versus 3 min with a dose of 100 iu VWF:RiCoF/kg.,Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826903/),min,9,38595,DB00025,Antihemophilic Factor
,8826903,bleeding time,At 4 h post infusion the median bleeding time was 9 min following a dose of 50 iu VWF:RiCoF/kg versus 3 min with a dose of 100 iu VWF:RiCoF/kg.,Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826903/),min,3,38596,DB00025,Antihemophilic Factor
,23578227,half-life,"A 40K glycoPEGylated, recombinant activated factor VII (rFVIIa) bypassing agent (N7-GP) with a prolonged half-life (15 h) compared with rFVIIa was developed as a potential candidate for bleed-preventive regimens in patients with hemophilia and inhibitors.","40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23578227/),h,15,39798,DB00025,Antihemophilic Factor
,33966319,time to troughs,"WAPPS-Hemo yielded a slightly longer mean t1 /2 , but the overall correlation between the methods was good (ICC ≥0.79) The time to troughs of 5%, 3% and 1% showed ICCs ≥0.86.",Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33966319/),%,5,42217,DB00025,Antihemophilic Factor
,33966319,time to troughs,"WAPPS-Hemo yielded a slightly longer mean t1 /2 , but the overall correlation between the methods was good (ICC ≥0.79) The time to troughs of 5%, 3% and 1% showed ICCs ≥0.86.",Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33966319/),%,3,42218,DB00025,Antihemophilic Factor
,33966319,time to troughs,"WAPPS-Hemo yielded a slightly longer mean t1 /2 , but the overall correlation between the methods was good (ICC ≥0.79) The time to troughs of 5%, 3% and 1% showed ICCs ≥0.86.",Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33966319/),%,1,42219,DB00025,Antihemophilic Factor
,24735117,half-life,The determined ACE910 pharmacokinetic parameters included a long half-life (3 weeks) and high subcutaneous bioavailability (nearly 100%).,Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735117/),weeks,3,42906,DB00025,Antihemophilic Factor
,24735117,subcutaneous bioavailability,The determined ACE910 pharmacokinetic parameters included a long half-life (3 weeks) and high subcutaneous bioavailability (nearly 100%).,Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735117/),%,100,42907,DB00025,Antihemophilic Factor
,8004880,clearance,Median clearance was low--31.0 ml/hr.,Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),[ml] / [h],31.0,44008,DB00025,Antihemophilic Factor
,8004880,mean residence time,"In nonbleeding episodes, median mean residence time was 3.44 hours and median half-life was 2.89 hours.",Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),h,3.44,44009,DB00025,Antihemophilic Factor
,8004880,half-life,"In nonbleeding episodes, median mean residence time was 3.44 hours and median half-life was 2.89 hours.",Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),h,2.89,44010,DB00025,Antihemophilic Factor
,8004880,mean residence time,"In bleeding episodes, the elimination rate appears to be higher, with a median mean residence time of 2.97 hours and a median half-life of 2.30 hours.",Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),h,2.97,44011,DB00025,Antihemophilic Factor
,8004880,half-life,"In bleeding episodes, the elimination rate appears to be higher, with a median mean residence time of 2.97 hours and a median half-life of 2.30 hours.",Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),h,2.30,44012,DB00025,Antihemophilic Factor
,8004880,Recovery,Recovery was 45.6% during nonbleeding conditions and 43.5% during bleeding episodes (p = 0.0006); it was statistically lower with the highest dose level than with the 17.5 and 35 micrograms/kg doses (p = 0.007).,Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),%,45.6,44013,DB00025,Antihemophilic Factor
,8004880,Recovery,Recovery was 45.6% during nonbleeding conditions and 43.5% during bleeding episodes (p = 0.0006); it was statistically lower with the highest dose level than with the 17.5 and 35 micrograms/kg doses (p = 0.007).,Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004880/),%,43.5,44014,DB00025,Antihemophilic Factor
,16194199,recoveries,"VWF:RCo and VWF:Ag recoveries were 2.1 +/- 0.3 and 1.8 +/- 0.3 per IU kg(-1), respectively, and the half-lives were 12.4 +/- 1.8 and 15.9 +/- 1.5 h.","Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16194199/),[iu] / [kg],2.1,46476,DB00025,Antihemophilic Factor
,16194199,recoveries,"VWF:RCo and VWF:Ag recoveries were 2.1 +/- 0.3 and 1.8 +/- 0.3 per IU kg(-1), respectively, and the half-lives were 12.4 +/- 1.8 and 15.9 +/- 1.5 h.","Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16194199/),[iu] / [kg],1.8,46477,DB00025,Antihemophilic Factor
,16194199,half-lives,"VWF:RCo and VWF:Ag recoveries were 2.1 +/- 0.3 and 1.8 +/- 0.3 per IU kg(-1), respectively, and the half-lives were 12.4 +/- 1.8 and 15.9 +/- 1.5 h.","Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16194199/),h,12.4,46478,DB00025,Antihemophilic Factor
,16194199,half-lives,"VWF:RCo and VWF:Ag recoveries were 2.1 +/- 0.3 and 1.8 +/- 0.3 per IU kg(-1), respectively, and the half-lives were 12.4 +/- 1.8 and 15.9 +/- 1.5 h.","Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16194199/),h,15.9,46479,DB00025,Antihemophilic Factor
,16194199,synthesis rate,"The FVIII synthesis rate was 5.8 +/- 1.0 IU dL(-1) h(-1), with a half-life of 15.8 +/- 2.4 h.","Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16194199/),[iu] / [dl·h],5.8,46480,DB00025,Antihemophilic Factor
,16194199,half-life,"The FVIII synthesis rate was 5.8 +/- 1.0 IU dL(-1) h(-1), with a half-life of 15.8 +/- 2.4 h.","Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16194199/),h,15.8,46481,DB00025,Antihemophilic Factor
,24252161,peak FVIII:C,The mean peak FVIII:C was 1.00 IU dL(-1) and the mean FVIII:C half-life was 10.14 h.,Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252161/),[iu] / [dl],1.00,47991,DB00025,Antihemophilic Factor
,24252161,half-life,The mean peak FVIII:C was 1.00 IU dL(-1) and the mean FVIII:C half-life was 10.14 h.,Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252161/),h,10.14,47992,DB00025,Antihemophilic Factor
,23534820,terminal half-life (T1/2 ),Pharmacokinetic studies in FVIII knockout (HaemA) mice showed that the terminal half-life (T1/2 ) of F8V was dramatically reduced relative to FVIII-BDD (0.6 h vs. 6.03 h).,von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23534820/),h,0.6,49776,DB00025,Antihemophilic Factor
,23534820,terminal half-life (T1/2 ),Pharmacokinetic studies in FVIII knockout (HaemA) mice showed that the terminal half-life (T1/2 ) of F8V was dramatically reduced relative to FVIII-BDD (0.6 h vs. 6.03 h).,von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23534820/),h,6.03,49777,DB00025,Antihemophilic Factor
,23534820,T1/2,PEG-F8V showed a shorter T1/2 than PEG-FVIII-BDD both in HaemA mice (7.7 h vs. 14.3 h) and in Sprague-Dawley male rats (2.0 ± 0.3 h vs. 6.0 ± 0.5 h).,von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23534820/),h,7.7,49778,DB00025,Antihemophilic Factor
,23534820,T1/2,PEG-F8V showed a shorter T1/2 than PEG-FVIII-BDD both in HaemA mice (7.7 h vs. 14.3 h) and in Sprague-Dawley male rats (2.0 ± 0.3 h vs. 6.0 ± 0.5 h).,von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23534820/),h,14.3,49779,DB00025,Antihemophilic Factor
,23534820,T1/2,PEG-F8V showed a shorter T1/2 than PEG-FVIII-BDD both in HaemA mice (7.7 h vs. 14.3 h) and in Sprague-Dawley male rats (2.0 ± 0.3 h vs. 6.0 ± 0.5 h).,von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23534820/),h,2.0,49780,DB00025,Antihemophilic Factor
,23534820,T1/2,PEG-F8V showed a shorter T1/2 than PEG-FVIII-BDD both in HaemA mice (7.7 h vs. 14.3 h) and in Sprague-Dawley male rats (2.0 ± 0.3 h vs. 6.0 ± 0.5 h).,von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23534820/),h,6.0,49781,DB00025,Antihemophilic Factor
,32107819,in vivo recovery (IVR),"The in vivo recovery (IVR) of rFVIII-Fc measured with one stage clotting assay (OSA) and chromogenic assay (CSA) was 2.2 and 2.8 IU/mL per IU/kg, respectively.",Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32107819/),[iu] / [iu·kg·ml],2.2,51096,DB00025,Antihemophilic Factor
,32107819,in vivo recovery (IVR),"The in vivo recovery (IVR) of rFVIII-Fc measured with one stage clotting assay (OSA) and chromogenic assay (CSA) was 2.2 and 2.8 IU/mL per IU/kg, respectively.",Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32107819/),[iu] / [iu·kg·ml],2.8,51097,DB00025,Antihemophilic Factor
,32107819,half-life (T1/2 ),"The median half-life (T1/2 ) of rFVIII-Fc was 14.5 hours whatever the FVIII:C assay used, but variable and correlated with preinfusion VWF:Ag levels (r = .76).",Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32107819/),h,14.5,51098,DB00025,Antihemophilic Factor
,32107819,IVR,"Both IVR and T1/2 were lower in patients under 12 years old (2.4 IU/mL per IU/kg and 11.1 hours, respectively; CSA).",Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32107819/),[iu] / [iu·kg·ml],2.4,51099,DB00025,Antihemophilic Factor
,32107819,T1/2,"Both IVR and T1/2 were lower in patients under 12 years old (2.4 IU/mL per IU/kg and 11.1 hours, respectively; CSA).",Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32107819/),h,11.1,51100,DB00025,Antihemophilic Factor
,32107819,T1/2 ratio,"PK study of rFVIII-Fc vs non-EHL FVIII showed a T1/2 ratio of 1.4 in favour of rFVIII-Fc, regardless of the patient's age.",Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32107819/),,1.4,51101,DB00025,Antihemophilic Factor
,23645693,recovery,The median factor VIII recovery was 2.16 for all patients.,Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23645693/),,2.16,53559,DB00025,Antihemophilic Factor
,23645693,recovery,"Each group had a significantly different median factor VIII recovery (P<0.001): 1.60, 2.14, and 2.70, respectively.",Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23645693/),,1.60,53560,DB00025,Antihemophilic Factor
,23645693,recovery,"Each group had a significantly different median factor VIII recovery (P<0.001): 1.60, 2.14, and 2.70, respectively.",Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23645693/),,2.14,53561,DB00025,Antihemophilic Factor
,23645693,recovery,"Each group had a significantly different median factor VIII recovery (P<0.001): 1.60, 2.14, and 2.70, respectively.",Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23645693/),,2.70,53562,DB00025,Antihemophilic Factor
,23645693,recovery,"In conclusion, factor VIII dosing should be adapted to underweight and overweight patients, as a factor VIII recovery of 2 does not apply to these patients.",Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23645693/),,2,53563,DB00025,Antihemophilic Factor
,27214717,half-lives,"As the half-lives of C in the patients varied from 7.8 to 18.3 h, it was obviously beneficial to base the dosage on individual pharmacokinetic data.",Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214717/),h,7.8 to 18.3,57023,DB00025,Antihemophilic Factor
,27214717,trough level,Mean trough level of exogenous C was raised from 0.89 (SD 0.73) U dL(-1) during standard dosage to 2.2 (1.5) U dL(-1) during pharmacokinetic dosage.,Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214717/),[u] / [dl],0.89,57024,DB00025,Antihemophilic Factor
,27214717,trough level,Mean trough level of exogenous C was raised from 0.89 (SD 0.73) U dL(-1) during standard dosage to 2.2 (1.5) U dL(-1) during pharmacokinetic dosage.,Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214717/),[u] / [dl],2.2,57025,DB00025,Antihemophilic Factor
,32979031,activity level,FVIII activity level increased from median 1.0 IU/dL (interquartile range < 1.0-6.0) to 71 IU/dL (62-82) 15 minutes after administration and decreased to 15 IU/dL (10-26) at 24 hours.,Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32979031/),[iu] / [dl],1.0,57114,DB00025,Antihemophilic Factor
,32979031,activity level,FVIII activity level increased from median 1.0 IU/dL (interquartile range < 1.0-6.0) to 71 IU/dL (62-82) 15 minutes after administration and decreased to 15 IU/dL (10-26) at 24 hours.,Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32979031/),[iu] / [dl],71,57115,DB00025,Antihemophilic Factor
,32979031,activity level,FVIII activity level increased from median 1.0 IU/dL (interquartile range < 1.0-6.0) to 71 IU/dL (62-82) 15 minutes after administration and decreased to 15 IU/dL (10-26) at 24 hours.,Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32979031/),i,15,57116,DB00025,Antihemophilic Factor
,32979031,peak height (TPH),"TG was enhanced simultaneously, with thrombin peak height (TPH) increasing from 22nM (15-35) to 222nM (159-255), and thrombin potential (TP) from 404nM/min (undetectable-876) to 1834nM/min (1546-2353).",Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32979031/),nM,22,57117,DB00025,Antihemophilic Factor
,32979031,peak height (TPH),"TG was enhanced simultaneously, with thrombin peak height (TPH) increasing from 22nM (15-35) to 222nM (159-255), and thrombin potential (TP) from 404nM/min (undetectable-876) to 1834nM/min (1546-2353).",Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32979031/),nM,222,57118,DB00025,Antihemophilic Factor
,32979031,potential (TP),"TG was enhanced simultaneously, with thrombin peak height (TPH) increasing from 22nM (15-35) to 222nM (159-255), and thrombin potential (TP) from 404nM/min (undetectable-876) to 1834nM/min (1546-2353).",Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32979031/),[nM] / [min],404,57119,DB00025,Antihemophilic Factor
,32979031,potential (TP),"TG was enhanced simultaneously, with thrombin peak height (TPH) increasing from 22nM (15-35) to 222nM (159-255), and thrombin potential (TP) from 404nM/min (undetectable-876) to 1834nM/min (1546-2353).",Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32979031/),[nM] / [min],1834,57120,DB00025,Antihemophilic Factor
,26626991,half-life,ACE910 exhibited a linear PK profile and had a half-life of ∼4 to 5 weeks.,"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626991/),weeks,∼4,57426,DB00025,Antihemophilic Factor
,26626991,half-life,ACE910 exhibited a linear PK profile and had a half-life of ∼4 to 5 weeks.,"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626991/),weeks,5,57427,DB00025,Antihemophilic Factor
,33709296,steady-state concentration,"At the average steady-state concentration across all regimens (53.5 µg/mL), the predicted mean annualized bleeding rate is 1.28, corresponding to a 94.0% reduction from baseline.",Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709296/),[μg] / [ml],53.5,59748,DB00025,Antihemophilic Factor
,12649880,half-life,kg-1 of factor VIII and the half-life of about 16 hours.,[Anesthetic management of a hemophilia A patient with HIV infection: a case report]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649880/),h,16,60576,DB00025,Antihemophilic Factor
,9345039,half-life,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),h,21.6,63345,DB00025,Antihemophilic Factor
,9345039,half-life,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),h,22.1,63346,DB00025,Antihemophilic Factor
,9345039,half-life,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),h,7.7,63347,DB00025,Antihemophilic Factor
,9345039,half-life,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),h,9,63348,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,59,63349,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,64,63350,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,70,63351,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,33,63352,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,92,63353,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,78,63354,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,110,63355,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,120,63356,DB00025,Antihemophilic Factor
,9345039,in vivo recovery,"In the vWF-deficient dogs, the half-life of vWF:Ag was 21.6 and 22.1 hours for rvWF, 7.7 hours for pdvWF, and 9 hours for LMW-rvWF; in vivo recovery of vWF:Ag was 59%, 64%, and 70% for rvWF, 33% for pdvWF and 92% for LMW-rvWF; in vivo recovery of RCoF was 78%, 110%, and 120% for rvWF, and 25% for pdvWF.",In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345039/),%,25,63357,DB00025,Antihemophilic Factor
,23398640,clearance,The clearance was 1.79 mL(-1) h(-1) kg(-1) .,Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398640/),1/[h·kg·ml],1.79,63504,DB00025,Antihemophilic Factor
,23398640,time,The estimated time from dosing of 50 U kg(-1) N8-GP to a plasma activity of 1% was 6.5 days (range: 3.6-7.9 days).,Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398640/),d,6.5,63505,DB00025,Antihemophilic Factor
,23398640,terminal half-life,"The mean terminal half-life of N8-GP was 19.0 h (range: 11.6-27.3 h), 1.6-fold longer than that of the patients' previous products.",Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398640/),h,19.0,63506,DB00025,Antihemophilic Factor
,34293540,trough levels (TL),"PK parameters analyzed were half-life, trough levels (TL) at 24, 48 and 72 h, and time to reach FVIII levels of 1, 2, 5% (T5%).",Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34293540/),h,24,63835,DB00025,Antihemophilic Factor
,34293540,trough levels (TL),"PK parameters analyzed were half-life, trough levels (TL) at 24, 48 and 72 h, and time to reach FVIII levels of 1, 2, 5% (T5%).",Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34293540/),h,48,63836,DB00025,Antihemophilic Factor
,34293540,trough levels (TL),"PK parameters analyzed were half-life, trough levels (TL) at 24, 48 and 72 h, and time to reach FVIII levels of 1, 2, 5% (T5%).",Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34293540/),h,72,63837,DB00025,Antihemophilic Factor
> or =,11449336,peak titer,"Of these, 16 patients were high responders (peak titer > or = 5 Bethesda units [BU]).",Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11449336/),bethesda·units,5,66021,DB00025,Antihemophilic Factor
,27140796,clearance,"The results of these analyses confirmed that rFVIIIFc clearance (1.65 dL/h) is much lower than that of rFVIII (2.53 dL/h), while the steady state volumes of distribution were similar.",Population pharmacokinetics of recombinant factor VIII Fc fusion protein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140796/),[dl] / [h],1.65,67765,DB00025,Antihemophilic Factor
,27140796,clearance,"The results of these analyses confirmed that rFVIIIFc clearance (1.65 dL/h) is much lower than that of rFVIII (2.53 dL/h), while the steady state volumes of distribution were similar.",Population pharmacokinetics of recombinant factor VIII Fc fusion protein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140796/),[dl] / [h],2.53,67766,DB00025,Antihemophilic Factor
>,29855112,trough activity,"For individuals with haemophilia A, prophylaxis with factor VIII (FVIII) is typically directed towards trough activity >1 IU/dL; however, some patients still experience spontaneous bleeding events (sBEs).",Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29855112/),[iu] / [dl],1,72379,DB00025,Antihemophilic Factor
,21535320,half-life,"Median terminal VWF:RCo half-life was 11.7 h, and median incremental in vivo recovery was 2.4 IU dL(-1) per IU kg(-1) infused.",von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535320/),h,11.7,72855,DB00025,Antihemophilic Factor
,21371202,recovery,The mean recovery of FVIII 10 min postinfusion was 69.7%.,Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371202/),%,69.7,75960,DB00025,Antihemophilic Factor
,21371202,half-life,Mean FVIII half-life was 14.2 h and clearance was 2.6 mL h⁻¹ kg⁻¹.,Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371202/),h,14.2,75961,DB00025,Antihemophilic Factor
,21371202,clearance,Mean FVIII half-life was 14.2 h and clearance was 2.6 mL h⁻¹ kg⁻¹.,Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371202/),h⁻¹·kg⁻¹·ml,2.6,75962,DB00025,Antihemophilic Factor
,24843882,half-life,"rFVIII-FS, with a half-life of ~ 19 h (vs. ~ 13.0 h for rFVIII-FS).","Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24843882/),h,19,76838,DB00025,Antihemophilic Factor
,24843882,half-life,"rFVIII-FS, with a half-life of ~ 19 h (vs. ~ 13.0 h for rFVIII-FS).","Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24843882/),h,13.0,76839,DB00025,Antihemophilic Factor
,29582525,recovery,"At baseline, mean (±SD) recovery ranged between 1.32 ± 0.65 (PUPs aged <2 years) and 2.13 ± 0.82 (PTPs aged 6 to <12 years).",Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582525/),,1.32,79400,DB00025,Antihemophilic Factor
,29582525,recovery,"At baseline, mean (±SD) recovery ranged between 1.32 ± 0.65 (PUPs aged <2 years) and 2.13 ± 0.82 (PTPs aged 6 to <12 years).",Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582525/),,2.13,79401,DB00025,Antihemophilic Factor
,29582525,half-life,The mean (±SD) half-life was 9.12 ± 1.94 hours in PTPs aged 6 to <12 years.,Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582525/),h,9.12,79402,DB00025,Antihemophilic Factor
,29582525,annual,"The annualised bleeding rate (ABR) in the PTP study was 27.5 and 4.2 for patients reporting an on-demand and routine prophylaxis regimen at baseline, respectively.",Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582525/),,27.5,79403,DB00025,Antihemophilic Factor
,29582525,annual,"The annualised bleeding rate (ABR) in the PTP study was 27.5 and 4.2 for patients reporting an on-demand and routine prophylaxis regimen at baseline, respectively.",Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582525/),,4.2,79404,DB00025,Antihemophilic Factor
,31557387,volume of distribution,Typical values for volume of distribution and clearance were 3.28 L/70 kg and 0.037 L/h/70 kg.,One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557387/),[l] / [70·kg],3.28,82967,DB00025,Antihemophilic Factor
,31557387,clearance,Typical values for volume of distribution and clearance were 3.28 L/70 kg and 0.037 L/h/70 kg.,One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557387/),[l] / [70·h·kg],0.037,82968,DB00025,Antihemophilic Factor
up to,32877516,bioavailability,"The HA mouse model was used to study the effects of VWF-12 or VWF-13 on the in vivo pharmacokinetics of rhFVIII, demonstrating (1) no significant impact on rhFVIII recovery or half-life after a single IV administration; (2) enhanced bioavailability (up to 18.5%) of rhFVIII after subcutaneous administration; and (3) slow absorption (peak concentration, 6 hours) and prolonged half-life (up to 2.5-fold) of rhFVIII after subcutaneous administration.",Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32877516/),%,18.5,83192,DB00025,Antihemophilic Factor
,28166608,annualized spontaneous bleeding rate,"Across all prophylaxis regimens, the median annualized spontaneous bleeding rate was 0.00.","Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28166608/),,0.00,84179,DB00025,Antihemophilic Factor
,33683340,clearance,"An average perioperative VWF:Act level of 1.23 IU/mL decreased FVIII clearance from 460 mL/h to 264 mL/h, and increased FVIII half-life from 6.6 to 11.4 hours.",Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683340/),[ml] / [h],460,84514,DB00025,Antihemophilic Factor
,33683340,clearance,"An average perioperative VWF:Act level of 1.23 IU/mL decreased FVIII clearance from 460 mL/h to 264 mL/h, and increased FVIII half-life from 6.6 to 11.4 hours.",Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683340/),[ml] / [h],264,84515,DB00025,Antihemophilic Factor
,33683340,half-life,"An average perioperative VWF:Act level of 1.23 IU/mL decreased FVIII clearance from 460 mL/h to 264 mL/h, and increased FVIII half-life from 6.6 to 11.4 hours.",Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683340/),h,6.6,84516,DB00025,Antihemophilic Factor
,33683340,half-life,"An average perioperative VWF:Act level of 1.23 IU/mL decreased FVIII clearance from 460 mL/h to 264 mL/h, and increased FVIII half-life from 6.6 to 11.4 hours.",Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683340/),h,11.4,84517,DB00025,Antihemophilic Factor
,20637972,t(1/2),"On pharmacokinetic analysis of TB-402, the t(1/2) values across doses were 22.9 days (age 18-45 years) and 19.5 days (age 55-75 years).",Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637972/),d,22.9,85953,DB00025,Antihemophilic Factor
,20637972,t(1/2),"On pharmacokinetic analysis of TB-402, the t(1/2) values across doses were 22.9 days (age 18-45 years) and 19.5 days (age 55-75 years).",Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637972/),d,19.5,85954,DB00025,Antihemophilic Factor
,24814969,KD,rVIII-SingleChain displayed a high affinity for von Willebrand factor (KD=44 pM vs. 139 pM for full-length recombinant FVIII).,"Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814969/),pM,44,86247,DB00025,Antihemophilic Factor
,24814969,KD,rVIII-SingleChain displayed a high affinity for von Willebrand factor (KD=44 pM vs. 139 pM for full-length recombinant FVIII).,"Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814969/),pM,139,86248,DB00025,Antihemophilic Factor
,25582282,half-life,"FVIII half-life differed widely from 6.2 to 20.7 h, with a median of 10.0 h.",Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582282/),h,10.0,87172,DB00025,Antihemophilic Factor
,25582282,half-life,"Patients with blood group O had shorter FVIII half-life compared to patients with non-O blood group (median FVIII half-life 9.0 h vs. 10.4 h, P = 0.018).",Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582282/),h,9.0,87173,DB00025,Antihemophilic Factor
,25582282,half-life,"Patients with blood group O had shorter FVIII half-life compared to patients with non-O blood group (median FVIII half-life 9.0 h vs. 10.4 h, P = 0.018).",Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582282/),h,10.4,87174,DB00025,Antihemophilic Factor
,3082391,clearance rate,The mean factor IX clearance rate in eight factor IX-deficient patients was 233 mL/h (range 159 to 340 mL/h).,Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082391/),[ml] / [h],233,87395,DB00025,Antihemophilic Factor
,3082391,normalized clearance rate,The mean normalized clearance rate was 3.4 mL/h/kg.,Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082391/),[ml] / [h·kg],3.4,87396,DB00025,Antihemophilic Factor
,3082391,clearance rate,The mean factor VIII clearance rate in eight factor VIII-deficient patients was 294 mL/h (range 229 to 361 mL/h) and the mean normalized rate was 5.0 mL/h/kg.,Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082391/),[ml] / [h],294,87397,DB00025,Antihemophilic Factor
,3082391,normalized rate,The mean factor VIII clearance rate in eight factor VIII-deficient patients was 294 mL/h (range 229 to 361 mL/h) and the mean normalized rate was 5.0 mL/h/kg.,Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082391/),[ml] / [h·kg],5.0,87398,DB00025,Antihemophilic Factor
,10613649,half-life,The aggregate 60 pharmacokinetic study showed a half-life of 12.7 and 13.0 h (p = 0.28) and recovery of 127 and 161 IU/dl (p = 0.0001) using one-stage clotting or chromogenic substrate respectively.,Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613649/),h,12.7,88059,DB00025,Antihemophilic Factor
,10613649,half-life,The aggregate 60 pharmacokinetic study showed a half-life of 12.7 and 13.0 h (p = 0.28) and recovery of 127 and 161 IU/dl (p = 0.0001) using one-stage clotting or chromogenic substrate respectively.,Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613649/),h,13.0,88060,DB00025,Antihemophilic Factor
,10613649,recovery,The aggregate 60 pharmacokinetic study showed a half-life of 12.7 and 13.0 h (p = 0.28) and recovery of 127 and 161 IU/dl (p = 0.0001) using one-stage clotting or chromogenic substrate respectively.,Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613649/),[iu] / [dl],127,88061,DB00025,Antihemophilic Factor
,10613649,recovery,The aggregate 60 pharmacokinetic study showed a half-life of 12.7 and 13.0 h (p = 0.28) and recovery of 127 and 161 IU/dl (p = 0.0001) using one-stage clotting or chromogenic substrate respectively.,Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613649/),[iu] / [dl],161,88062,DB00025,Antihemophilic Factor
,32100950,annual bleeding rates,"Simulations showed that the mean spontaneous annual bleeding rate decreased with increasing baseline ETP or dosing: with ETP values of 200, 400 and 600 (nmol/L)·min annual bleeding rates were 2.36, 1.25 and 0.66, respectively, on 40 IU/kg human-cl rhFVIII every 3 days; and annual bleeding rates were 2.09, 1.10, and 0.60, respectively, on 60 IU/kg every 3 days.",A new paradigm for personalized prophylaxis for patients with severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32100950/),,2.36,88395,DB00025,Antihemophilic Factor
,32100950,annual bleeding rates,"Simulations showed that the mean spontaneous annual bleeding rate decreased with increasing baseline ETP or dosing: with ETP values of 200, 400 and 600 (nmol/L)·min annual bleeding rates were 2.36, 1.25 and 0.66, respectively, on 40 IU/kg human-cl rhFVIII every 3 days; and annual bleeding rates were 2.09, 1.10, and 0.60, respectively, on 60 IU/kg every 3 days.",A new paradigm for personalized prophylaxis for patients with severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32100950/),,1.25,88396,DB00025,Antihemophilic Factor
,32100950,annual bleeding rates,"Simulations showed that the mean spontaneous annual bleeding rate decreased with increasing baseline ETP or dosing: with ETP values of 200, 400 and 600 (nmol/L)·min annual bleeding rates were 2.36, 1.25 and 0.66, respectively, on 40 IU/kg human-cl rhFVIII every 3 days; and annual bleeding rates were 2.09, 1.10, and 0.60, respectively, on 60 IU/kg every 3 days.",A new paradigm for personalized prophylaxis for patients with severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32100950/),,0.66,88397,DB00025,Antihemophilic Factor
,32100950,annual bleeding rates,"Simulations showed that the mean spontaneous annual bleeding rate decreased with increasing baseline ETP or dosing: with ETP values of 200, 400 and 600 (nmol/L)·min annual bleeding rates were 2.36, 1.25 and 0.66, respectively, on 40 IU/kg human-cl rhFVIII every 3 days; and annual bleeding rates were 2.09, 1.10, and 0.60, respectively, on 60 IU/kg every 3 days.",A new paradigm for personalized prophylaxis for patients with severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32100950/),,2.09,88398,DB00025,Antihemophilic Factor
,32100950,annual bleeding rates,"Simulations showed that the mean spontaneous annual bleeding rate decreased with increasing baseline ETP or dosing: with ETP values of 200, 400 and 600 (nmol/L)·min annual bleeding rates were 2.36, 1.25 and 0.66, respectively, on 40 IU/kg human-cl rhFVIII every 3 days; and annual bleeding rates were 2.09, 1.10, and 0.60, respectively, on 60 IU/kg every 3 days.",A new paradigm for personalized prophylaxis for patients with severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32100950/),,1.10,88399,DB00025,Antihemophilic Factor
,32100950,annual bleeding rates,"Simulations showed that the mean spontaneous annual bleeding rate decreased with increasing baseline ETP or dosing: with ETP values of 200, 400 and 600 (nmol/L)·min annual bleeding rates were 2.36, 1.25 and 0.66, respectively, on 40 IU/kg human-cl rhFVIII every 3 days; and annual bleeding rates were 2.09, 1.10, and 0.60, respectively, on 60 IU/kg every 3 days.",A new paradigm for personalized prophylaxis for patients with severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32100950/),,0.60,88400,DB00025,Antihemophilic Factor
∼,22223821,half-life (t(1/2)),"Current factor VIII (FVIII) products display a half-life (t(1/2)) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A.",Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22223821/),h,8-12,96371,DB00025,Antihemophilic Factor
,28550352,annualized bleeding rates,The mean [standard deviation (SD)] annualized bleeding rates in the prophylactic treatment arm were 3.7 (4.7) for the overall population (n = 120) and 4.0 (3.4) for the Japanese subpopulation (n = 11).,Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550352/),,3.7,97232,DB00025,Antihemophilic Factor
,28550352,annualized bleeding rates,The mean [standard deviation (SD)] annualized bleeding rates in the prophylactic treatment arm were 3.7 (4.7) for the overall population (n = 120) and 4.0 (3.4) for the Japanese subpopulation (n = 11).,Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550352/),,4.0,97233,DB00025,Antihemophilic Factor
,32905674,half-life,The half-life of recombinant factor VIII ranges from 15 to 19 hours because of the von Willebrand factor chaperone effect.,BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905674/),h,15 to 19,100583,DB00025,Antihemophilic Factor
,32905674,half-life,The geometric mean half-life of BIVV001 was three to four times as long as that of recombinant factor VIII (37.6 hours vs. 9.1 hours in the lower-dose group and 42.5 vs.,BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905674/),h,37.6,100584,DB00025,Antihemophilic Factor
,32905674,half-life,The geometric mean half-life of BIVV001 was three to four times as long as that of recombinant factor VIII (37.6 hours vs. 9.1 hours in the lower-dose group and 42.5 vs.,BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905674/),h,9.1,100585,DB00025,Antihemophilic Factor
,32905674,half-life,The geometric mean half-life of BIVV001 was three to four times as long as that of recombinant factor VIII (37.6 hours vs. 9.1 hours in the lower-dose group and 42.5 vs.,BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905674/),,42.5,100586,DB00025,Antihemophilic Factor
,32905674,area under the curve (AUC),"13.2 hours in the higher-dose group); the area under the curve (AUC) for product exposure was six to seven times as great in the two dose groups (4470 hours vs. 638 hours × IU per deciliter in the lower-dose group and 12,800 hours vs. 1960 hours × IU per deciliter in the higher-dose group).",BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905674/),h,4470,100587,DB00025,Antihemophilic Factor
,32905674,area under the curve (AUC),"13.2 hours in the higher-dose group); the area under the curve (AUC) for product exposure was six to seven times as great in the two dose groups (4470 hours vs. 638 hours × IU per deciliter in the lower-dose group and 12,800 hours vs. 1960 hours × IU per deciliter in the higher-dose group).",BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905674/),[h·iu] / [dl],638,100588,DB00025,Antihemophilic Factor
,32905674,area under the curve (AUC),"13.2 hours in the higher-dose group); the area under the curve (AUC) for product exposure was six to seven times as great in the two dose groups (4470 hours vs. 638 hours × IU per deciliter in the lower-dose group and 12,800 hours vs. 1960 hours × IU per deciliter in the higher-dose group).",BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905674/),h,"12,800",100589,DB00025,Antihemophilic Factor
,32905674,area under the curve (AUC),"13.2 hours in the higher-dose group); the area under the curve (AUC) for product exposure was six to seven times as great in the two dose groups (4470 hours vs. 638 hours × IU per deciliter in the lower-dose group and 12,800 hours vs. 1960 hours × IU per deciliter in the higher-dose group).",BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905674/),[h·iu] / [dl],1960,100590,DB00025,Antihemophilic Factor
,30036280,half-life,"However, 14 participants had a slight variation of FVIII half-life with exercise compared to rest (from -3.42 h to +2.51 h).",Effect of ABO blood group on haemostatic parameters in severe haemophilia A patients performing acute moderate-intensity exercise. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30036280/),h,3.42,101473,DB00025,Antihemophilic Factor
,30036280,half-life,"However, 14 participants had a slight variation of FVIII half-life with exercise compared to rest (from -3.42 h to +2.51 h).",Effect of ABO blood group on haemostatic parameters in severe haemophilia A patients performing acute moderate-intensity exercise. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30036280/),h,2.51,101474,DB00025,Antihemophilic Factor
,27434619,half-life (t1/2 ),"rVIII-SingleChain had a longer mean half-life (t1/2 ) (14.5 vs. 13.3 h), lower mean clearance (CL) (2.64 vs.",Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434619/),h,14.5,105779,DB00025,Antihemophilic Factor
,27434619,half-life (t1/2 ),"rVIII-SingleChain had a longer mean half-life (t1/2 ) (14.5 vs. 13.3 h), lower mean clearance (CL) (2.64 vs.",Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434619/),h,13.3,105780,DB00025,Antihemophilic Factor
,27434619,clearance (CL),"rVIII-SingleChain had a longer mean half-life (t1/2 ) (14.5 vs. 13.3 h), lower mean clearance (CL) (2.64 vs.",Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434619/),,2.64,105781,DB00025,Antihemophilic Factor
,27434619,mean residence time,"3.68 mL h(-1) kg(-1) ), higher mean residence time (20.4 vs. 17.1 h) and larger mean AUCinf (2090 vs. 1550 IU?h dL(-1) ) than octocog alfa, respectively.",Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434619/),h,20.4,105782,DB00025,Antihemophilic Factor
,27434619,mean residence time,"3.68 mL h(-1) kg(-1) ), higher mean residence time (20.4 vs. 17.1 h) and larger mean AUCinf (2090 vs. 1550 IU?h dL(-1) ) than octocog alfa, respectively.",Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434619/),h,17.1,105783,DB00025,Antihemophilic Factor
,27434619,AUCinf,"3.68 mL h(-1) kg(-1) ), higher mean residence time (20.4 vs. 17.1 h) and larger mean AUCinf (2090 vs. 1550 IU?h dL(-1) ) than octocog alfa, respectively.",Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434619/),[iu?h] / [dl],2090,105784,DB00025,Antihemophilic Factor
,27434619,AUCinf,"3.68 mL h(-1) kg(-1) ), higher mean residence time (20.4 vs. 17.1 h) and larger mean AUCinf (2090 vs. 1550 IU?h dL(-1) ) than octocog alfa, respectively.",Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27434619/),[iu?h] / [dl],1550,105785,DB00025,Antihemophilic Factor
,1947960,in vivo recovery,The mean in vivo recovery of factor VIII was calculated to be 77 +/- 14%; the rise in factor VIII activity in plasma following injection of one unit/kg body weight was 1.6 +/- 0.3 units/dl.,"[Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies]. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1947960/),%,77,106465,DB00025,Antihemophilic Factor
,1947960,halflife,The mean halflife was 11.9 +/- 4.6 hours.,"[Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1947960/),h,11.9,106466,DB00025,Antihemophilic Factor
,30924607,Kss,"The plasma concentration-time profiles of total rFVIII and VWF, and the luminescent oxygen channeling immunoassay signal-time profiles of the rFVIII:VWF complex were adequately described using a two-compartment quasi-steady-state target-mediated drug disposition model (Kss = 0.14 nmol L-1 ).",Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924607/),[nM] / [l],0.14,106573,DB00025,Antihemophilic Factor
,34077951,apparent equilibrium dissociation constant (KD),"The resulting biAb (Mim8) assembled efficiently with FIXa and FX on membranes, and supported activation with an apparent equilibrium dissociation constant (KD) of 16 nM.",FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077951/),nM,16,107766,DB00025,Antihemophilic Factor
,34077951,KD,"Binding affinity with FIXa and FX in solution was much lower, with KD-values for FIXa and FX of 2.3 and 1.5 µM, respectively.",FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077951/),μM,2.3,107767,DB00025,Antihemophilic Factor
,34077951,KD,"Binding affinity with FIXa and FX in solution was much lower, with KD-values for FIXa and FX of 2.3 and 1.5 µM, respectively.",FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077951/),μM,1.5,107768,DB00025,Antihemophilic Factor
,34077951,half-life,"Furthermore, the pharmacokinetics of Mim8 were investigated and a half-life of 14 days demonstrated in cynomolgus monkey.",FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077951/),d,14,107769,DB00025,Antihemophilic Factor
,31267741,initial half-life,A PK analysis in a CD3 humanized mouse revealed that EGFRvIII:CD3 bi-scFv in plasma and whole blood has an initial half-life of ∼8 min and a terminal half-life of ∼2.5 h.,Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31267741/),min,∼8,109108,DB00025,Antihemophilic Factor
,31267741,terminal half-life,A PK analysis in a CD3 humanized mouse revealed that EGFRvIII:CD3 bi-scFv in plasma and whole blood has an initial half-life of ∼8 min and a terminal half-life of ∼2.5 h.,Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31267741/),h,∼2.5,109109,DB00025,Antihemophilic Factor
,15213847,in vivo recoveries,"A pharmacokinetic study showed, based on a content of FVIII:C of 1 U/mL, in vivo recoveries (%) of 106 (56-150) (median and range) for FVIII:C, 105 (62-187) for VWF:Ag, 25 (7-41) for VWF:CBA and 43 (11-76) for VWF:RCo.","In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15213847/),%,106,110724,DB00025,Antihemophilic Factor
,15213847,in vivo recoveries,"A pharmacokinetic study showed, based on a content of FVIII:C of 1 U/mL, in vivo recoveries (%) of 106 (56-150) (median and range) for FVIII:C, 105 (62-187) for VWF:Ag, 25 (7-41) for VWF:CBA and 43 (11-76) for VWF:RCo.","In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15213847/),%,105,110725,DB00025,Antihemophilic Factor
,15213847,in vivo recoveries,"A pharmacokinetic study showed, based on a content of FVIII:C of 1 U/mL, in vivo recoveries (%) of 106 (56-150) (median and range) for FVIII:C, 105 (62-187) for VWF:Ag, 25 (7-41) for VWF:CBA and 43 (11-76) for VWF:RCo.","In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15213847/),%,25,110726,DB00025,Antihemophilic Factor
,15213847,in vivo recoveries,"A pharmacokinetic study showed, based on a content of FVIII:C of 1 U/mL, in vivo recoveries (%) of 106 (56-150) (median and range) for FVIII:C, 105 (62-187) for VWF:Ag, 25 (7-41) for VWF:CBA and 43 (11-76) for VWF:RCo.","In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15213847/),%,43,110727,DB00025,Antihemophilic Factor
,15213847,Half-lives,"Half-lives were 14.1 h (7.4-36.9) for FVIII:C, 10.8 h (7.7-26.2) for VWF:Ag, 15.3 h (7.8-44.6) for VWF:CBA and 16.4 h (4.2-26.5) for VWF:RCo.","In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15213847/),h,14.1,110728,DB00025,Antihemophilic Factor
,15213847,Half-lives,"Half-lives were 14.1 h (7.4-36.9) for FVIII:C, 10.8 h (7.7-26.2) for VWF:Ag, 15.3 h (7.8-44.6) for VWF:CBA and 16.4 h (4.2-26.5) for VWF:RCo.","In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15213847/),h,10.8,110729,DB00025,Antihemophilic Factor
,15213847,Half-lives,"Half-lives were 14.1 h (7.4-36.9) for FVIII:C, 10.8 h (7.7-26.2) for VWF:Ag, 15.3 h (7.8-44.6) for VWF:CBA and 16.4 h (4.2-26.5) for VWF:RCo.","In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15213847/),h,15.3,110730,DB00025,Antihemophilic Factor
,15213847,Half-lives,"Half-lives were 14.1 h (7.4-36.9) for FVIII:C, 10.8 h (7.7-26.2) for VWF:Ag, 15.3 h (7.8-44.6) for VWF:CBA and 16.4 h (4.2-26.5) for VWF:RCo.","In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15213847/),h,16.4,110731,DB00025,Antihemophilic Factor
,26930418,peak FVIII levels,"Average peak FVIII levels ranged from 24 to 168 IU dL(-1) , with higher values associated with a decreased risk for all bleeding (joint and non-joint; P < 0.01) and joint bleeding (P < 0.01).",Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26930418/),[iu] / [dl],24 to 168,111227,DB00025,Antihemophilic Factor
,26930418,AUC,"Following rFVIII infusion, median percent of time spent with FVIII levels >20 IU dL(-1) was 22%; median AUC was 1363.",Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26930418/),,1363,111228,DB00025,Antihemophilic Factor
,12614214,plasma,"The median plasma FVII coagulant activity (FVII:C) at 24 h, 72 h and 20 d after surgery was 38 IU/ml (range 22-169 IU/ml), 45 IU/ml (range 17-88 IU/ml) and 31 IU/ml (range 27-46 IU/ml) respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],38,111825,DB00025,Antihemophilic Factor
,12614214,coagulant activity (FVII:C),"The median plasma FVII coagulant activity (FVII:C) at 24 h, 72 h and 20 d after surgery was 38 IU/ml (range 22-169 IU/ml), 45 IU/ml (range 17-88 IU/ml) and 31 IU/ml (range 27-46 IU/ml) respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],38,111826,DB00025,Antihemophilic Factor
,12614214,coagulant activity (FVII:C),"The median plasma FVII coagulant activity (FVII:C) at 24 h, 72 h and 20 d after surgery was 38 IU/ml (range 22-169 IU/ml), 45 IU/ml (range 17-88 IU/ml) and 31 IU/ml (range 27-46 IU/ml) respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],45,111827,DB00025,Antihemophilic Factor
,12614214,coagulant activity (FVII:C),"The median plasma FVII coagulant activity (FVII:C) at 24 h, 72 h and 20 d after surgery was 38 IU/ml (range 22-169 IU/ml), 45 IU/ml (range 17-88 IU/ml) and 31 IU/ml (range 27-46 IU/ml) respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],31,111828,DB00025,Antihemophilic Factor
,12614214,plasma,"The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],51,111829,DB00025,Antihemophilic Factor
,12614214,plasma,"The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],63,111830,DB00025,Antihemophilic Factor
,12614214,FVIIa:C,"The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],51,111831,DB00025,Antihemophilic Factor
,12614214,FVIIa:C,"The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],63,111832,DB00025,Antihemophilic Factor
,12614214,FVIIa:C,"The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[iu] / [ml],44,111833,DB00025,Antihemophilic Factor
,12614214,total rFVIIa clearance,"Median total rFVIIa clearance remained stable during the rFVIIa continuous infusion period and was 40 (range 9-70), 34 (range 17-86) and 48 (range 32-55)ml/kg/h at the end of 24 h, 72 h and 20 d infusion respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[ml] / [h·kg],40,111834,DB00025,Antihemophilic Factor
,12614214,total rFVIIa clearance,"Median total rFVIIa clearance remained stable during the rFVIIa continuous infusion period and was 40 (range 9-70), 34 (range 17-86) and 48 (range 32-55)ml/kg/h at the end of 24 h, 72 h and 20 d infusion respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[ml] / [h·kg],34,111835,DB00025,Antihemophilic Factor
,12614214,total rFVIIa clearance,"Median total rFVIIa clearance remained stable during the rFVIIa continuous infusion period and was 40 (range 9-70), 34 (range 17-86) and 48 (range 32-55)ml/kg/h at the end of 24 h, 72 h and 20 d infusion respectively.",A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614214/),[ml] / [h·kg],48,111836,DB00025,Antihemophilic Factor
,33506481,area under the curve (AUC,"Although the elimination half-life values were comparable for rFVIII-FC, BAX 855, and BAY 94-9027, a higher area under the curve (AUC; 2,779 IU/h/dL) for BAY 94-9027 was obtained.",Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33506481/),[iu] / [dl·h],"2,779",112037,DB00025,Antihemophilic Factor
,33506481,trough level,"During steady-state dosing of 40 IU/kg every 72 hours, 58.5% (rFVIII-SC), 69.3% (BAY 81-8972), 89.0% (rFVIII-Fc), 83.9% (BAX 855), and 93.7% (BAY 94-9027) of the patients maintained a trough level of 1 IU/dL, compared with 56.0% for SHL rFVIII.",Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33506481/),[iu] / [dl],1,112038,DB00025,Antihemophilic Factor
,33506481,trough level,"Following dosing schemes described in the SmPC, between 51.0 and 65.4% or 23.2 and 31.1% of the patients maintained a target trough level of 1 IU/dL or 3 IU/dL, respectively.",Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33506481/),[iu] / [dl],1,112039,DB00025,Antihemophilic Factor
,33506481,trough level,"Following dosing schemes described in the SmPC, between 51.0 and 65.4% or 23.2 and 31.1% of the patients maintained a target trough level of 1 IU/dL or 3 IU/dL, respectively.",Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33506481/),[iu] / [dl],3,112040,DB00025,Antihemophilic Factor
,26069114,overall efficacy rate,The drug showed an overall efficacy rate of 87.1%.,"Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26069114/),%,87.1,112789,DB00025,Antihemophilic Factor
,26069114,final elimination half-life,"The final elimination half-life was 13.3 h and 12.6 h at baseline and 6 months after administration, respectively.","Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26069114/),h,13.3,112790,DB00025,Antihemophilic Factor
,26069114,final elimination half-life,"The final elimination half-life was 13.3 h and 12.6 h at baseline and 6 months after administration, respectively.","Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26069114/),h,12.6,112791,DB00025,Antihemophilic Factor
,26960296,functional half-life,"FVa retained full activity over 30 h in buffer, the functional half-life in human plasma was 4.9 h, and circulating half-life in FVIII-deficient mice was ~30 min.","Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960296/),h,4.9,113114,DB00025,Antihemophilic Factor
,26960296,circulating half-life,"FVa retained full activity over 30 h in buffer, the functional half-life in human plasma was 4.9 h, and circulating half-life in FVIII-deficient mice was ~30 min.","Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960296/),min,30,113115,DB00025,Antihemophilic Factor
,19664015,T/2,"No significant difference was detected between the half-life measurements during the switch from FL FVIII (T/2 median 9.15 h, range 6.4-22) to BDD rFVIII (T/2 median 9.7, range 4.7-16.8) and back to FL FVIII (T/2 median 9.0, range 5.0-19.5).","Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19664015/),h,9.15,113148,DB00025,Antihemophilic Factor
,19664015,T/2,"No significant difference was detected between the half-life measurements during the switch from FL FVIII (T/2 median 9.15 h, range 6.4-22) to BDD rFVIII (T/2 median 9.7, range 4.7-16.8) and back to FL FVIII (T/2 median 9.0, range 5.0-19.5).","Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19664015/),,9.7,113149,DB00025,Antihemophilic Factor
,19664015,T/2,"No significant difference was detected between the half-life measurements during the switch from FL FVIII (T/2 median 9.15 h, range 6.4-22) to BDD rFVIII (T/2 median 9.7, range 4.7-16.8) and back to FL FVIII (T/2 median 9.0, range 5.0-19.5).","Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19664015/),,9.0,113150,DB00025,Antihemophilic Factor
,21771205,clearances,The clearances were 11 ± 1 vs.,Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771205/),,11,113339,DB00025,Antihemophilic Factor
,21771205,half-lives,10 ± 2 mL h(-1) kg(-1) (P = 0.14) and the half-lives 7.2 ± 0.9 vs. 7.7 ± 1.4 h (P = 0.31) after administration of N8 and Advate(®) respectively.,Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771205/),h,7.2,113340,DB00025,Antihemophilic Factor
,21771205,half-lives,10 ± 2 mL h(-1) kg(-1) (P = 0.14) and the half-lives 7.2 ± 0.9 vs. 7.7 ± 1.4 h (P = 0.31) after administration of N8 and Advate(®) respectively.,Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771205/),h,7.7,113341,DB00025,Antihemophilic Factor
,21771205,ED(50),"Both compounds normalized the bleeding at the dose of 200 IU kg(-1), and for blood loss ED(50) values of 27 IU kg(-1) (N8) and 28 IU/kg (Advate(®)) were found (P = 0.97).",Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771205/),[iu] / [kg],27,113342,DB00025,Antihemophilic Factor
,21771205,ED(50),"Both compounds normalized the bleeding at the dose of 200 IU kg(-1), and for blood loss ED(50) values of 27 IU kg(-1) (N8) and 28 IU/kg (Advate(®)) were found (P = 0.97).",Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771205/),[iu] / [kg],28,113343,DB00025,Antihemophilic Factor
,8772219,C2/C6 ratio,"10 patients with cerebrovascular circulatory disturbance received hemodilution therapy for 10 days, consisting of 10% HES 200/0.5 (mean molecular weight 200 kD, degree of substitution 0.5) with a C2/C6 ratio of 13.4.","HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772219/),,13.4,116767,DB00025,Antihemophilic Factor
,8772219,C2/C6 ratio,A second group of 10 patients received a starch solution with identical initial molecular weight and degree of substitution but with a C2/C6 ratio of 5.7.,"HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772219/),,5.7,116768,DB00025,Antihemophilic Factor
,2128855,half-life,The mean half-life was 14.2 +/- 5.0 while recovery in predicted plasma volume was 72 +/- 12% corresponding to a response of 1.99 +/- 0.66 U/dL for every U/kg administered.,Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128855/),,14.2,117302,DB00025,Antihemophilic Factor
,2128855,recovery,The mean half-life was 14.2 +/- 5.0 while recovery in predicted plasma volume was 72 +/- 12% corresponding to a response of 1.99 +/- 0.66 U/dL for every U/kg administered.,Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128855/),%,72,117303,DB00025,Antihemophilic Factor
,10028320,half-life,Administration of rvWF in these vWF-deficient dogs resulted in a vWF:Ag half-life of 21.6 h in one dog and 22.1 h in a second dog.,Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),h,21.6,118864,DB00025,Antihemophilic Factor
,10028320,half-life,Administration of rvWF in these vWF-deficient dogs resulted in a vWF:Ag half-life of 21.6 h in one dog and 22.1 h in a second dog.,Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),h,22.1,118865,DB00025,Antihemophilic Factor
,10028320,half-life,"Administration of pdvWF resulted in a half-life for vWF:Ag of 7.7 h, and LMW-rvWF, 9 h.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),h,7.7,118866,DB00025,Antihemophilic Factor
,10028320,half-life,"Administration of pdvWF resulted in a half-life for vWF:Ag of 7.7 h, and LMW-rvWF, 9 h.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),h,9,118867,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of vWF:Ag after administration of rvWF was 59%, 64% and 70% in three dogs, respectively; 33% after pdvWF, and 92% after LMW-rvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,59,118868,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of vWF:Ag after administration of rvWF was 59%, 64% and 70% in three dogs, respectively; 33% after pdvWF, and 92% after LMW-rvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,64,118869,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of vWF:Ag after administration of rvWF was 59%, 64% and 70% in three dogs, respectively; 33% after pdvWF, and 92% after LMW-rvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,70,118870,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of vWF:Ag after administration of rvWF was 59%, 64% and 70% in three dogs, respectively; 33% after pdvWF, and 92% after LMW-rvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,33,118871,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of vWF:Ag after administration of rvWF was 59%, 64% and 70% in three dogs, respectively; 33% after pdvWF, and 92% after LMW-rvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,92,118872,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of ristocetin cofactor (RCoF) was 78%, 110% and 120% for rvWF, and 25% for pdvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,78,118873,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of ristocetin cofactor (RCoF) was 78%, 110% and 120% for rvWF, and 25% for pdvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,110,118874,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of ristocetin cofactor (RCoF) was 78%, 110% and 120% for rvWF, and 25% for pdvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,120,118875,DB00025,Antihemophilic Factor
,10028320,in vivo recovery,"The in vivo recovery of ristocetin cofactor (RCoF) was 78%, 110% and 120% for rvWF, and 25% for pdvWF.",Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028320/),%,25,118876,DB00025,Antihemophilic Factor
,29534249,Half-life,"Half-life was different among the three methods: medians were 12.6 hours (n = 24), 11.2 hours (n = 30) and 13.0 hours (n = 30) for myPKFiT, WAPPS and NONMEM (p < 0.001), respectively.",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),h,12.6,119732,DB00025,Antihemophilic Factor
,29534249,Half-life,"Half-life was different among the three methods: medians were 12.6 hours (n = 24), 11.2 hours (n = 30) and 13.0 hours (n = 30) for myPKFiT, WAPPS and NONMEM (p < 0.001), respectively.",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),h,11.2,119733,DB00025,Antihemophilic Factor
,29534249,Half-life,"Half-life was different among the three methods: medians were 12.6 hours (n = 24), 11.2 hours (n = 30) and 13.0 hours (n = 30) for myPKFiT, WAPPS and NONMEM (p < 0.001), respectively.",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),h,13.0,119734,DB00025,Antihemophilic Factor
,29534249,trough level,"To maintain a FVIII trough level of 0.01 IU mL-1 after 48 hours, doses for myPKFiT and NONMEM were 15.1 and 11.0 IU kg-1 (p < 0.01, n = 11) and for WAPPS and NONMEM were 9.0 and 8.0 IU kg-1 (p < 0.01, n = 23), respectively.",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),[iu] / [ml],0.01,119735,DB00025,Antihemophilic Factor
,29534249,trough level,"To maintain a FVIII trough level of 0.01 IU mL-1 after 48 hours, doses for myPKFiT and NONMEM were 15.1 and 11.0 IU kg-1 (p < 0.01, n = 11) and for WAPPS and NONMEM were 9.0 and 8.0 IU kg-1 (p < 0.01, n = 23), respectively.",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),i,15.1,119736,DB00025,Antihemophilic Factor
,29534249,trough level,"To maintain a FVIII trough level of 0.01 IU mL-1 after 48 hours, doses for myPKFiT and NONMEM were 15.1 and 11.0 IU kg-1 (p < 0.01, n = 11) and for WAPPS and NONMEM were 9.0 and 8.0 IU kg-1 (p < 0.01, n = 23), respectively.",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),i,11.0,119737,DB00025,Antihemophilic Factor
,29534249,trough level,"To maintain a FVIII trough level of 0.01 IU mL-1 after 48 hours, doses for myPKFiT and NONMEM were 15.1 and 11.0 IU kg-1 (p < 0.01, n = 11) and for WAPPS and NONMEM were 9.0 and 8.0 IU kg-1 (p < 0.01, n = 23), respectively.",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),[iu] / [kg],9.0,119738,DB00025,Antihemophilic Factor
,29534249,trough level,"To maintain a FVIII trough level of 0.01 IU mL-1 after 48 hours, doses for myPKFiT and NONMEM were 15.1 and 11.0 IU kg-1 (p < 0.01, n = 11) and for WAPPS and NONMEM were 9.0 and 8.0 IU kg-1 (p < 0.01, n = 23), respectively.",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),[iu] / [kg],8.0,119739,DB00025,Antihemophilic Factor
,29534249,half-life,"In nine patients receiving Kogenate, WAPPS and NONMEM produced different PK-parameter estimates; half-life was 15.0 and 12.3 hours and time to 0.05 IU mL-1 was 69.2 and 60.8 hours, respectively (p < 0.01, n = 9).",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),h,15.0,119740,DB00025,Antihemophilic Factor
,29534249,half-life,"In nine patients receiving Kogenate, WAPPS and NONMEM produced different PK-parameter estimates; half-life was 15.0 and 12.3 hours and time to 0.05 IU mL-1 was 69.2 and 60.8 hours, respectively (p < 0.01, n = 9).",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),h,12.3,119741,DB00025,Antihemophilic Factor
,29534249,time to 0.05 I,"In nine patients receiving Kogenate, WAPPS and NONMEM produced different PK-parameter estimates; half-life was 15.0 and 12.3 hours and time to 0.05 IU mL-1 was 69.2 and 60.8 hours, respectively (p < 0.01, n = 9).",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),h,69.2,119742,DB00025,Antihemophilic Factor
,29534249,time to 0.05 I,"In nine patients receiving Kogenate, WAPPS and NONMEM produced different PK-parameter estimates; half-life was 15.0 and 12.3 hours and time to 0.05 IU mL-1 was 69.2 and 60.8 hours, respectively (p < 0.01, n = 9).",Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534249/),h,60.8,119743,DB00025,Antihemophilic Factor
,31314609,half-life,"Changes of the FVIII molecule (single chain), pegylation of B-domain deleted FVIII, and fusion with Fc succeeded to improve the FVIII half-life, about 4 hours.",Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31314609/),h,4,119766,DB00025,Antihemophilic Factor
,3936044,half-life (t1/2),"The isolated F.VIII:C immediately complexed with endogenous vWF in hemophilic plasma and was eliminated exponentially, with a half-life (t1/2) of about 9 hr.",Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3936044/),h,9,120201,DB00025,Antihemophilic Factor
,3936044,first-phase t1/2,"In contrast, F.VIII:C complexed to vWF in a therapeutic concentrate administered to hemophilic dogs was eliminated biexponentially with first-phase t1/2 of 3.2 hr and second-phase t1/2 of 9 hr.",Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3936044/),h,3.2,120202,DB00025,Antihemophilic Factor
,3936044,second-phase t1/2,"In contrast, F.VIII:C complexed to vWF in a therapeutic concentrate administered to hemophilic dogs was eliminated biexponentially with first-phase t1/2 of 3.2 hr and second-phase t1/2 of 9 hr.",Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3936044/),h,9,120203,DB00025,Antihemophilic Factor
,3936044,t1/2,"It was rapidly eliminated from plasma with a t1/2 of about 1 hr, as was the complexed F.VIII:C in the concentrate.",Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3936044/),h,1,120204,DB00025,Antihemophilic Factor
,19557401,trough level,"Model-predicted doses (based on age and body weight) to maintain a recommended 0.01 U/mL trough level of FVIII with administration on alternate days started at around 60 U/kg in the small children, decreasing to 10 U/kg or less in middle age.",Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19557401/),[u] / [ml],0.01,120838,DB00025,Antihemophilic Factor
,26239086,terminal half-life,The PK profile of rVWF was not influenced by rFVIII (mean VWF:RCo terminal half-life: 21.9 hours for rVWF and 19.6 hours for rVWF:rFVIII).,"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26239086/),h,21.9,122223,DB00025,Antihemophilic Factor
,26239086,terminal half-life,The PK profile of rVWF was not influenced by rFVIII (mean VWF:RCo terminal half-life: 21.9 hours for rVWF and 19.6 hours for rVWF:rFVIII).,"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26239086/),h,19.6,122224,DB00025,Antihemophilic Factor
,18305381,Bleeding episodes,Bleeding episodes (623) were reported in 47/56 subjects.,"Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18305381/),,62,122530,DB00025,Antihemophilic Factor
,22812621,clearance,"After intravenous administration to haemophilic dogs, the plasma concentration at the first sampling point was comparable for turoctocog alfa and N8-GP, and the clearance was estimated to be 6.5 and 3.9 mL h(-1) kg(-1) for turoctocog alfa and N8-GP respectively.",Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22812621/),[ml] / [h·kg],6.5,123292,DB00025,Antihemophilic Factor
,22812621,clearance,"After intravenous administration to haemophilic dogs, the plasma concentration at the first sampling point was comparable for turoctocog alfa and N8-GP, and the clearance was estimated to be 6.5 and 3.9 mL h(-1) kg(-1) for turoctocog alfa and N8-GP respectively.",Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22812621/),[ml] / [h·kg],3.9,123293,DB00025,Antihemophilic Factor
,1505144,terminal half-life,"The mean terminal half-life of FVIII:C was slightly assay-dependent, being 14h by a 1-stage clotting assay and 12h by a chromogenic assay.",Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505144/),h,14,123398,DB00025,Antihemophilic Factor
,1505144,terminal half-life,"The mean terminal half-life of FVIII:C was slightly assay-dependent, being 14h by a 1-stage clotting assay and 12h by a chromogenic assay.",Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505144/),h,12,123399,DB00025,Antihemophilic Factor
,8735792,clearance,"With a single-compartment model, we found median factor VIII clearance values of 3.11 (range 1.79-7.78) x 10(3) litres/kg per h, elimination rates of 5.0-19.4 x 10(-2)/h and a median half-life of 9.9 h (range 4.8-20.0 h).",Continuous infusion of factor VIII for surgery and major bleeding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735792/),[l] / [h·kg],3.11,125272,DB00025,Antihemophilic Factor
,8735792,elimination rates,"With a single-compartment model, we found median factor VIII clearance values of 3.11 (range 1.79-7.78) x 10(3) litres/kg per h, elimination rates of 5.0-19.4 x 10(-2)/h and a median half-life of 9.9 h (range 4.8-20.0 h).",Continuous infusion of factor VIII for surgery and major bleeding. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735792/),,5.0-19.4 x 10(,125273,DB00025,Antihemophilic Factor
,8735792,half-life,"With a single-compartment model, we found median factor VIII clearance values of 3.11 (range 1.79-7.78) x 10(3) litres/kg per h, elimination rates of 5.0-19.4 x 10(-2)/h and a median half-life of 9.9 h (range 4.8-20.0 h).",Continuous infusion of factor VIII for surgery and major bleeding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735792/),h,9.9,125274,DB00025,Antihemophilic Factor
,1904520,infusion rates,"Mean infusion rates of 1.99 +/- 0.45 IU/kg/h, 1.47 +/- 0.28 IU/kg/h, and 0.86 +/- 0.12 IU/kg/h were enough to maintain FVIII plasma levels of 1 IU/ml, 0.3 IU/ml, and 0.3 IU/ml, respectively.",[The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904520/),[iu] / [h·kg],1.99,125722,DB00025,Antihemophilic Factor
,1904520,infusion rates,"Mean infusion rates of 1.99 +/- 0.45 IU/kg/h, 1.47 +/- 0.28 IU/kg/h, and 0.86 +/- 0.12 IU/kg/h were enough to maintain FVIII plasma levels of 1 IU/ml, 0.3 IU/ml, and 0.3 IU/ml, respectively.",[The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904520/),[iu] / [h·kg],1.47,125723,DB00025,Antihemophilic Factor
,1904520,infusion rates,"Mean infusion rates of 1.99 +/- 0.45 IU/kg/h, 1.47 +/- 0.28 IU/kg/h, and 0.86 +/- 0.12 IU/kg/h were enough to maintain FVIII plasma levels of 1 IU/ml, 0.3 IU/ml, and 0.3 IU/ml, respectively.",[The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904520/),[iu] / [h·kg],0.86,125724,DB00025,Antihemophilic Factor
,1904520,infusion rates,"Mean infusion rates of 1.99 +/- 0.45 IU/kg/h, 1.47 +/- 0.28 IU/kg/h, and 0.86 +/- 0.12 IU/kg/h were enough to maintain FVIII plasma levels of 1 IU/ml, 0.3 IU/ml, and 0.3 IU/ml, respectively.",[The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904520/),,0,125725,DB00025,Antihemophilic Factor
,1904520,plasma,"Mean infusion rates of 1.99 +/- 0.45 IU/kg/h, 1.47 +/- 0.28 IU/kg/h, and 0.86 +/- 0.12 IU/kg/h were enough to maintain FVIII plasma levels of 1 IU/ml, 0.3 IU/ml, and 0.3 IU/ml, respectively.",[The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904520/),,0,125726,DB00025,Antihemophilic Factor
,26988074,half-life,"For all subjects, mean half-life of infused FVIII did not change significantly with exercise vs. at rest (577 ± 190 vs. 614 ± 163 min; P = 0.4131).",Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988074/),min,577,128500,DB00025,Antihemophilic Factor
,26988074,half-life,"For all subjects, mean half-life of infused FVIII did not change significantly with exercise vs. at rest (577 ± 190 vs. 614 ± 163 min; P = 0.4131).",Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988074/),min,614,128501,DB00025,Antihemophilic Factor
>,33645868,trough level,"Patients with trough level >3 IU/dL demonstrated lower annual bleeding rate (ABR) (p < .01), annual joint bleeding rate (AJBR) (p < .01) and annual spontaneous bleeding rate (ASBR) (p < .01).",Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33645868/),[iu] / [dl],3,133946,DB00025,Antihemophilic Factor
,28470862,consumption,"Mean N8-GP consumption on day of surgery was 80.0 IU kg-1 ; patients received a mean of 1.7 doses (median: 2, range: 1-3).",First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28470862/),[iu] / [kg],80.0,136391,DB00025,Antihemophilic Factor
,27587878,half-life,"Several novel recombinant FVIII (rFVIII) therapies for hemophilia A have been in clinical development, which aim to increase the half-life of FVIII (∼12 hours) and reduce dosing frequency by utilizing bioengineering techniques including PEGylation, Fc fusion, and single-chain design.",Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27587878/),h,∼12,138025,DB00025,Antihemophilic Factor
,27587878,half-life,"Therefore, the half-life of VWF (∼15 hours) appears to be the limiting factor that has confounded attempts to extend the half-life of rFVIII.",Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27587878/),h,∼15,138026,DB00025,Antihemophilic Factor
,9134639,half-lives,The mean in vivo half-lives of rFVIII and pdFVIII were both 14.7 h.,A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134639/),h,14.7,141526,DB00025,Antihemophilic Factor
,9134639,incremental recoveries,"In vivo incremental recoveries at baseline were 2.40%/IU/kg and 2.47%/IU/kg, respectively (p = 0.59).",A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134639/),[%] / [iu·kg],2.40,141527,DB00025,Antihemophilic Factor
,9134639,incremental recoveries,"In vivo incremental recoveries at baseline were 2.40%/IU/kg and 2.47%/IU/kg, respectively (p = 0.59).",A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134639/),[%] / [iu·kg],2.47,141528,DB00025,Antihemophilic Factor
≥,25196897,steady-state FVIII activity trough levels,Simulated dosing regimens predicted a greater proportion of subjects with steady-state FVIII activity trough levels of ≥ 1 IU dL(-1) (1%) with rFVIIIFc than with equivalent rFVIII regimens.,Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25196897/),[iu] / [dl],1,142030,DB00025,Antihemophilic Factor
≥,25196897,trough levels,"These results suggest that patients on rFVIIIFc prophylaxis can reduce their infusion frequency as compared with their prior FVIII regimen while maintaining low bleeding rates, affording more patients trough levels of ≥ 1 IU dL(-1) than with rFVIII products requiring more frequent dosing regimens.",Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25196897/),[iu] / [dl],1,142031,DB00025,Antihemophilic Factor
,3148473,clearance,"The pharmacokinetic parameters [mean (SD)] estimated from single-dose curves were: clearance 3.85 ml.h-1.kg-1, volume of distribution 58.2 ml.kg-1, mean residence time 15.9 h.",Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148473/),[ml] / [h·kg],3.85,142912,DB00025,Antihemophilic Factor
,3148473,volume of distribution,"The pharmacokinetic parameters [mean (SD)] estimated from single-dose curves were: clearance 3.85 ml.h-1.kg-1, volume of distribution 58.2 ml.kg-1, mean residence time 15.9 h.",Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148473/),[ml] / [kg],58.2,142913,DB00025,Antihemophilic Factor
,3148473,mean residence time,"The pharmacokinetic parameters [mean (SD)] estimated from single-dose curves were: clearance 3.85 ml.h-1.kg-1, volume of distribution 58.2 ml.kg-1, mean residence time 15.9 h.",Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148473/),h,15.9,142914,DB00025,Antihemophilic Factor
,3148473,clearance,"Parameters calculated from repeated-dose curves were: clearance 3.93 ml.h-1.kg-1, volume of distribution 61.8 ml.kg-1, and half-life 12.2 h.",Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148473/),[ml] / [h·kg],3.93,142915,DB00025,Antihemophilic Factor
,3148473,volume of distribution,"Parameters calculated from repeated-dose curves were: clearance 3.93 ml.h-1.kg-1, volume of distribution 61.8 ml.kg-1, and half-life 12.2 h.",Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148473/),[ml] / [kg],61.8,142916,DB00025,Antihemophilic Factor
,3148473,half-life,"Parameters calculated from repeated-dose curves were: clearance 3.93 ml.h-1.kg-1, volume of distribution 61.8 ml.kg-1, and half-life 12.2 h.",Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148473/),h,12.2,142917,DB00025,Antihemophilic Factor
,14629472,maximum rate of substrate conversion,"The maximum rate of substrate conversion, which indicates the highest thrombin concentration, was approximately 1900 FU min(-1) in a normal plasma pool.",Monitoring the bioavailability of FEIBA with a thrombin generation assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629472/),[fu] / [min],1900,143112,DB00025,Antihemophilic Factor
,14629472,half-life,"Plasma samples from FVIII inhibitor patients treated with a single dose of FEIBA had an improved thrombin maximum within an hour after treatment, which gradually returned to baseline values with a half-life of 4-7 h.",Monitoring the bioavailability of FEIBA with a thrombin generation assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629472/),h,4-7,143113,DB00025,Antihemophilic Factor
,30873482,MRT,"The MRT of FVIII concentrate increased in all patients (mean from 17.6 h to 19.9 h, p < 0.001, 95% CI for MRT change: +4.7 to -0.3 h).",Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30873482/),h,17.6,143774,DB00025,Antihemophilic Factor
,30873482,MRT,"The MRT of FVIII concentrate increased in all patients (mean from 17.6 h to 19.9 h, p < 0.001, 95% CI for MRT change: +4.7 to -0.3 h).",Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30873482/),h,19.9,143775,DB00025,Antihemophilic Factor
,32223610,dosing frequency,"Mean dosing frequency for prior prophylaxis was 2.8 per week for SHL rFVIII and 1.8 per week for EHL rFVIII, and 2.2 per week for all PWHA after switching to rurioctocog alfa pegol prophylaxis.",A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32223610/),,2.8,145214,DB00025,Antihemophilic Factor
,32223610,dosing frequency,"Mean dosing frequency for prior prophylaxis was 2.8 per week for SHL rFVIII and 1.8 per week for EHL rFVIII, and 2.2 per week for all PWHA after switching to rurioctocog alfa pegol prophylaxis.",A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32223610/),,1.8,145215,DB00025,Antihemophilic Factor
,32223610,time,The median time on rurioctocog alfa pegol prophylaxis was 12.0 months versus 80.8 months on previous SHL rFVIII and 13.5 months on previous EHL rFVIII.,A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32223610/),month,12.0,145216,DB00025,Antihemophilic Factor
,32223610,time,The median time on rurioctocog alfa pegol prophylaxis was 12.0 months versus 80.8 months on previous SHL rFVIII and 13.5 months on previous EHL rFVIII.,A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32223610/),month,80.8,145217,DB00025,Antihemophilic Factor
,32223610,time,The median time on rurioctocog alfa pegol prophylaxis was 12.0 months versus 80.8 months on previous SHL rFVIII and 13.5 months on previous EHL rFVIII.,A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32223610/),month,13.5,145218,DB00025,Antihemophilic Factor
,25767894,trough FVIII level,"After the first infusion, mean trough FVIII level in the Wilate group (31.7 IU/dl) was greater by 82% (P = 0.017) than that in the Haemate P/Humate P group (17.4 IU/dl).",Utility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767894/),[iu] / [dl],31.7,146531,DB00025,Antihemophilic Factor
,25767894,trough FVIII level,"After the first infusion, mean trough FVIII level in the Wilate group (31.7 IU/dl) was greater by 82% (P = 0.017) than that in the Haemate P/Humate P group (17.4 IU/dl).",Utility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767894/),[iu] / [dl],17.4,146532,DB00025,Antihemophilic Factor
,25767894,trough FVIII,"After the final infusion, mean trough FVIII of animals receiving Wilate (55.1 IU/dl) continued to exceed that of Haemate P/Humate P recipients (30.2 IU/dl) significantly (P < 0.001).",Utility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767894/),[iu] / [dl],55.1,146533,DB00025,Antihemophilic Factor
,25767894,trough FVIII,"After the final infusion, mean trough FVIII of animals receiving Wilate (55.1 IU/dl) continued to exceed that of Haemate P/Humate P recipients (30.2 IU/dl) significantly (P < 0.001).",Utility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767894/),[iu] / [dl],30.2,146534,DB00025,Antihemophilic Factor
,26806305,ED50,"Pharmacodynamics study revealed comparable ED50 values of SCT800 and Xyntha in the tail bleeding model: 14.78 and 15.81 IU/kg for bleeding time, respectively; 13.50 and 13.58 IU/kg for blood loss, respectively.","Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806305/),[iu] / [kg],14.78,146874,DB00025,Antihemophilic Factor
,26806305,ED50,"Pharmacodynamics study revealed comparable ED50 values of SCT800 and Xyntha in the tail bleeding model: 14.78 and 15.81 IU/kg for bleeding time, respectively; 13.50 and 13.58 IU/kg for blood loss, respectively.","Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806305/),[iu] / [kg],15.81,146875,DB00025,Antihemophilic Factor
,26806305,ED50,"Pharmacodynamics study revealed comparable ED50 values of SCT800 and Xyntha in the tail bleeding model: 14.78 and 15.81 IU/kg for bleeding time, respectively; 13.50 and 13.58 IU/kg for blood loss, respectively.","Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806305/),[iu] / [kg],13.50,146876,DB00025,Antihemophilic Factor
,26806305,ED50,"Pharmacodynamics study revealed comparable ED50 values of SCT800 and Xyntha in the tail bleeding model: 14.78 and 15.81 IU/kg for bleeding time, respectively; 13.50 and 13.58 IU/kg for blood loss, respectively.","Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26806305/),[iu] / [kg],13.58,146877,DB00025,Antihemophilic Factor
,15357767,half-life,Mean (+/-SD) half-life for rAHF-PFM was 12.0 +/- 4.3 h.,"Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357767/),h,12.0,148333,DB00025,Antihemophilic Factor
,15357767,bleeding rate,Subjects who were less adherent to the prophylactic regimen had a higher bleeding rate (9.9 episodes subject(-1) year(-1)) than subjects who were more adherent (4.4 episodes subject(-1) year(-1); P < 0.03).,"Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357767/),[episodes] / [subject·year],9.9,148334,DB00025,Antihemophilic Factor
,15357767,bleeding rate,Subjects who were less adherent to the prophylactic regimen had a higher bleeding rate (9.9 episodes subject(-1) year(-1)) than subjects who were more adherent (4.4 episodes subject(-1) year(-1); P < 0.03).,"Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357767/),[episodes] / [subject·year],4.4,148335,DB00025,Antihemophilic Factor
⁓,30151972,terminal half-life,"MarzAA showed linear dose-response PK across the 4.5-30 μg kg-1 dose range, with a terminal half-life of ⁓ 3.5 h.","Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30151972/),h,3.5,148692,DB00025,Antihemophilic Factor
,32326156,volume of central compartment (V1),"The estimated PK parameters (between-subject variability) were: 2640 mL (23.2%) for volume of central compartment (V1), 339 mL (46.8%) for volume of peripheral compartment (V2), 135 mL/h for Q (fixed random effect), and 204 mL/h (34.9%) for clearance (Cl).",Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32326156/),ml,2640,149950,DB00025,Antihemophilic Factor
,32326156,volume of peripheral compartment (V2),"The estimated PK parameters (between-subject variability) were: 2640 mL (23.2%) for volume of central compartment (V1), 339 mL (46.8%) for volume of peripheral compartment (V2), 135 mL/h for Q (fixed random effect), and 204 mL/h (34.9%) for clearance (Cl).",Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32326156/),ml,339,149951,DB00025,Antihemophilic Factor
,32326156,Q,"The estimated PK parameters (between-subject variability) were: 2640 mL (23.2%) for volume of central compartment (V1), 339 mL (46.8%) for volume of peripheral compartment (V2), 135 mL/h for Q (fixed random effect), and 204 mL/h (34.9%) for clearance (Cl).",Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32326156/),[ml] / [h],135,149952,DB00025,Antihemophilic Factor
,32326156,clearance (Cl),"The estimated PK parameters (between-subject variability) were: 2640 mL (23.2%) for volume of central compartment (V1), 339 mL (46.8%) for volume of peripheral compartment (V2), 135 mL/h for Q (fixed random effect), and 204 mL/h (34.9%) for clearance (Cl).",Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32326156/),[ml] / [h],204,149953,DB00025,Antihemophilic Factor
above,31749076,time to maintain FVIII levels,"A popPK model was developed and used to simulate pharmacokinetic endpoints difficult to observe from measured FVIII levels, including time to maintain FVIII levels above 1, 3, and 5 IU/dL after different BAY 94-9027 doses.",Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31749076/),i,1,152278,DB00025,Antihemophilic Factor
above,31749076,time to maintain FVIII levels,"A popPK model was developed and used to simulate pharmacokinetic endpoints difficult to observe from measured FVIII levels, including time to maintain FVIII levels above 1, 3, and 5 IU/dL after different BAY 94-9027 doses.",Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31749076/),i,3,152279,DB00025,Antihemophilic Factor
above,31749076,time to maintain FVIII levels,"A popPK model was developed and used to simulate pharmacokinetic endpoints difficult to observe from measured FVIII levels, including time to maintain FVIII levels above 1, 3, and 5 IU/dL after different BAY 94-9027 doses.",Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31749076/),i,5,152280,DB00025,Antihemophilic Factor
,31749076,time to maintain F,Median predicted time to maintain FVIII levels > 1 IU/dL in patients aged ≥ 12 years ranged from 120.1 to 127.2 h after single BAY 94-9027 doses of 45‒60 IU/kg.,Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31749076/),h,120.1 to 127.2,152281,DB00025,Antihemophilic Factor
,10669157,half-life,"Patients with blood group O exhibited a statistically significant shorter factor VIII half-life than patients with blood group A (15.3 versus 19.7 h, respectively) (p = 0.003).",The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669157/),h,15.3,156367,DB00025,Antihemophilic Factor
,10669157,half-life,"Patients with blood group O exhibited a statistically significant shorter factor VIII half-life than patients with blood group A (15.3 versus 19.7 h, respectively) (p = 0.003).",The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669157/),h,19.7,156368,DB00025,Antihemophilic Factor
,30654111,initial half-life,Plasma concentrations in male rats after a single 11-mg/kg intravenous dose of BAY 1025662 (approximating the cumulative PEG-60 exposure in patients during 30 years of BAY 94-9027 treatment) decreased with an initial half-life of 119 h (5 days) in the interval of 114-336 h post administration.,"Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654111/),h,119,158382,DB00025,Antihemophilic Factor
,30654111,terminal half-life of radioactivity elimination,The terminal half-life of radioactivity elimination was approximately 24 days in blood and plasma and was 31-68 days in the majority of other organs up to Day 168.,"Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654111/),d,24,158383,DB00025,Antihemophilic Factor
,30654111,terminal half-life of radioactivity elimination,The terminal half-life of radioactivity elimination was approximately 24 days in blood and plasma and was 31-68 days in the majority of other organs up to Day 168.,"Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654111/),d,31-68,158384,DB00025,Antihemophilic Factor
,29448295,annualized bleeding rate (ABR),Mean annualized bleeding rate (ABR) was 0.043/patient-year.,Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29448295/),1/[patient-year],0.043,158484,DB00025,Antihemophilic Factor
,29448295,spontaneous ABR,Mean spontaneous ABR was 0.011/patient-year.,Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29448295/),1/[patient-year],0.011,158485,DB00025,Antihemophilic Factor
,29448295,trough level,Geometric mean FXIII trough level was 0.17 IU/mL.,Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29448295/),[iu] / [ml],0.17,158486,DB00025,Antihemophilic Factor
,29448295,terminal half-life,Geometric terminal half-life was 13.7 days.,Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29448295/),d,13.7,158487,DB00025,Antihemophilic Factor
,10730521,in vivo half-life,The mean in vivo half-life of factor VIII clotting activity (F VIII:C) was 12.6 hours and the mean in vivo incremental recovery at baseline was 2.1 per cent/unit/kg.,The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730521/),h,12.6,164072,DB00025,Antihemophilic Factor
,10730521,in vivo incremental recovery,The mean in vivo half-life of factor VIII clotting activity (F VIII:C) was 12.6 hours and the mean in vivo incremental recovery at baseline was 2.1 per cent/unit/kg.,The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730521/),[%] / [kg·unit],2.1,164073,DB00025,Antihemophilic Factor
,10730521,clearance,The mean clearance was 3.22 ml/kg/h.,The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10730521/),[ml] / [h·kg],3.22,164074,DB00025,Antihemophilic Factor
>,33719084,trough,The proportion of subjects maintaining SS trough >1 and >3 IU/dL and time >10 IU/dL were estimated.,Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33719084/),[iu] / [dl],1,164887,DB00025,Antihemophilic Factor
>,33719084,trough,The proportion of subjects maintaining SS trough >1 and >3 IU/dL and time >10 IU/dL were estimated.,Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33719084/),[iu] / [dl],3,164888,DB00025,Antihemophilic Factor
,27832514,annualized bleeding rate,The median annualized bleeding rate was 59.9/year in the on-demand group and 1.9/year in the prophylaxis group for Japanese subjects.,"Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27832514/),1/[year],59.9,165078,DB00025,Antihemophilic Factor
,27832514,annualized bleeding rate,The median annualized bleeding rate was 59.9/year in the on-demand group and 1.9/year in the prophylaxis group for Japanese subjects.,"Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27832514/),1/[year],1.9,165079,DB00025,Antihemophilic Factor
,8547097,half-lives,"In contrast, inter-individual variation in half-life was large (range of half-lives 6-28.8 h).",Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547097/),h,6-28.8,166825,DB00025,Antihemophilic Factor
,33749970,recovery,"In LBM vs TBW and IBW vs TBW-based dosing, there was a non-significant increase in the proportion of participants with a targeted FVIII recovery of 2.00 ± 0.20 IU/dl per IU/kg, OR = 1.93 (95% CI: 0.44, 8.55) and OR = 3.65 (0.80, 16.72), respectively.","Factor VIII concentrate dosing with lean body mass, ideal body weight and total body weight in overweight and obesity: A randomized, controlled, open-label, 3 × 3 crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33749970/),,2,167859,DB00025,Antihemophilic Factor
,10215955,volume of distribution at steady state (Vss),"The mean increases in the volume of distribution at steady state (Vss) (13.2+/-9.3 dL) and mean residence time (MRT) (4.4+/-3.9 h) between the FVIII-only arm and the FVIII plus Stimate arm were highly significant (P = 0.0015 and P = 0. 0059, respectively).",Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215955/),dl,13.2,171276,DB00025,Antihemophilic Factor
,10215955,mean residence time (MRT),"The mean increases in the volume of distribution at steady state (Vss) (13.2+/-9.3 dL) and mean residence time (MRT) (4.4+/-3.9 h) between the FVIII-only arm and the FVIII plus Stimate arm were highly significant (P = 0.0015 and P = 0. 0059, respectively).",Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215955/),h,4.4,171277,DB00025,Antihemophilic Factor
,31495135,half-lives,"②The administration doses in the Kogenate FS and Advate groups were (31.5±13.1) IU/kg and (38.17±14.83) IU/kg, respectively; the half-lives of the two drugs were (12.3±3.5) h and (10.8±2.9) h, respectively; and the TAT 2% were (65.2±21.7) h and (57.0±17.9) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,12.3,172095,DB00025,Antihemophilic Factor
,31495135,half-lives,"②The administration doses in the Kogenate FS and Advate groups were (31.5±13.1) IU/kg and (38.17±14.83) IU/kg, respectively; the half-lives of the two drugs were (12.3±3.5) h and (10.8±2.9) h, respectively; and the TAT 2% were (65.2±21.7) h and (57.0±17.9) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,10.8,172096,DB00025,Antihemophilic Factor
,31495135,TAT,"②The administration doses in the Kogenate FS and Advate groups were (31.5±13.1) IU/kg and (38.17±14.83) IU/kg, respectively; the half-lives of the two drugs were (12.3±3.5) h and (10.8±2.9) h, respectively; and the TAT 2% were (65.2±21.7) h and (57.0±17.9) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,65.2,172097,DB00025,Antihemophilic Factor
,31495135,2%,"②The administration doses in the Kogenate FS and Advate groups were (31.5±13.1) IU/kg and (38.17±14.83) IU/kg, respectively; the half-lives of the two drugs were (12.3±3.5) h and (10.8±2.9) h, respectively; and the TAT 2% were (65.2±21.7) h and (57.0±17.9) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,65.2,172098,DB00025,Antihemophilic Factor
,31495135,2%,"②The administration doses in the Kogenate FS and Advate groups were (31.5±13.1) IU/kg and (38.17±14.83) IU/kg, respectively; the half-lives of the two drugs were (12.3±3.5) h and (10.8±2.9) h, respectively; and the TAT 2% were (65.2±21.7) h and (57.0±17.9) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,57.0,172099,DB00025,Antihemophilic Factor
,31495135,half-lives,"③In the Kogenate FS group, the drug half-lives in patients aged ≥12 and <12 years old were (12.7±3.7) h and (11.1±2.5) h, respectively; the TAT 2% were (68.6±22.9) h and (55.8±14.6) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,12.7,172100,DB00025,Antihemophilic Factor
,31495135,half-lives,"③In the Kogenate FS group, the drug half-lives in patients aged ≥12 and <12 years old were (12.7±3.7) h and (11.1±2.5) h, respectively; the TAT 2% were (68.6±22.9) h and (55.8±14.6) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,11.1,172101,DB00025,Antihemophilic Factor
,31495135,half-lives,"③In the Kogenate FS group, the drug half-lives in patients aged ≥12 and <12 years old were (12.7±3.7) h and (11.1±2.5) h, respectively; the TAT 2% were (68.6±22.9) h and (55.8±14.6) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,55.8,172102,DB00025,Antihemophilic Factor
,31495135,2%,"③In the Kogenate FS group, the drug half-lives in patients aged ≥12 and <12 years old were (12.7±3.7) h and (11.1±2.5) h, respectively; the TAT 2% were (68.6±22.9) h and (55.8±14.6) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,68.6,172103,DB00025,Antihemophilic Factor
,31495135,2%,"③In the Kogenate FS group, the drug half-lives in patients aged ≥12 and <12 years old were (12.7±3.7) h and (11.1±2.5) h, respectively; the TAT 2% were (68.6±22.9) h and (55.8±14.6) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,55.8,172104,DB00025,Antihemophilic Factor
,31495135,half-lives,"In the Advate group, the drug half-lives in patients aged ≥12 and <12 years old were (11.4±3.1) h and (9.4±1.8) h, respectively; and the TAT 2% were (61.1±18.0) h and (45.2±11.3) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,11.4,172105,DB00025,Antihemophilic Factor
,31495135,half-lives,"In the Advate group, the drug half-lives in patients aged ≥12 and <12 years old were (11.4±3.1) h and (9.4±1.8) h, respectively; and the TAT 2% were (61.1±18.0) h and (45.2±11.3) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,9.4,172106,DB00025,Antihemophilic Factor
,31495135,2%,"In the Advate group, the drug half-lives in patients aged ≥12 and <12 years old were (11.4±3.1) h and (9.4±1.8) h, respectively; and the TAT 2% were (61.1±18.0) h and (45.2±11.3) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,61.1,172107,DB00025,Antihemophilic Factor
,31495135,2%,"In the Advate group, the drug half-lives in patients aged ≥12 and <12 years old were (11.4±3.1) h and (9.4±1.8) h, respectively; and the TAT 2% were (61.1±18.0) h and (45.2±11.3) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,45.2,172108,DB00025,Antihemophilic Factor
,31495135,drug,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,13.3,172109,DB00025,Antihemophilic Factor
,31495135,half-lives,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,13.3,172110,DB00025,Antihemophilic Factor
,31495135,half-lives,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,12.3,172111,DB00025,Antihemophilic Factor
,31495135,half-lives,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,12.2,172112,DB00025,Antihemophilic Factor
,31495135,half-lives,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,11.6,172113,DB00025,Antihemophilic Factor
,31495135,2%,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,61.5,172114,DB00025,Antihemophilic Factor
,31495135,2%,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,63.9,172115,DB00025,Antihemophilic Factor
,31495135,2%,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,67.0,172116,DB00025,Antihemophilic Factor
,31495135,2%,"④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,68.0,172117,DB00025,Antihemophilic Factor
,31495135,drug,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,11.5,172118,DB00025,Antihemophilic Factor
,31495135,half-lives,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,11.5,172119,DB00025,Antihemophilic Factor
,31495135,half-lives,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,11.4,172120,DB00025,Antihemophilic Factor
,31495135,half-lives,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,11.0,172121,DB00025,Antihemophilic Factor
,31495135,half-lives,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,10.4,172122,DB00025,Antihemophilic Factor
,31495135,TAT,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,50.8,172123,DB00025,Antihemophilic Factor
,31495135,TAT,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,56.7,172124,DB00025,Antihemophilic Factor
,31495135,TAT,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,58.1,172125,DB00025,Antihemophilic Factor
,31495135,2%,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,50.8,172126,DB00025,Antihemophilic Factor
,31495135,2%,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,56.7,172127,DB00025,Antihemophilic Factor
,31495135,2%,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,58.2,172128,DB00025,Antihemophilic Factor
,31495135,2%,"In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively.",[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31495135/),h,58.1,172129,DB00025,Antihemophilic Factor
,10444285,clearance,"The mean (CV%) pharmacokinetic parameters estimated preoperatively by noncompartmental analysis were: clearance 3.2 mL kg-1 h-1 (35.5%), volume of distribution 52.1 mL kg-1 (40.2%), mean residence time 17.4 h (23.3%), and half-life 12.7 h (23.6%).",Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10444285/),[ml] / [h·kg],3.2,173312,DB00025,Antihemophilic Factor
,10444285,volume of distribution,"The mean (CV%) pharmacokinetic parameters estimated preoperatively by noncompartmental analysis were: clearance 3.2 mL kg-1 h-1 (35.5%), volume of distribution 52.1 mL kg-1 (40.2%), mean residence time 17.4 h (23.3%), and half-life 12.7 h (23.6%).",Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10444285/),[ml] / [kg],52.1,173313,DB00025,Antihemophilic Factor
,10444285,mean residence time,"The mean (CV%) pharmacokinetic parameters estimated preoperatively by noncompartmental analysis were: clearance 3.2 mL kg-1 h-1 (35.5%), volume of distribution 52.1 mL kg-1 (40.2%), mean residence time 17.4 h (23.3%), and half-life 12.7 h (23.6%).",Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10444285/),h,17.4,173314,DB00025,Antihemophilic Factor
,10444285,half-life,"The mean (CV%) pharmacokinetic parameters estimated preoperatively by noncompartmental analysis were: clearance 3.2 mL kg-1 h-1 (35.5%), volume of distribution 52.1 mL kg-1 (40.2%), mean residence time 17.4 h (23.3%), and half-life 12.7 h (23.6%).",Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10444285/),h,12.7,173315,DB00025,Antihemophilic Factor
,10444285,clearance,A progressive decrease in the clearance of FVIII from a mean of 3.1 mL kg-1 h-1 to 2.0 mL kg-1 h-1 (P = 0.125) over the first 5 days was observed.,Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10444285/),[ml] / [h·kg],3.1,173316,DB00025,Antihemophilic Factor
,10444285,clearance,A progressive decrease in the clearance of FVIII from a mean of 3.1 mL kg-1 h-1 to 2.0 mL kg-1 h-1 (P = 0.125) over the first 5 days was observed.,Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10444285/),[ml] / [h·kg],2.0,173317,DB00025,Antihemophilic Factor
>,11136378,half-life,"Patients were given 100 IU kg(-1) day(-1) until the inhibitor was shown to be absent by at least two negative assays 1 month apart, with normal recovery of infused factor VIII and normal half-life (> 6 h), as assessed after a 3-day washout period.",Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136378/),h,6,175370,DB00025,Antihemophilic Factor
,21726357,trough level,"Mean FVIII trough level after the first Wilate infusion was 50.6 IU dL⁻¹ with a 95% confidence interval (CI) of 43.1-58.2 IU dL⁻¹, compared with 31.8 IU dL⁻¹ (CI, 24.4-39.1 IU dL⁻¹) for Haemate P (P<0.001).",Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726357/),dl⁻¹·iu,50.6,177609,DB00025,Antihemophilic Factor
,21726357,trough level,"Mean FVIII trough level after the first Wilate infusion was 50.6 IU dL⁻¹ with a 95% confidence interval (CI) of 43.1-58.2 IU dL⁻¹, compared with 31.8 IU dL⁻¹ (CI, 24.4-39.1 IU dL⁻¹) for Haemate P (P<0.001).",Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726357/),dl⁻¹·iu,31.8,177610,DB00025,Antihemophilic Factor
,21726357,peak FVIII concentration,"Mean peak FVIII concentration after infusion was 67% higher in the Wilate group (167 vs. 100 IU dL⁻¹ , respectively; P = 0.002).",Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726357/),dl⁻¹·iu,167,177611,DB00025,Antihemophilic Factor
,21726357,peak FVIII concentration,"Mean peak FVIII concentration after infusion was 67% higher in the Wilate group (167 vs. 100 IU dL⁻¹ , respectively; P = 0.002).",Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726357/),dl⁻¹·iu,100,177612,DB00025,Antihemophilic Factor
,11686352,rate,"The CI rates and the corresponding FVII:C levels in plasma were similar in effective, partially effective and ineffective courses (median rate: 17, 20 and 20 microg/kg/h, respectively; median FVII:C:14, 18 and 18 IU/ml, respectively).",Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11686352/),[μg] / [h·kg],17,177818,DB00025,Antihemophilic Factor
,11686352,rate,"The CI rates and the corresponding FVII:C levels in plasma were similar in effective, partially effective and ineffective courses (median rate: 17, 20 and 20 microg/kg/h, respectively; median FVII:C:14, 18 and 18 IU/ml, respectively).",Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11686352/),[μg] / [h·kg],20,177819,DB00025,Antihemophilic Factor
,10423583,half-maximal effects,"Mean maximum pharmacodynamic activity for both factors was estimated to be three- to four-times higher than baseline activity, and the mean desmopressin concentrations that produce half-maximal effects were approximately 250 to 300 pg/mL.",The pharmacokinetics and pharmacodynamics of desmopressin: effect on plasma factor VIII:C and von Willebrand factor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423583/),,250 to 300,179011,DB00025,Antihemophilic Factor
,25721936,half-life in the circulation,"Recombinant Factor VIIa (rFVIIa) is utilized for on-demand treatment of bleeding episodes in hemophilia patients with neutralizing antibodies (inhibitors) against Factor VIII or Factor IX, but a short half-life in the circulation (~2.5hrs) limits its use in a prophylactic setting.",Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25721936/),h,2.5,179255,DB00025,Antihemophilic Factor
,17304146,clearance,"Population parameters were clearance 2.6 mL/h per kilogram (CV 45.4%), initial volume of distribution 2.8 L (CV 21.1%).",A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304146/),[ml] / [h·kg],2.6,179342,DB00025,Antihemophilic Factor
,17304146,initial volume of distribution,"Population parameters were clearance 2.6 mL/h per kilogram (CV 45.4%), initial volume of distribution 2.8 L (CV 21.1%).",A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304146/),l,2.8,179343,DB00025,Antihemophilic Factor
,32974838,AUCnorm,"Based on actual dosing, a significantly higher geometric mean (coefficient of variation [%CV]) AUCnorm was observed for damoctocog alfa pegol (43.8 h kg/dL [44.0]) versus rurioctocog alfa pegol (36.0 h kg/dL [40.1, P < 0.001]).","Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974838/),[h·kg] / [dl],43.8,179473,DB00025,Antihemophilic Factor
,32974838,AUCnorm,"Based on actual dosing, a significantly higher geometric mean (coefficient of variation [%CV]) AUCnorm was observed for damoctocog alfa pegol (43.8 h kg/dL [44.0]) versus rurioctocog alfa pegol (36.0 h kg/dL [40.1, P < 0.001]).","Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974838/),[h·kg] / [dl],36.0,179474,DB00025,Antihemophilic Factor
,32974838,time to reach 1,"Based on population PK modeling, median time to reach 1 IU/dL was 16 h longer for damoctocog alfa pegol compared with rurioctocog alfa pegol.","Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974838/),h,16,179475,DB00025,Antihemophilic Factor
,12188426,factor,The incremental factor VIII activity was 2.37 +/- 1.05 per cent (mean +/- SD) per U infused per kilogram body weight.,Lyophilized cryoprecipitate for children with hemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12188426/),%,2.37,180587,DB00025,Antihemophilic Factor
,12188426,half-life,The half-life of infused factor VIII was 10.5 hours.,Lyophilized cryoprecipitate for children with hemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12188426/),h,10.5,180588,DB00025,Antihemophilic Factor
,33733034,in vivo recovery,"There were minor PK differences between Eloctate and Adynovate, but some parameters did reach statistical significance, namely in vivo recovery (mean, 2.73 IU/dL per IU/kg vs 2.41 IU/dL per IU/kg), clearance (mean, 0.163 mL/h vs 0.194 mL/h), and volume of distribution at steady state (mean, 42.5 ml/kg vs 49.8 mL/kg).",Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33733034/),[iu] / [dl·iu·kg],2.73,180917,DB00025,Antihemophilic Factor
,33733034,in vivo recovery,"There were minor PK differences between Eloctate and Adynovate, but some parameters did reach statistical significance, namely in vivo recovery (mean, 2.73 IU/dL per IU/kg vs 2.41 IU/dL per IU/kg), clearance (mean, 0.163 mL/h vs 0.194 mL/h), and volume of distribution at steady state (mean, 42.5 ml/kg vs 49.8 mL/kg).",Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33733034/),[iu] / [dl·iu·kg],2.41,180918,DB00025,Antihemophilic Factor
,33733034,clearance,"There were minor PK differences between Eloctate and Adynovate, but some parameters did reach statistical significance, namely in vivo recovery (mean, 2.73 IU/dL per IU/kg vs 2.41 IU/dL per IU/kg), clearance (mean, 0.163 mL/h vs 0.194 mL/h), and volume of distribution at steady state (mean, 42.5 ml/kg vs 49.8 mL/kg).",Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33733034/),[ml] / [h],0.163,180919,DB00025,Antihemophilic Factor
,33733034,clearance,"There were minor PK differences between Eloctate and Adynovate, but some parameters did reach statistical significance, namely in vivo recovery (mean, 2.73 IU/dL per IU/kg vs 2.41 IU/dL per IU/kg), clearance (mean, 0.163 mL/h vs 0.194 mL/h), and volume of distribution at steady state (mean, 42.5 ml/kg vs 49.8 mL/kg).",Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33733034/),[ml] / [h],0.194,180920,DB00025,Antihemophilic Factor
,33733034,volume of distribution at steady state,"There were minor PK differences between Eloctate and Adynovate, but some parameters did reach statistical significance, namely in vivo recovery (mean, 2.73 IU/dL per IU/kg vs 2.41 IU/dL per IU/kg), clearance (mean, 0.163 mL/h vs 0.194 mL/h), and volume of distribution at steady state (mean, 42.5 ml/kg vs 49.8 mL/kg).",Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33733034/),[ml] / [kg],42.5,180921,DB00025,Antihemophilic Factor
,33733034,volume of distribution at steady state,"There were minor PK differences between Eloctate and Adynovate, but some parameters did reach statistical significance, namely in vivo recovery (mean, 2.73 IU/dL per IU/kg vs 2.41 IU/dL per IU/kg), clearance (mean, 0.163 mL/h vs 0.194 mL/h), and volume of distribution at steady state (mean, 42.5 ml/kg vs 49.8 mL/kg).",Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33733034/),[ml] / [kg],49.8,180922,DB00025,Antihemophilic Factor
,17439628,in vivo recovery,Median in vivo recovery of VWF ristocetin cofactor (VWF:RCo) was 1.9 IU dL(-1) (IU kg(-1))(-1) with an interquartile range (IQR) of 1.6-2.5 IU dL(-1) (IU kg(-1))(-1).,von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439628/),[iu] / [dl],1.9,183326,DB00025,Antihemophilic Factor
,17439628,response,"Median response, half-life and clearance were 74.0% (IQR, 55.5-100%), 15.6 h (IQR, 9.0-28.4 h) and 3.26 mL kg(-1) h(-1) (IQR, 2.29-5.21 mL kg(-1) h(-1)), respectively.",von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439628/),%,74.0,183327,DB00025,Antihemophilic Factor
,17439628,clearance,"Median response, half-life and clearance were 74.0% (IQR, 55.5-100%), 15.6 h (IQR, 9.0-28.4 h) and 3.26 mL kg(-1) h(-1) (IQR, 2.29-5.21 mL kg(-1) h(-1)), respectively.",von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439628/),[ml] / [h·kg],3.26,183328,DB00025,Antihemophilic Factor
,17439628,loading dose,"A PK-guided median VWF:RCo loading dose of 62.4 IU kg(-1) (IQR, 50.1-87.0 IU kg(-1)) was administered.",von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439628/),[iu] / [kg],62.4,183329,DB00025,Antihemophilic Factor
,17439628,trough VWF:RCo,Postoperative mean trough VWF:RCo levels of 62-73 IU dL(-1) were sufficient to prevent bleeding.,von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439628/),[iu] / [dl],62-73,183330,DB00025,Antihemophilic Factor
,23651313,annualized bleeding rate,"Overall, the median annualized bleeding rate was 3.0 (interquartile range: 8.5) bleeds patient(-1) year(-1) .","Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23651313/),[bleeds] / [patient·year],3.0,186098,DB00025,Antihemophilic Factor
,25274155,AUC ratio,In vivo recovery (IVR) of rFVIII was slightly higher than that of pd-FVIII and rFVIII/pd-FVIII AUC ratio was 1.37 in 11/17 patients.,Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25274155/),,1.37,186206,DB00025,Antihemophilic Factor
,29582559,bioavailability,"Results Subcutaneously administered N8-GP had a bioavailability, a first-order absorption rate and a half-life, respectively, of 24%, 0.094 h-1 and 14 h in F8-KO mice, and 26%, 0.33 h-1 and 15 h in cynomolgus monkeys.",Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582559/),%,24,186653,DB00025,Antihemophilic Factor
,29582559,first-order absorption rate,"Results Subcutaneously administered N8-GP had a bioavailability, a first-order absorption rate and a half-life, respectively, of 24%, 0.094 h-1 and 14 h in F8-KO mice, and 26%, 0.33 h-1 and 15 h in cynomolgus monkeys.",Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582559/),1/[h],0.094,186654,DB00025,Antihemophilic Factor
,29582559,first-order absorption rate,"Results Subcutaneously administered N8-GP had a bioavailability, a first-order absorption rate and a half-life, respectively, of 24%, 0.094 h-1 and 14 h in F8-KO mice, and 26%, 0.33 h-1 and 15 h in cynomolgus monkeys.",Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582559/),%,26,186655,DB00025,Antihemophilic Factor
,29582559,first-order absorption rate,"Results Subcutaneously administered N8-GP had a bioavailability, a first-order absorption rate and a half-life, respectively, of 24%, 0.094 h-1 and 14 h in F8-KO mice, and 26%, 0.33 h-1 and 15 h in cynomolgus monkeys.",Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582559/),1/[h],0.33,186656,DB00025,Antihemophilic Factor
,29582559,half-life,"Results Subcutaneously administered N8-GP had a bioavailability, a first-order absorption rate and a half-life, respectively, of 24%, 0.094 h-1 and 14 h in F8-KO mice, and 26%, 0.33 h-1 and 15 h in cynomolgus monkeys.",Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582559/),h,14,186657,DB00025,Antihemophilic Factor
,29582559,half-life,"Results Subcutaneously administered N8-GP had a bioavailability, a first-order absorption rate and a half-life, respectively, of 24%, 0.094 h-1 and 14 h in F8-KO mice, and 26%, 0.33 h-1 and 15 h in cynomolgus monkeys.",Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582559/),h,15,186658,DB00025,Antihemophilic Factor
,27216215,half-life,"The presence of FVIII-specific IgG subclass titer ≥1:40 antibodies was significantly associated with shorter FVIII half-life (median, 7.8 hours [interquartile range, 6.6-9.2 hours]) vs 10.4 hours [interquartile range, 8.9-13.8 hours]); the regression coefficient adjusted for log age and log von Willebrand factor (VWF) antigen was -0.32 (P = .004), accounting for 16.9% of the observed variability of FVIII half-life in our cohort.",FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216215/),h,7.8,187817,DB00025,Antihemophilic Factor
,27216215,half-life,"The presence of FVIII-specific IgG subclass titer ≥1:40 antibodies was significantly associated with shorter FVIII half-life (median, 7.8 hours [interquartile range, 6.6-9.2 hours]) vs 10.4 hours [interquartile range, 8.9-13.8 hours]); the regression coefficient adjusted for log age and log von Willebrand factor (VWF) antigen was -0.32 (P = .004), accounting for 16.9% of the observed variability of FVIII half-life in our cohort.",FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216215/),h,10.4,187818,DB00025,Antihemophilic Factor
,23731351,clearance,The average FIX clearance was 8.4 mL h(-1) kg(-1) .,Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23731351/),[ml] / [h·kg],8.4,190740,DB00025,Antihemophilic Factor
,23731351,Elimination half-life,Elimination half-life ranged between 14 and 27 h.,Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23731351/),h,14 and 27,190741,DB00025,Antihemophilic Factor
,23731351,trough FIX level,"Doses to produce a target trough FIX level (set at 0.01 IU mL(-1) ) at 72 h predicted by the Bayesian analysis, with blood sampling at either 24, 48 and 72 h or at only 24 and 48 h, were within -40% to +67% of those predicted using the three-compartment model, and within -57% to +125% for targeting a level at 96 h.",Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23731351/),[iu] / [ml],0.01,190742,DB00025,Antihemophilic Factor
,9157585,half-life,"The in vivo recovery and half-life of r-VIII SQ were similar to those of plasma-derived (pd) FVIII (mean half-life of r-VIII SQ, 11.7 h).","Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9157585/),h,11.7,194593,DB00025,Antihemophilic Factor
,25641556,maximum mean AUC0-∞,A maximum mean AUC0-∞ of 33 960 h μg mL(-1) and a maximum mean concentration of 247 μg mL(-1) was measured at the highest dose.,Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25641556/),[h·μg] / [ml],33 960,196633,DB00025,Antihemophilic Factor
,25641556,maximum mean concentration,A maximum mean AUC0-∞ of 33 960 h μg mL(-1) and a maximum mean concentration of 247 μg mL(-1) was measured at the highest dose.,Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25641556/),[μg] / [ml],247,196634,DB00025,Antihemophilic Factor
,14629459,one-stage/chromogenic ratio,"When the plasma standard was used, the one-stage/chromogenic ratio was 0.82 +/- 0.12 for FVIII levels above 25 U dL(-1) and 1.42 +/- 0.99 for FVIII levels below 25 U dL(-1).",A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629459/),,0.82,197559,DB00025,Antihemophilic Factor
,14629459,one-stage/chromogenic ratio,"When the plasma standard was used, the one-stage/chromogenic ratio was 0.82 +/- 0.12 for FVIII levels above 25 U dL(-1) and 1.42 +/- 0.99 for FVIII levels below 25 U dL(-1).",A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629459/),,1.42,197560,DB00025,Antihemophilic Factor
,12098083,recovery,"Kogenate, has shown a recovery of 2.7% per IU/kg and a half-life of 15.8 hours.","The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12098083/),[%] / [iu·kg],2.7,201600,DB00025,Antihemophilic Factor
,12098083,half-life,"Kogenate, has shown a recovery of 2.7% per IU/kg and a half-life of 15.8 hours.","The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12098083/),h,15.8,201601,DB00025,Antihemophilic Factor
,12098083,recovery,"For Recombinate, the recovery was 2.4% per IU/kg and the half-life was 14.7 hours.","The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12098083/),[%] / [iu·kg],2.4,201602,DB00025,Antihemophilic Factor
,12098083,half-life,"For Recombinate, the recovery was 2.4% per IU/kg and the half-life was 14.7 hours.","The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12098083/),h,14.7,201603,DB00025,Antihemophilic Factor
,12098083,half-life,"B-domain depleted rFVIII, Refacto, has shown a recovery of 2.7% per IU/kg and a half-life of 14 hours.","The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12098083/),h,14,201604,DB00025,Antihemophilic Factor
,11735604,CL,"Typical average CL in patients with normal vWF levels is 3 ml/h/kg, with an apparent volume of distribution at steady state (Vss) that slightly exceeds the plasma volume of the patient, and the average elimination half-life (t1/2) is around 14 hours.",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),[ml] / [h·kg],3,205345,DB00025,Antihemophilic Factor
,11735604,elimination half-life (t1/2),"Typical average CL in patients with normal vWF levels is 3 ml/h/kg, with an apparent volume of distribution at steady state (Vss) that slightly exceeds the plasma volume of the patient, and the average elimination half-life (t1/2) is around 14 hours.",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),h,14,205346,DB00025,Antihemophilic Factor
,11735604,CL,"The average CL of plasma-derived FIX seems to be 4 ml/h/kg, the Vss is 3 to 4 times the plasma volume and the elimination t1/2 often exceeds 30 hours.",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),[ml] / [h·kg],4,205347,DB00025,Antihemophilic Factor
exceeds,11735604,elimination t1/2,"The average CL of plasma-derived FIX seems to be 4 ml/h/kg, the Vss is 3 to 4 times the plasma volume and the elimination t1/2 often exceeds 30 hours.",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),h,30,205348,DB00025,Antihemophilic Factor
,11735604,CL,"FVIIa has a much higher CL (average of 33 ml/h/kg), and a short terminal t1/2 (at 2 to 3 hours).",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),[ml] / [h·kg],33,205349,DB00025,Antihemophilic Factor
,11735604,terminal t1/2,"FVIIa has a much higher CL (average of 33 ml/h/kg), and a short terminal t1/2 (at 2 to 3 hours).",Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735604/),h,2 to 3,205350,DB00025,Antihemophilic Factor
,28692108,annual,"Median annualised bleeding rate was 1.95 (1.94 and 1.97 in the younger and older cohorts, respectively).","Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692108/),,1.95,206704,DB00025,Antihemophilic Factor
,28692108,Half-life ratio,Half-life ratio between N8-GP and the patients' previous FVIII product was 1.85.,"Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. ",t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692108/),,1.85,206705,DB00025,Antihemophilic Factor
,9873772,half-life (T 1/2),We developed an aqueous-formulated human coagulation factor IX (hCFIX) with in vitro half-life (T 1/2) of 6 weeks at 37 degrees C and 18 months at 4 degrees C.,Novel delivery systems for coagulation proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873772/),weeks,6,207664,DB00025,Antihemophilic Factor
,9873772,half-life (T 1/2),We developed an aqueous-formulated human coagulation factor IX (hCFIX) with in vitro half-life (T 1/2) of 6 weeks at 37 degrees C and 18 months at 4 degrees C.,Novel delivery systems for coagulation proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873772/),month,18,207665,DB00025,Antihemophilic Factor
up to,9873772,bioavailability,"Upon bolus subcutaneous (s.c.) injection in animals, hCFIX had a bioavailability of up to 16% compared to intravenous (i.v.) dose.",Novel delivery systems for coagulation proteins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873772/),%,16,207666,DB00025,Antihemophilic Factor
up to,9873772,T 1/2,Freeze-dried human coagulation factor VIII (hCFVIII) formulated in non-aqueous solvents had in vitro T 1/2 up to 80 days at 37 degrees C.,Novel delivery systems for coagulation proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873772/),d,80,207667,DB00025,Antihemophilic Factor
,18503631,terminal phase half-life (t(1/2)),"The mean terminal phase half-life (t(1/2)) was 9.88 +/- 1.89 h, and the mean adjusted in vivo recovery (IVR) was 1.90 +/- 0.43 IU dL(-1) (IU kg(-1))(-1).","Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503631/),h,9.88,211394,DB00025,Antihemophilic Factor
,18503631,in vivo recovery (IVR),"The mean terminal phase half-life (t(1/2)) was 9.88 +/- 1.89 h, and the mean adjusted in vivo recovery (IVR) was 1.90 +/- 0.43 IU dL(-1) (IU kg(-1))(-1).","Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503631/),[iu] / [dl],1.90,211395,DB00025,Antihemophilic Factor
,18503631,t(1/2),"Over the 1-6-year age range, t(1/2) of rAHF-PFM increased by 0.40 h year(-1).","Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503631/),[h] / [year],0.40,211396,DB00025,Antihemophilic Factor
,18503631,annual joint bleeds,"Median (range) annual joint bleeds were 0.0 (0.0-5.8), 0.0 (0.0-6.1) and 14.2 (0.0-34.5) for standard prophylaxis, modified prophylaxis and on-demand treatment, respectively.","Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503631/),,0.0,211397,DB00025,Antihemophilic Factor
,18503631,annual joint bleeds,"Median (range) annual joint bleeds were 0.0 (0.0-5.8), 0.0 (0.0-6.1) and 14.2 (0.0-34.5) for standard prophylaxis, modified prophylaxis and on-demand treatment, respectively.","Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503631/),,0.0,211398,DB00025,Antihemophilic Factor
,18503631,annual joint bleeds,"Median (range) annual joint bleeds were 0.0 (0.0-5.8), 0.0 (0.0-6.1) and 14.2 (0.0-34.5) for standard prophylaxis, modified prophylaxis and on-demand treatment, respectively.","Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503631/),,14.2,211399,DB00025,Antihemophilic Factor
,2492760,half-life,"In this subgroup of patients, factor VIII half-life, measured immediately after surgery, was considerably shorter (mean = 9.6 hr, n = 10) than that determined in the same individual during the late operative period (mean = 17.8 hr, n = 10).",Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492760/),h,9.6,216119,DB00025,Antihemophilic Factor
,2492760,half-life,"In this subgroup of patients, factor VIII half-life, measured immediately after surgery, was considerably shorter (mean = 9.6 hr, n = 10) than that determined in the same individual during the late operative period (mean = 17.8 hr, n = 10).",Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492760/),h,17.8,216120,DB00025,Antihemophilic Factor
,2492760,steady-state concentration,"The nomogram, which is based on the ""single point after a single dose"" method, uses a value of factor VIII concentration measured at 10 hr after preoperative loading dose to predict the regimen producing the desired average steady-state concentration of factor VIII (30, 60, or 90 units/dl).",Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492760/),[units] / [dl],30,216121,DB00025,Antihemophilic Factor
,2492760,steady-state concentration,"The nomogram, which is based on the ""single point after a single dose"" method, uses a value of factor VIII concentration measured at 10 hr after preoperative loading dose to predict the regimen producing the desired average steady-state concentration of factor VIII (30, 60, or 90 units/dl).",Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492760/),[units] / [dl],60,216122,DB00025,Antihemophilic Factor
,2492760,steady-state concentration,"The nomogram, which is based on the ""single point after a single dose"" method, uses a value of factor VIII concentration measured at 10 hr after preoperative loading dose to predict the regimen producing the desired average steady-state concentration of factor VIII (30, 60, or 90 units/dl).",Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492760/),[units] / [dl],90,216123,DB00025,Antihemophilic Factor
,31038793,terminal half-lives,Mean (range) terminal half-lives with the OSA were 16.1 hours (10.4 to 23.4; Eloctate) and 16.7 hours (11.0 to 23.6; Adynovate) (NS).,Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31038793/),h,16.1,217157,DB00025,Antihemophilic Factor
,31038793,terminal half-lives,Mean (range) terminal half-lives with the OSA were 16.1 hours (10.4 to 23.4; Eloctate) and 16.7 hours (11.0 to 23.6; Adynovate) (NS).,Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31038793/),h,16.7,217158,DB00025,Antihemophilic Factor
,29848837,half-life (t1/2),"The mean FVIII half-life (t1/2) was 10.99 ± 3.45 h (range 5.52-20.02 h), the mean in vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24-3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg-1·h-1 (range 2.29-7.90 ml·kg-1·h-1).",Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29848837/),h,10.99,218159,DB00025,Antihemophilic Factor
,29848837,in vivo recovery (IVR),"The mean FVIII half-life (t1/2) was 10.99 ± 3.45 h (range 5.52-20.02 h), the mean in vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24-3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg-1·h-1 (range 2.29-7.90 ml·kg-1·h-1).",Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29848837/),[iu] / [dl·iu·kg],2.01,218160,DB00025,Antihemophilic Factor
,29848837,clearance (CL),"The mean FVIII half-life (t1/2) was 10.99 ± 3.45 h (range 5.52-20.02 h), the mean in vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24-3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg-1·h-1 (range 2.29-7.90 ml·kg-1·h-1).",Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29848837/),[ml] / [h·kg],4.34,218161,DB00025,Antihemophilic Factor
,29848837,t1/2,The t1/2of FVIII increased by 0.59 h per year.,Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29848837/),h,0,218162,DB00025,Antihemophilic Factor
,29848837,half-life,"Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h, t = 2.70, P = 0.01).",Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29848837/),h,9.40,218163,DB00025,Antihemophilic Factor
,29848837,half-life,"Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h, t = 2.70, P = 0.01).",Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29848837/),h,12.3,218164,DB00025,Antihemophilic Factor
,29848837,CL rates,"CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg-1·h-1, t = 2.53, P = 0.02).",Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29848837/),[ml] / [h·kg],5.02,218165,DB00025,Antihemophilic Factor
,29848837,CL rates,"CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg-1·h-1, t = 2.53, P = 0.02).",Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29848837/),[ml] / [h·kg],4.00,218166,DB00025,Antihemophilic Factor
,16353946,Half-lives,"Half-lives for dimer, heterotetramer, and monomer (3.33 hours, 2.83 days, and 3.94 hours for A(2), A(2)B(2), and B, respectively) were estimated, along with their variability in the population studied.",Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353946/),h,3.33,219678,DB00025,Antihemophilic Factor
,16353946,Half-lives,"Half-lives for dimer, heterotetramer, and monomer (3.33 hours, 2.83 days, and 3.94 hours for A(2), A(2)B(2), and B, respectively) were estimated, along with their variability in the population studied.",Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353946/),d,2.83,219679,DB00025,Antihemophilic Factor
,16353946,Half-lives,"Half-lives for dimer, heterotetramer, and monomer (3.33 hours, 2.83 days, and 3.94 hours for A(2), A(2)B(2), and B, respectively) were estimated, along with their variability in the population studied.",Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353946/),h,3.94,219680,DB00025,Antihemophilic Factor
,18078394,in vivo recovery,The mean in vivo recovery (IU dL(-1) per IU kg(-1)) was 1.9 +/- 0.6 for VWF:RCof; 2.1 +/- 0.6 for VWF:Ag and 2.6 +/- 0.6 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),[iu·iu] / [dl·kg],1.9,219998,DB00025,Antihemophilic Factor
,18078394,in vivo recovery,The mean in vivo recovery (IU dL(-1) per IU kg(-1)) was 1.9 +/- 0.6 for VWF:RCof; 2.1 +/- 0.6 for VWF:Ag and 2.6 +/- 0.6 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),[iu·iu] / [dl·kg],2.1,219999,DB00025,Antihemophilic Factor
,18078394,in vivo recovery,The mean in vivo recovery (IU dL(-1) per IU kg(-1)) was 1.9 +/- 0.6 for VWF:RCof; 2.1 +/- 0.6 for VWF:Ag and 2.6 +/- 0.6 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),[iu·iu] / [dl·kg],2.6,220000,DB00025,Antihemophilic Factor
,18078394,half-life,The mean half-life (h) was 14.4 +/- 10.5 for VWF:RCof; 27.5 +/- 11.0 for VWF:Ag and 33.4 +/- 16.4 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),h,14.4,220001,DB00025,Antihemophilic Factor
,18078394,half-life,The mean half-life (h) was 14.4 +/- 10.5 for VWF:RCof; 27.5 +/- 11.0 for VWF:Ag and 33.4 +/- 16.4 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),h,27.5,220002,DB00025,Antihemophilic Factor
,18078394,half-life,The mean half-life (h) was 14.4 +/- 10.5 for VWF:RCof; 27.5 +/- 11.0 for VWF:Ag and 33.4 +/- 16.4 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),h,33.4,220003,DB00025,Antihemophilic Factor
,24259187,terminal half-life,"Human simulations at 40 IU/kg project an increase in the terminal half-life and the time to reach a minimum therapeutic threshold of 0.01 IU/ml of 5.4 h and 40 h, respectively, compared with free FVIII.",Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24259187/),h,0.01,224181,DB00025,Antihemophilic Factor
,24259187,terminal half-life,"Human simulations at 40 IU/kg project an increase in the terminal half-life and the time to reach a minimum therapeutic threshold of 0.01 IU/ml of 5.4 h and 40 h, respectively, compared with free FVIII.",Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24259187/),h,5.4,224182,DB00025,Antihemophilic Factor
,24259187,time to reach a minimum therapeutic threshold,"Human simulations at 40 IU/kg project an increase in the terminal half-life and the time to reach a minimum therapeutic threshold of 0.01 IU/ml of 5.4 h and 40 h, respectively, compared with free FVIII.",Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24259187/),h,0.01,224183,DB00025,Antihemophilic Factor
,24259187,time to reach a minimum therapeutic threshold,"Human simulations at 40 IU/kg project an increase in the terminal half-life and the time to reach a minimum therapeutic threshold of 0.01 IU/ml of 5.4 h and 40 h, respectively, compared with free FVIII.",Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24259187/),h,5.4,224184,DB00025,Antihemophilic Factor
,24259187,time to reach a minimum therapeutic threshold,"Human simulations at 40 IU/kg project an increase in the terminal half-life and the time to reach a minimum therapeutic threshold of 0.01 IU/ml of 5.4 h and 40 h, respectively, compared with free FVIII.",Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24259187/),h,40,224185,DB00025,Antihemophilic Factor
,10979218,biological half-life (t1/2),"However, the biological half-life (t1/2) did not differ significantly between the 2 preparations (13.96 +/- 4.18 vs. 13.48 +/- 2.40 hours).","Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10979218/),h,13.96,227441,DB00025,Antihemophilic Factor
,10979218,biological half-life (t1/2),"However, the biological half-life (t1/2) did not differ significantly between the 2 preparations (13.96 +/- 4.18 vs. 13.48 +/- 2.40 hours).","Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10979218/),h,13.48,227442,DB00025,Antihemophilic Factor
,10979218,in vivo recovery,The in vivo recovery of FVIII was 67.9 +/- 11.3% after the administration of BAY 14-2222 and 74.4 +/- 5.3% after the administration of Kogenate.,"Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10979218/),%,67.9,227443,DB00025,Antihemophilic Factor
,10979218,in vivo recovery,The in vivo recovery of FVIII was 67.9 +/- 11.3% after the administration of BAY 14-2222 and 74.4 +/- 5.3% after the administration of Kogenate.,"Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10979218/),%,74.4,227444,DB00025,Antihemophilic Factor
,21070496,non-compartmental half-lives,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),h,14.1,231086,DB00025,Antihemophilic Factor
,21070496,non-compartmental half-lives,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),h,12.4,231087,DB00025,Antihemophilic Factor
,21070496,non-compartmental half-lives,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),h,12.1,231088,DB00025,Antihemophilic Factor
,21070496,clearances,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[ml] / [h·kg],3.6,231089,DB00025,Antihemophilic Factor
,21070496,clearances,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[ml] / [h·kg],3.2,231090,DB00025,Antihemophilic Factor
,21070496,clearances,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[ml] / [h·kg],3.1,231091,DB00025,Antihemophilic Factor
,21070496,MRTs,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),h,19.0,231092,DB00025,Antihemophilic Factor
,21070496,MRTs,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),h,17.3,231093,DB00025,Antihemophilic Factor
,21070496,MRTs,"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),h,17.4,231094,DB00025,Antihemophilic Factor
,21070496,AUC(0-48h),"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[h·iu] / [ml],14.3,231095,DB00025,Antihemophilic Factor
,21070496,AUC(0-48h),"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[h·iu] / [ml],15.4,231096,DB00025,Antihemophilic Factor
,21070496,AUC(0-48h),"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[h·iu] / [ml],16.6,231097,DB00025,Antihemophilic Factor
,21070496,AUC(0-∞),"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[h·iu] / [ml],15.9,231098,DB00025,Antihemophilic Factor
,21070496,AUC(0-∞),"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[h·iu] / [ml],16.4,231099,DB00025,Antihemophilic Factor
,21070496,AUC(0-∞),"Mean non-compartmental half-lives (h) were 14.1, 12.4 and 12.1, respectively (P = 0.45), mean clearances (mL h(-1) kg(-1)) were 3.6, 3.2 and 3.1, respectively (P = 0.051), MRTs (h) were 19.0, 17.3 and 17.4, respectively (P = 0.39) and mean AUC(0-48h) (h IU mL(-1)) were 14.3, 15.4 and 16.6, respectively (P = 0.051) and mean AUC(0-∞) (h IU mL(-1)) were 15.9, 16.4 and 17.9, respectively (P = 0.18).","Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070496/),[h·iu] / [ml],17.9,231100,DB00025,Antihemophilic Factor
,15166918,peak levels,"Pre-treatment and peak levels (1 h after Haemate-P loading dose) rose from 0.43-0.66 to 1.5-2.5 U/ml for FVIII:C, from 0.23-0.45 to 1.5-2.5 U/ml for vWF:Ag, from 0.10-< 0.20 to 1.5-2.5 U/ml for vWF:RCo, and from < 0.05-0.10 to 1.0-2.0 U/ml for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),[u] / [ml],0.43-0.66,232799,DB00025,Antihemophilic Factor
,15166918,peak levels,"Pre-treatment and peak levels (1 h after Haemate-P loading dose) rose from 0.43-0.66 to 1.5-2.5 U/ml for FVIII:C, from 0.23-0.45 to 1.5-2.5 U/ml for vWF:Ag, from 0.10-< 0.20 to 1.5-2.5 U/ml for vWF:RCo, and from < 0.05-0.10 to 1.0-2.0 U/ml for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),[u] / [ml],1.5-2.5,232800,DB00025,Antihemophilic Factor
,15166918,peak levels,"Pre-treatment and peak levels (1 h after Haemate-P loading dose) rose from 0.43-0.66 to 1.5-2.5 U/ml for FVIII:C, from 0.23-0.45 to 1.5-2.5 U/ml for vWF:Ag, from 0.10-< 0.20 to 1.5-2.5 U/ml for vWF:RCo, and from < 0.05-0.10 to 1.0-2.0 U/ml for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),[u] / [ml],0.23-0.45,232801,DB00025,Antihemophilic Factor
,15166918,peak levels,"Pre-treatment and peak levels (1 h after Haemate-P loading dose) rose from 0.43-0.66 to 1.5-2.5 U/ml for FVIII:C, from 0.23-0.45 to 1.5-2.5 U/ml for vWF:Ag, from 0.10-< 0.20 to 1.5-2.5 U/ml for vWF:RCo, and from < 0.05-0.10 to 1.0-2.0 U/ml for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),[u] / [ml],0.10-< 0.20,232802,DB00025,Antihemophilic Factor
,15166918,peak levels,"Pre-treatment and peak levels (1 h after Haemate-P loading dose) rose from 0.43-0.66 to 1.5-2.5 U/ml for FVIII:C, from 0.23-0.45 to 1.5-2.5 U/ml for vWF:Ag, from 0.10-< 0.20 to 1.5-2.5 U/ml for vWF:RCo, and from < 0.05-0.10 to 1.0-2.0 U/ml for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),[u] / [ml],0.05-0.10,232803,DB00025,Antihemophilic Factor
,15166918,peak levels,"Pre-treatment and peak levels (1 h after Haemate-P loading dose) rose from 0.43-0.66 to 1.5-2.5 U/ml for FVIII:C, from 0.23-0.45 to 1.5-2.5 U/ml for vWF:Ag, from 0.10-< 0.20 to 1.5-2.5 U/ml for vWF:RCo, and from < 0.05-0.10 to 1.0-2.0 U/ml for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),[u] / [ml],1.0-2.0,232804,DB00025,Antihemophilic Factor
,15166918,in vivo recoveries,"Mean in vivo recoveries per transfused IU FVIII:C/kg body weight were 3.2% for FVIII:C, 3.9% for vWF:RCo, and 2.8% for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),%,3.2,232805,DB00025,Antihemophilic Factor
,15166918,in vivo recoveries,"Mean in vivo recoveries per transfused IU FVIII:C/kg body weight were 3.2% for FVIII:C, 3.9% for vWF:RCo, and 2.8% for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),%,3.9,232806,DB00025,Antihemophilic Factor
,15166918,in vivo recoveries,"Mean in vivo recoveries per transfused IU FVIII:C/kg body weight were 3.2% for FVIII:C, 3.9% for vWF:RCo, and 2.8% for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),%,2.8,232807,DB00025,Antihemophilic Factor
,15166918,in vivo recoveries,"Mean in vivo recoveries per transfused IU vWF:RCo/kg were 1.45% for FVIII:C, 1.7% for vWF:RCo and 1.25% for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),%,1.45,232808,DB00025,Antihemophilic Factor
,15166918,in vivo recoveries,"Mean in vivo recoveries per transfused IU vWF:RCo/kg were 1.45% for FVIII:C, 1.7% for vWF:RCo and 1.25% for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),%,1.7,232809,DB00025,Antihemophilic Factor
,15166918,in vivo recoveries,"Mean in vivo recoveries per transfused IU vWF:RCo/kg were 1.45% for FVIII:C, 1.7% for vWF:RCo and 1.25% for vWF:CB.",Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),%,1.25,232810,DB00025,Antihemophilic Factor
,15166918,biological half-life times,The biological half-life times after transfused Haemate-P were about 12 h for both vWF:RCo and vWF:CB.,Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166918/),h,12,232811,DB00025,Antihemophilic Factor
,31294338,trough levels,"Adults/adolescents received 50 IU/kg every 4 days, achieving mean trough levels of 3.0 IU/dL (95% confidence interval, 2.6-3.5, adults) and 2.7 IU/dL (1.8-4.0, adolescents).",Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31294338/),[iu] / [dl],3.0,234075,DB00025,Antihemophilic Factor
,31294338,trough levels,"Adults/adolescents received 50 IU/kg every 4 days, achieving mean trough levels of 3.0 IU/dL (95% confidence interval, 2.6-3.5, adults) and 2.7 IU/dL (1.8-4.0, adolescents).",Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31294338/),[iu] / [dl],2.7,234076,DB00025,Antihemophilic Factor
,31294338,trough levels,"Children received 60 IU/kg twice weekly, leading to mean trough levels of 1.2 IU/dL (0.8-1.6, 0- to 5-year-olds) and 2.0 IU/dL (1.5-2.7, 6- to 11-year-olds).",Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31294338/),[iu] / [dl],1.2,234077,DB00025,Antihemophilic Factor
,31294338,trough levels,"Children received 60 IU/kg twice weekly, leading to mean trough levels of 1.2 IU/dL (0.8-1.6, 0- to 5-year-olds) and 2.0 IU/dL (1.5-2.7, 6- to 11-year-olds).",Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31294338/),[iu] / [dl],2.0,234078,DB00025,Antihemophilic Factor
,8560482,relative mobilities (M(r)),"Recombinant human (rh) factor VIII is a glycoprotein consisting of multiple polypeptides with relative mobilities (M(r)) ranging from 80,000 to 210,000.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),,"80,",235401,DB00025,Antihemophilic Factor
,8560482,relative mobilities (M(r)),"Recombinant human (rh) factor VIII is a glycoprotein consisting of multiple polypeptides with relative mobilities (M(r)) ranging from 80,000 to 210,000.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),,210,235402,DB00025,Antihemophilic Factor
,8560482,clearance,"The pharmacokinetics of rh factor VIII in mouse were as follows: clearance, 27.7 ml/hr/kg; initial volume of distribution, 72 ml/kg; steady-state volume of distribution, 148 ml/kg; and terminal half-life, 4.1 hr.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),[ml] / [h·kg],27.7,235403,DB00025,Antihemophilic Factor
,8560482,initial volume of distribution,"The pharmacokinetics of rh factor VIII in mouse were as follows: clearance, 27.7 ml/hr/kg; initial volume of distribution, 72 ml/kg; steady-state volume of distribution, 148 ml/kg; and terminal half-life, 4.1 hr.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),[ml] / [kg],72,235404,DB00025,Antihemophilic Factor
,8560482,steady-state volume of distribution,"The pharmacokinetics of rh factor VIII in mouse were as follows: clearance, 27.7 ml/hr/kg; initial volume of distribution, 72 ml/kg; steady-state volume of distribution, 148 ml/kg; and terminal half-life, 4.1 hr.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),[ml] / [kg],148,235405,DB00025,Antihemophilic Factor
,8560482,terminal half-life,"The pharmacokinetics of rh factor VIII in mouse were as follows: clearance, 27.7 ml/hr/kg; initial volume of distribution, 72 ml/kg; steady-state volume of distribution, 148 ml/kg; and terminal half-life, 4.1 hr.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),h,4.1,235406,DB00025,Antihemophilic Factor
,8560482,clearance,"In rat, the mean estimates were as follows: clearance, 16.0 ml/hr/kg; initial volume of distribution, 41 ml/kg; steady-state volume of distribution, 125 ml/kg; and terminal half-life, 5.5 hr.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),[ml] / [h·kg],16.0,235407,DB00025,Antihemophilic Factor
,8560482,initial volume of distribution,"In rat, the mean estimates were as follows: clearance, 16.0 ml/hr/kg; initial volume of distribution, 41 ml/kg; steady-state volume of distribution, 125 ml/kg; and terminal half-life, 5.5 hr.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),[ml] / [kg],41,235408,DB00025,Antihemophilic Factor
,8560482,steady-state volume of distribution,"In rat, the mean estimates were as follows: clearance, 16.0 ml/hr/kg; initial volume of distribution, 41 ml/kg; steady-state volume of distribution, 125 ml/kg; and terminal half-life, 5.5 hr.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),[ml] / [kg],125,235409,DB00025,Antihemophilic Factor
,8560482,terminal half-life,"In rat, the mean estimates were as follows: clearance, 16.0 ml/hr/kg; initial volume of distribution, 41 ml/kg; steady-state volume of distribution, 125 ml/kg; and terminal half-life, 5.5 hr.",Pharmacokinetics and interspecies scaling of recombinant human factor VIII. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560482/),h,5.5,235410,DB00025,Antihemophilic Factor
,32078672,half-life ceiling,"Endogenous von Willebrand factor (VWF) stabilizes and protects FVIII from degradation and clearance, but it also subjects FVIII to a half-life ceiling of ∼15 to 19 hours.","BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078672/),h,∼15 to,236406,DB00025,Antihemophilic Factor
,32078672,half-life ceiling,"Endogenous von Willebrand factor (VWF) stabilizes and protects FVIII from degradation and clearance, but it also subjects FVIII to a half-life ceiling of ∼15 to 19 hours.","BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078672/),h,19,236407,DB00025,Antihemophilic Factor
,32078672,half-life,"Plasma FVIII half-life after BIVV001 administration in mice and monkeys was 25 to 31 hours and 33 to 34 hours, respectively, representing a three- to fourfold increase in FVIII half-life.","BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078672/),h,25 to 31,236408,DB00025,Antihemophilic Factor
,32078672,half-life,"Plasma FVIII half-life after BIVV001 administration in mice and monkeys was 25 to 31 hours and 33 to 34 hours, respectively, representing a three- to fourfold increase in FVIII half-life.","BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078672/),h,33 to 34,236409,DB00025,Antihemophilic Factor
,21689209,in vivo recovery (IVR),"The group median incremental in vivo recovery (IVR) for VWF:RCo was 2.4 IU dL⁻¹ per IU kg⁻¹, for VWF:Ag 2.3 IU dL⁻¹ kg⁻¹ and for FVIII:C was 2.7 IU dL⁻¹ per IU kg⁻¹.",Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21689209/),[dl⁻¹·iu] / [iu·kg⁻¹],2.4,239608,DB00025,Antihemophilic Factor
,21689209,in vivo recovery (IVR),"The group median incremental in vivo recovery (IVR) for VWF:RCo was 2.4 IU dL⁻¹ per IU kg⁻¹, for VWF:Ag 2.3 IU dL⁻¹ kg⁻¹ and for FVIII:C was 2.7 IU dL⁻¹ per IU kg⁻¹.",Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21689209/),dl⁻¹·iu·kg⁻¹,2.3,239609,DB00025,Antihemophilic Factor
,21689209,in vivo recovery (IVR),"The group median incremental in vivo recovery (IVR) for VWF:RCo was 2.4 IU dL⁻¹ per IU kg⁻¹, for VWF:Ag 2.3 IU dL⁻¹ kg⁻¹ and for FVIII:C was 2.7 IU dL⁻¹ per IU kg⁻¹.",Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21689209/),[dl⁻¹·iu] / [iu·kg⁻¹],2.7,239610,DB00025,Antihemophilic Factor
,3087013,clearance,The following pharmacokinetic parameters of Factor VIII (mean +/- SD) were estimated: clearance = 3.83 +/- 0.99 ml/h/kg; mean residence time = 15.9 +/- 4.5 h; volume of distribution at steady state = 55.6 +/- 9.3 ml/kg; in-vivo recovery = 129 +/- 29%.,Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087013/),[ml] / [h·kg],3.83,241126,DB00025,Antihemophilic Factor
,3087013,mean residence time,The following pharmacokinetic parameters of Factor VIII (mean +/- SD) were estimated: clearance = 3.83 +/- 0.99 ml/h/kg; mean residence time = 15.9 +/- 4.5 h; volume of distribution at steady state = 55.6 +/- 9.3 ml/kg; in-vivo recovery = 129 +/- 29%.,Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087013/),h,15.9,241127,DB00025,Antihemophilic Factor
,3087013,volume of distribution at steady state,The following pharmacokinetic parameters of Factor VIII (mean +/- SD) were estimated: clearance = 3.83 +/- 0.99 ml/h/kg; mean residence time = 15.9 +/- 4.5 h; volume of distribution at steady state = 55.6 +/- 9.3 ml/kg; in-vivo recovery = 129 +/- 29%.,Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087013/),[ml] / [kg],55.6,241128,DB00025,Antihemophilic Factor
,3087013,in-vivo recovery,The following pharmacokinetic parameters of Factor VIII (mean +/- SD) were estimated: clearance = 3.83 +/- 0.99 ml/h/kg; mean residence time = 15.9 +/- 4.5 h; volume of distribution at steady state = 55.6 +/- 9.3 ml/kg; in-vivo recovery = 129 +/- 29%.,Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087013/),%,129,241129,DB00025,Antihemophilic Factor
,11882082,clearances,"The respective clearances (mL h(-1)kg(-1)) at doses 50 U, 25 U or 10 U kg (-1) were 1.32, 1.33 1.8 (bioassay) and 2.54, 2.93, 9.43 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[ml] / [h],1.32,242452,DB00025,Antihemophilic Factor
,11882082,clearances,"The respective clearances (mL h(-1)kg(-1)) at doses 50 U, 25 U or 10 U kg (-1) were 1.32, 1.33 1.8 (bioassay) and 2.54, 2.93, 9.43 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[ml] / [h],1.33,242453,DB00025,Antihemophilic Factor
,11882082,clearances,"The respective clearances (mL h(-1)kg(-1)) at doses 50 U, 25 U or 10 U kg (-1) were 1.32, 1.33 1.8 (bioassay) and 2.54, 2.93, 9.43 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[ml] / [h],1.8,242454,DB00025,Antihemophilic Factor
,11882082,clearances,"The respective clearances (mL h(-1)kg(-1)) at doses 50 U, 25 U or 10 U kg (-1) were 1.32, 1.33 1.8 (bioassay) and 2.54, 2.93, 9.43 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[ml] / [h],2.54,242455,DB00025,Antihemophilic Factor
,11882082,clearances,"The respective clearances (mL h(-1)kg(-1)) at doses 50 U, 25 U or 10 U kg (-1) were 1.32, 1.33 1.8 (bioassay) and 2.54, 2.93, 9.43 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[ml] / [h],2.93,242456,DB00025,Antihemophilic Factor
,11882082,clearances,"The respective clearances (mL h(-1)kg(-1)) at doses 50 U, 25 U or 10 U kg (-1) were 1.32, 1.33 1.8 (bioassay) and 2.54, 2.93, 9.43 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[ml] / [h],9.43,242457,DB00025,Antihemophilic Factor
,11882082,half-lives,"The respective half-lives (h) at doses 50 U, 25 U, and 10 U kg (-1) were 23.71, 16.54, 25.17 (bioassay) and 15.71, 17.39, and 10.66 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),h,23.71,242458,DB00025,Antihemophilic Factor
,11882082,half-lives,"The respective half-lives (h) at doses 50 U, 25 U, and 10 U kg (-1) were 23.71, 16.54, 25.17 (bioassay) and 15.71, 17.39, and 10.66 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),h,16.54,242459,DB00025,Antihemophilic Factor
,11882082,half-lives,"The respective half-lives (h) at doses 50 U, 25 U, and 10 U kg (-1) were 23.71, 16.54, 25.17 (bioassay) and 15.71, 17.39, and 10.66 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),h,25.17,242460,DB00025,Antihemophilic Factor
,11882082,half-lives,"The respective half-lives (h) at doses 50 U, 25 U, and 10 U kg (-1) were 23.71, 16.54, 25.17 (bioassay) and 15.71, 17.39, and 10.66 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),h,15.71,242461,DB00025,Antihemophilic Factor
,11882082,half-lives,"The respective half-lives (h) at doses 50 U, 25 U, and 10 U kg (-1) were 23.71, 16.54, 25.17 (bioassay) and 15.71, 17.39, and 10.66 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),h,17.39,242462,DB00025,Antihemophilic Factor
,11882082,half-lives,"The respective half-lives (h) at doses 50 U, 25 U, and 10 U kg (-1) were 23.71, 16.54, 25.17 (bioassay) and 15.71, 17.39, and 10.66 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),h,10.66,242463,DB00025,Antihemophilic Factor
,11882082,recoveries,"The respective recoveries (u dL(-1)/u kg(-1)) at doses 50 U, 25 U, and 10 U kg (-1) were 2.32, 2.44, 2.7 (bioassay) and 1.42, 1.16 and 0.9 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[u·u] / [dl·kg],2.32,242464,DB00025,Antihemophilic Factor
,11882082,recoveries,"The respective recoveries (u dL(-1)/u kg(-1)) at doses 50 U, 25 U, and 10 U kg (-1) were 2.32, 2.44, 2.7 (bioassay) and 1.42, 1.16 and 0.9 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[u·u] / [dl·kg],2.44,242465,DB00025,Antihemophilic Factor
,11882082,recoveries,"The respective recoveries (u dL(-1)/u kg(-1)) at doses 50 U, 25 U, and 10 U kg (-1) were 2.32, 2.44, 2.7 (bioassay) and 1.42, 1.16 and 0.9 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[u·u] / [dl·kg],2.7,242466,DB00025,Antihemophilic Factor
,11882082,recoveries,"The respective recoveries (u dL(-1)/u kg(-1)) at doses 50 U, 25 U, and 10 U kg (-1) were 2.32, 2.44, 2.7 (bioassay) and 1.42, 1.16 and 0.9 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[u·u] / [dl·kg],1.42,242467,DB00025,Antihemophilic Factor
,11882082,recoveries,"The respective recoveries (u dL(-1)/u kg(-1)) at doses 50 U, 25 U, and 10 U kg (-1) were 2.32, 2.44, 2.7 (bioassay) and 1.42, 1.16 and 0.9 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[u·u] / [dl·kg],1.16,242468,DB00025,Antihemophilic Factor
,11882082,recoveries,"The respective recoveries (u dL(-1)/u kg(-1)) at doses 50 U, 25 U, and 10 U kg (-1) were 2.32, 2.44, 2.7 (bioassay) and 1.42, 1.16 and 0.9 (chromogenic).",Single-dose pharmacokinetics of porcine factor VIII (Hyate C). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11882082/),[u·u] / [dl·kg],0.9,242469,DB00025,Antihemophilic Factor
,34089210,Total exposure,Total exposure was 5643 exposure days.,"Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089210/),,5643,243206,DB00025,Antihemophilic Factor
,22512291,C(max),"Mean C(max) appeared higher for OBI-1 (OSCA: 176.00 U dL(-1), standard deviation ± 88.00; chromogenic: 151.00 ± 31.51 U dL(-1)) than Hyate:C (OSCA: 82.3 ± 19.22 U dL(-1); chromogenic: 52.67 ± 13.8 U dL(-1)).","Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22512291/),[u] / [dl],176.00,244097,DB00025,Antihemophilic Factor
,22512291,C(max),"Mean C(max) appeared higher for OBI-1 (OSCA: 176.00 U dL(-1), standard deviation ± 88.00; chromogenic: 151.00 ± 31.51 U dL(-1)) than Hyate:C (OSCA: 82.3 ± 19.22 U dL(-1); chromogenic: 52.67 ± 13.8 U dL(-1)).","Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22512291/),[u] / [dl],151.00,244098,DB00025,Antihemophilic Factor
,22512291,C(max),"Mean C(max) appeared higher for OBI-1 (OSCA: 176.00 U dL(-1), standard deviation ± 88.00; chromogenic: 151.00 ± 31.51 U dL(-1)) than Hyate:C (OSCA: 82.3 ± 19.22 U dL(-1); chromogenic: 52.67 ± 13.8 U dL(-1)).","Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22512291/),[u] / [dl],82.3,244099,DB00025,Antihemophilic Factor
,22512291,C(max),"Mean C(max) appeared higher for OBI-1 (OSCA: 176.00 U dL(-1), standard deviation ± 88.00; chromogenic: 151.00 ± 31.51 U dL(-1)) than Hyate:C (OSCA: 82.3 ± 19.22 U dL(-1); chromogenic: 52.67 ± 13.8 U dL(-1)).","Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22512291/),[u] / [dl],52.67,244100,DB00025,Antihemophilic Factor
,22512291,AUC,Mean AUC also appeared higher for OBI-1 (OSCA: 2082.87 ± 1323.43 U h(-1) dL(-1) ; chromogenic: 1817.28 ± 625.14 U h(-1) dL(-1)) than Hyate:C (OSCA: 1177.8 ± 469.49 U h(-1) dL(-1); chromogenic: 707.61 ± 420.05 U h(-1) dL(-1)).,"Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22512291/),[u] / [dl·h],2082.87,244101,DB00025,Antihemophilic Factor
,22512291,AUC,Mean AUC also appeared higher for OBI-1 (OSCA: 2082.87 ± 1323.43 U h(-1) dL(-1) ; chromogenic: 1817.28 ± 625.14 U h(-1) dL(-1)) than Hyate:C (OSCA: 1177.8 ± 469.49 U h(-1) dL(-1); chromogenic: 707.61 ± 420.05 U h(-1) dL(-1)).,"Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22512291/),[u] / [dl·h],1817.28,244102,DB00025,Antihemophilic Factor
,22512291,AUC,Mean AUC also appeared higher for OBI-1 (OSCA: 2082.87 ± 1323.43 U h(-1) dL(-1) ; chromogenic: 1817.28 ± 625.14 U h(-1) dL(-1)) than Hyate:C (OSCA: 1177.8 ± 469.49 U h(-1) dL(-1); chromogenic: 707.61 ± 420.05 U h(-1) dL(-1)).,"Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22512291/),[u] / [dl·h],1177.8,244103,DB00025,Antihemophilic Factor
,22512291,AUC,Mean AUC also appeared higher for OBI-1 (OSCA: 2082.87 ± 1323.43 U h(-1) dL(-1) ; chromogenic: 1817.28 ± 625.14 U h(-1) dL(-1)) than Hyate:C (OSCA: 1177.8 ± 469.49 U h(-1) dL(-1); chromogenic: 707.61 ± 420.05 U h(-1) dL(-1)).,"Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22512291/),[u] / [dl·h],707.61,244104,DB00025,Antihemophilic Factor
,32851288,total factor consumption,"In the PK-tailored group, the median annual joint bleeding rate was reduced from 7.8 in phase I to 1.4 in phase II, mean annual total factor consumption increased from 1619.0 IU/kg in phase I to 2401.9 IU/kg in phase II, and median infusion frequency for prophylaxis increased from 104 times/year in phase I to 156 times/year in phase II (P < 0.05).",PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32851288/),[iu] / [kg],1619.0,245321,DB00025,Antihemophilic Factor
,32851288,total factor consumption,"In the PK-tailored group, the median annual joint bleeding rate was reduced from 7.8 in phase I to 1.4 in phase II, mean annual total factor consumption increased from 1619.0 IU/kg in phase I to 2401.9 IU/kg in phase II, and median infusion frequency for prophylaxis increased from 104 times/year in phase I to 156 times/year in phase II (P < 0.05).",PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32851288/),[iu] / [kg],2401.9,245322,DB00025,Antihemophilic Factor
,32433829,area under the concentration-time curve from time 0 to infinity,"Mean (± standard deviation) area under the concentration-time curve from time 0 to infinity and maximum concentration were 287 ± 74.2 μg⋅d/mL and 7.11 ± 1.77 μg/mL, respectively, with a terminal half-life of 26.7 (±4.3) days.","Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32433829/),[d·μg] / [ml],287,246783,DB00025,Antihemophilic Factor
,32433829,maximum concentration,"Mean (± standard deviation) area under the concentration-time curve from time 0 to infinity and maximum concentration were 287 ± 74.2 μg⋅d/mL and 7.11 ± 1.77 μg/mL, respectively, with a terminal half-life of 26.7 (±4.3) days.","Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32433829/),[μg] / [ml],7.11,246784,DB00025,Antihemophilic Factor
,32433829,terminal half-life,"Mean (± standard deviation) area under the concentration-time curve from time 0 to infinity and maximum concentration were 287 ± 74.2 μg⋅d/mL and 7.11 ± 1.77 μg/mL, respectively, with a terminal half-life of 26.7 (±4.3) days.","Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32433829/),d,26.7,246785,DB00025,Antihemophilic Factor
,15357768,terminal elimination half-life,"Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively.","Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357768/),h,11.8,247349,DB00025,Antihemophilic Factor
,15357768,terminal elimination half-life,"Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively.","Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357768/),h,11.9,247350,DB00025,Antihemophilic Factor
,15357768,incremental recovery,"Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively.","Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357768/),[iu·iu] / [dl·kg],2.3,247351,DB00025,Antihemophilic Factor
,15357768,incremental recovery,"Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively.","Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357768/),[iu·iu] / [dl·kg],2.0,247352,DB00025,Antihemophilic Factor
,18300296,"area under the activity curve, AUAC(0-24h)","Pharmacokinetic studies following intravenous dosing indicated that the systemic exposure (area under the activity curve, AUAC(0-24h)) of PEGylated liposomal-rFVIII was approximately 59 IU/mL x h and significantly higher than that of non-PEGylated liposomal-rFVIII (AUAC(0-24h) approximately 36 IU/mL x h).",Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300296/),[iu] / [h·ml],59,249466,DB00025,Antihemophilic Factor
,18300296,AUAC(0-24h),"Pharmacokinetic studies following intravenous dosing indicated that the systemic exposure (area under the activity curve, AUAC(0-24h)) of PEGylated liposomal-rFVIII was approximately 59 IU/mL x h and significantly higher than that of non-PEGylated liposomal-rFVIII (AUAC(0-24h) approximately 36 IU/mL x h).",Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18300296/),[iu] / [h·ml],36,249467,DB00025,Antihemophilic Factor
,29732708,half-life,"With 2×/wk dosing, totalling 80 or 90 IU/kg/wk, half-life extensions required to maintain 56.6% of patients at FVIII levels >1 IU/dL were 1.30 and 1.26, respectively.",Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29732708/),,1.30,250245,DB00025,Antihemophilic Factor
,29732708,half-life,"With 2×/wk dosing, totalling 80 or 90 IU/kg/wk, half-life extensions required to maintain 56.6% of patients at FVIII levels >1 IU/dL were 1.30 and 1.26, respectively.",Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29732708/),,1.26,250246,DB00025,Antihemophilic Factor
,29732708,half-life extension ratio,A half-life extension ratio of 1.33 was required to change dosing from every 48 hours to every 72 hours (both at 105 IU/kg/wk) while maintaining 92.8% of patients with FVIII >1 IU/dL.,Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29732708/),,1.33,250247,DB00025,Antihemophilic Factor
,29732708,minimum half-life extension ratio,"Based on this investigation, EHL rFVIII products should have a minimum half-life extension ratio of 1.3 to provide a reduction in dosing frequency from 3× to 2×/wk compared with standard rFVIII products while maintaining the same minimum FVIII trough level.",Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29732708/),,1.3,250248,DB00025,Antihemophilic Factor
,16357174,t(1/2),Pharmacokinetic and biodistribution studies confirmed long circulation times (t(1/2) = 21 hours) and efficient accumulation in tumors (up to 15% ID/g) irrespective of the presence of the targeting ligand.,Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16357174/),h,21,253278,DB00025,Antihemophilic Factor
,8616836,Total systemic clearance,Total systemic clearance (39.8 +/- 7 versus 44.2 +/- 14 ml min(-1) kg(-1)) and volume of distribution (5.4 +/- 2 versus 5.2 +/- 0.8 L kg(-1)) were not significantly different in control and TNP-470-treated animals.,Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[ml] / [kg·min],39.8,254356,DB00025,Antihemophilic Factor
,8616836,Total systemic clearance,Total systemic clearance (39.8 +/- 7 versus 44.2 +/- 14 ml min(-1) kg(-1)) and volume of distribution (5.4 +/- 2 versus 5.2 +/- 0.8 L kg(-1)) were not significantly different in control and TNP-470-treated animals.,Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[ml] / [kg·min],44.2,254357,DB00025,Antihemophilic Factor
,8616836,volume of distribution,Total systemic clearance (39.8 +/- 7 versus 44.2 +/- 14 ml min(-1) kg(-1)) and volume of distribution (5.4 +/- 2 versus 5.2 +/- 0.8 L kg(-1)) were not significantly different in control and TNP-470-treated animals.,Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[l] / [kg],5.4,254358,DB00025,Antihemophilic Factor
,8616836,volume of distribution,Total systemic clearance (39.8 +/- 7 versus 44.2 +/- 14 ml min(-1) kg(-1)) and volume of distribution (5.4 +/- 2 versus 5.2 +/- 0.8 L kg(-1)) were not significantly different in control and TNP-470-treated animals.,Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[l] / [kg],5.2,254359,DB00025,Antihemophilic Factor
,8616836,area under the interstitial fluid concentration-time curve,"However, the mean TMZ area under the interstitial fluid concentration-time curve was reduced by 25% in the TNP-470-treated group compared to the control (5450 +/- 1892 versus 4120 +/- 1790 micrograms min ml(-1); P < 0.05).",Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[min·μg] / [ml],5450,254360,DB00025,Antihemophilic Factor
,8616836,area under the interstitial fluid concentration-time curve,"However, the mean TMZ area under the interstitial fluid concentration-time curve was reduced by 25% in the TNP-470-treated group compared to the control (5450 +/- 1892 versus 4120 +/- 1790 micrograms min ml(-1); P < 0.05).",Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616836/),[min·μg] / [ml],4120,254361,DB00025,Antihemophilic Factor
,12199669,recovery,The recovery of vWF: RCo was significantly lower in patients with type 3 vWD (1.4 +/- 0.05% U(-1) kg(-1)) compared with that of the patients with types 1 (2.3 +/- 0.52% U(-1) kg(-1)) or 2A (2.0 +/- 0.06% U(-1) kg(-1)) vWD (P = 0.015).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[%] / [kg·u],1.4,256978,DB00025,Antihemophilic Factor
,12199669,recovery,The recovery of vWF: RCo was significantly lower in patients with type 3 vWD (1.4 +/- 0.05% U(-1) kg(-1)) compared with that of the patients with types 1 (2.3 +/- 0.52% U(-1) kg(-1)) or 2A (2.0 +/- 0.06% U(-1) kg(-1)) vWD (P = 0.015).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[%] / [kg·u],2.3,256979,DB00025,Antihemophilic Factor
,12199669,recovery,The recovery of vWF: RCo was significantly lower in patients with type 3 vWD (1.4 +/- 0.05% U(-1) kg(-1)) compared with that of the patients with types 1 (2.3 +/- 0.52% U(-1) kg(-1)) or 2A (2.0 +/- 0.06% U(-1) kg(-1)) vWD (P = 0.015).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[%] / [kg·u],2.0,256980,DB00025,Antihemophilic Factor
,12199669,clearance,Type 3 vWD patients exhibited significantly higher vWF:RCo clearance (5.1 +/- 1.1 mL kg(-1) h(-1)) compared with that of patients with type 2A (2.8 +/- 0.7 mL kg(-1) h(-1)) and type 1 (2.6 +/- 1.0 mL kg(-1) h(-1)) vWD (P = 0.028).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[ml] / [h·kg],5.1,256981,DB00025,Antihemophilic Factor
,12199669,clearance,Type 3 vWD patients exhibited significantly higher vWF:RCo clearance (5.1 +/- 1.1 mL kg(-1) h(-1)) compared with that of patients with type 2A (2.8 +/- 0.7 mL kg(-1) h(-1)) and type 1 (2.6 +/- 1.0 mL kg(-1) h(-1)) vWD (P = 0.028).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[ml] / [h·kg],2.8,256982,DB00025,Antihemophilic Factor
,12199669,clearance,Type 3 vWD patients exhibited significantly higher vWF:RCo clearance (5.1 +/- 1.1 mL kg(-1) h(-1)) compared with that of patients with type 2A (2.8 +/- 0.7 mL kg(-1) h(-1)) and type 1 (2.6 +/- 1.0 mL kg(-1) h(-1)) vWD (P = 0.028).,"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),[ml] / [h·kg],2.6,256983,DB00025,Antihemophilic Factor
,12199669,terminal half-life,"Accordingly, terminal half-life was lower in patients with type 3 vWD (8.0 +/- 0.6 h(-1)) compared with type 2A (12.7 +/- 5.9 h(-1)) or type 1 (14 +/- 1.2 h(-1)) vWD patients.","Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),1/[h],8.0,256984,DB00025,Antihemophilic Factor
,12199669,terminal half-life,"Accordingly, terminal half-life was lower in patients with type 3 vWD (8.0 +/- 0.6 h(-1)) compared with type 2A (12.7 +/- 5.9 h(-1)) or type 1 (14 +/- 1.2 h(-1)) vWD patients.","Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),1/[h],12.7,256985,DB00025,Antihemophilic Factor
,12199669,terminal half-life,"Accordingly, terminal half-life was lower in patients with type 3 vWD (8.0 +/- 0.6 h(-1)) compared with type 2A (12.7 +/- 5.9 h(-1)) or type 1 (14 +/- 1.2 h(-1)) vWD patients.","Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12199669/),1/[h],14,256986,DB00025,Antihemophilic Factor
,22540161,half-life (t(1/2) ),"In men, the mean half-life (t(1/2) ) of TB-402 was 14.2 days.","Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIII. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22540161/),d,14.2,258096,DB00025,Antihemophilic Factor
,9873885,clearance (Cl),"Single-dose pharmacokinetic parameter values were clearance (Cl) 34.6 mL h-1 kg-1, volume of distribution (Vd) 40.6 mL kg-1 and mean residence time (MRT) 1.17 h.",Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873885/),[ml] / [h·kg],34.6,262834,DB00025,Antihemophilic Factor
,9873885,volume of distribution (Vd),"Single-dose pharmacokinetic parameter values were clearance (Cl) 34.6 mL h-1 kg-1, volume of distribution (Vd) 40.6 mL kg-1 and mean residence time (MRT) 1.17 h.",Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873885/),[ml] / [kg],40.6,262835,DB00025,Antihemophilic Factor
,9873885,mean residence time (MRT),"Single-dose pharmacokinetic parameter values were clearance (Cl) 34.6 mL h-1 kg-1, volume of distribution (Vd) 40.6 mL kg-1 and mean residence time (MRT) 1.17 h.",Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873885/),h,1.17,262836,DB00025,Antihemophilic Factor
,9873885,recovery,The recovery was 2.27% U-1 kg-1.,Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873885/),[%] / [kg·u],2.27,262837,DB00025,Antihemophilic Factor
,9873885,Cl,Cl during continuous infusion was 23.4 +/- 6.9 mL h-1 kg-1.,Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9873885/),[ml] / [h·kg],23.4,262838,DB00025,Antihemophilic Factor
,20590596,intrinsic affinities,"Kinetic binding analyses by surface plasmon resonance revealed intrinsic affinities of 55 nM and 97 nM for the monovalent EG(2) to immobilized extracellular domains of EGFR and EGFRvIII, respectively, and a 10- to 600-fold increases in apparent affinities for the multivalent binders, V2C-EG(2) and EG(2)-hFc, respectively.",Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590596/),nM,55,264479,DB00025,Antihemophilic Factor
,20590596,intrinsic affinities,"Kinetic binding analyses by surface plasmon resonance revealed intrinsic affinities of 55 nM and 97 nM for the monovalent EG(2) to immobilized extracellular domains of EGFR and EGFRvIII, respectively, and a 10- to 600-fold increases in apparent affinities for the multivalent binders, V2C-EG(2) and EG(2)-hFc, respectively.",Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590596/),nM,97,264480,DB00025,Antihemophilic Factor
,20590596,plasma half-lives,"In vivo pharmacokinetic and biodistribution studies in mice revealed plasma half-lives for EG(2), V2C-EG(2) and EG(2)-hFc of 41 min, 80 min and 12.5 h, respectively, as well as a significantly higher retention of EG(2)-hFc compared to the other two constructs in EGFR/EGFRvIII-expressing orthotopic brain tumours, resulting in the highest signal in the tumour region in optical imaging studies.",Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590596/),min,41,264481,DB00025,Antihemophilic Factor
,20590596,plasma half-lives,"In vivo pharmacokinetic and biodistribution studies in mice revealed plasma half-lives for EG(2), V2C-EG(2) and EG(2)-hFc of 41 min, 80 min and 12.5 h, respectively, as well as a significantly higher retention of EG(2)-hFc compared to the other two constructs in EGFR/EGFRvIII-expressing orthotopic brain tumours, resulting in the highest signal in the tumour region in optical imaging studies.",Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590596/),min,80,264482,DB00025,Antihemophilic Factor
,20590596,plasma half-lives,"In vivo pharmacokinetic and biodistribution studies in mice revealed plasma half-lives for EG(2), V2C-EG(2) and EG(2)-hFc of 41 min, 80 min and 12.5 h, respectively, as well as a significantly higher retention of EG(2)-hFc compared to the other two constructs in EGFR/EGFRvIII-expressing orthotopic brain tumours, resulting in the highest signal in the tumour region in optical imaging studies.",Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590596/),h,12.5,264483,DB00025,Antihemophilic Factor
,34015176,half-life time,"The half-life time, in vivo recovery and clearance of Kovaltry were 14.34 ± 2.68 h, 1.78 ± 0.29 kg/dl and 3.38 ± 0.94 ml/kg/h, respectively.",Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34015176/),h,14.34,268498,DB00025,Antihemophilic Factor
,34015176,in vivo recovery,"The half-life time, in vivo recovery and clearance of Kovaltry were 14.34 ± 2.68 h, 1.78 ± 0.29 kg/dl and 3.38 ± 0.94 ml/kg/h, respectively.",Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34015176/),[kg] / [dl],1.78,268499,DB00025,Antihemophilic Factor
,34015176,clearance,"The half-life time, in vivo recovery and clearance of Kovaltry were 14.34 ± 2.68 h, 1.78 ± 0.29 kg/dl and 3.38 ± 0.94 ml/kg/h, respectively.",Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34015176/),[kg] / [dl],1.78,268500,DB00025,Antihemophilic Factor
,34015176,clearance,"The half-life time, in vivo recovery and clearance of Kovaltry were 14.34 ± 2.68 h, 1.78 ± 0.29 kg/dl and 3.38 ± 0.94 ml/kg/h, respectively.",Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34015176/),[ml] / [h·kg],3.38,268501,DB00025,Antihemophilic Factor
,34015176,trough level,"In 18 patients without any change in the dosing regimen, the trough level was 4.0 ± 2.41 IU/dl and the bleeding rates were similar after PK tests.",Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34015176/),[iu] / [dl],4.0,268502,DB00025,Antihemophilic Factor
,24227821,terminal half-life,The terminal half-life of rFVIIIFc (19.0 hours) was extended 1.5-fold vs rFVIII (12.4 hours; P < .001).,Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24227821/),h,19.0,269195,DB00025,Antihemophilic Factor
,24227821,terminal half-life,The terminal half-life of rFVIIIFc (19.0 hours) was extended 1.5-fold vs rFVIII (12.4 hours; P < .001).,Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24227821/),h,12.4,269196,DB00025,Antihemophilic Factor
,25761639,apparent clearance from the central (CLc),"The population estimates of the apparent clearance from the central (CLc) and peripheral (CLp) compartments were 0.011 and 0.025 L/h, respectively.","Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761639/),[l] / [h],0.011,270086,DB00025,Antihemophilic Factor
,25761639,apparent clearance from the central (CLc),"The population estimates of the apparent clearance from the central (CLc) and peripheral (CLp) compartments were 0.011 and 0.025 L/h, respectively.","Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761639/),[l] / [h],0.025,270087,DB00025,Antihemophilic Factor
,25761639,apparent volume of distribution,"The apparent volume of distribution estimates of the central (V 1) and peripheral (V 2) compartments were 3.5 and 3.3 L, respectively.","Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761639/),l,3.5,270088,DB00025,Antihemophilic Factor
,25761639,V 1,"The apparent volume of distribution estimates of the central (V 1) and peripheral (V 2) compartments were 3.5 and 3.3 L, respectively.","Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761639/),l,3.5,270089,DB00025,Antihemophilic Factor
,25761639,V 2,"The apparent volume of distribution estimates of the central (V 1) and peripheral (V 2) compartments were 3.5 and 3.3 L, respectively.","Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761639/),l,3.5,270090,DB00025,Antihemophilic Factor
,25761639,V 2,"The apparent volume of distribution estimates of the central (V 1) and peripheral (V 2) compartments were 3.5 and 3.3 L, respectively.","Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761639/),l,3.3,270091,DB00025,Antihemophilic Factor
,8701403,half-life,"A drawback in the use of rFVIIa has been its half-life of only about 2 h, which necessitates very frequent and punctual injections.",Feasibility of using recombinant factor VIIa in continuous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),h,2,270452,DB00025,Antihemophilic Factor
,8701403,clearance,The second patient had a progressive decrease of the clearance from 86.4 to 24.7 ml/h/kg.,Feasibility of using recombinant factor VIIa in continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),[ml] / [h·kg],86.4,270453,DB00025,Antihemophilic Factor
,8701403,clearance,The second patient had a progressive decrease of the clearance from 86.4 to 24.7 ml/h/kg.,Feasibility of using recombinant factor VIIa in continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),[ml] / [h·kg],24.7,270454,DB00025,Antihemophilic Factor
,33778426,terminal elimination half-life time (t1/2),"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),h,12.24,272571,DB00025,Antihemophilic Factor
,33778426,terminal elimination half-life time (t1/2),"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),h,10.18,272572,DB00025,Antihemophilic Factor
,33778426,terminal elimination half-life time (t1/2),"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),h,9.62,272573,DB00025,Antihemophilic Factor
,33778426,clearance,"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),[ml] / [h·kg],4.16,272574,DB00025,Antihemophilic Factor
,33778426,clearance,"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),[ml] / [h·kg],6.23,272575,DB00025,Antihemophilic Factor
,33778426,clearance,"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),[ml] / [h·kg],5.11,272576,DB00025,Antihemophilic Factor
,33778426,in vivo recovery,"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),[iu] / [dl·iu·kg],1.97,272577,DB00025,Antihemophilic Factor
,33778426,in vivo recovery,"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),[iu] / [dl·iu·kg],1.55,272578,DB00025,Antihemophilic Factor
,33778426,in vivo recovery,"Mean values of terminal elimination half-life time (t1/2) for the Kogenate FS®, Advate®, and GreenMono™ FVIII groups were 12.24 h, 10.18 h, and 9.62 h; median clearance values were 4.16, 6.23, and 5.11 mL·kg-1·h-1; and median in vivo recovery values were 1.97, 1.55, and 1.61 IU/dL per IU/kg.",Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33778426/),[iu] / [dl·iu·kg],1.61,272579,DB00025,Antihemophilic Factor
,26370328,half-life,Mean (SD) half-life was 11.9 (5.4) and 13.1 (2.6) hours in children aged 2-5 years and 6-12 years respectively (one-stage assay).,"Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370328/),h,11.9,272953,DB00025,Antihemophilic Factor
,26370328,half-life,Mean (SD) half-life was 11.9 (5.4) and 13.1 (2.6) hours in children aged 2-5 years and 6-12 years respectively (one-stage assay).,"Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370328/),h,13.1,272954,DB00025,Antihemophilic Factor
,26370328,annualized bleeding rate,"Mean (SD) annualized bleeding rate was 4.12 (5.22) [median 1.9] for all bleeds, 1.50 (3.32) [median 0] for spontaneous bleeds and 2.34 (3.54) [median 1.57] for traumatic bleeds.","Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370328/),,4.12,272955,DB00025,Antihemophilic Factor
,26370328,annualized bleeding rate,"Mean (SD) annualized bleeding rate was 4.12 (5.22) [median 1.9] for all bleeds, 1.50 (3.32) [median 0] for spontaneous bleeds and 2.34 (3.54) [median 1.57] for traumatic bleeds.","Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370328/),,1.50,272956,DB00025,Antihemophilic Factor
,26370328,annualized bleeding rate,"Mean (SD) annualized bleeding rate was 4.12 (5.22) [median 1.9] for all bleeds, 1.50 (3.32) [median 0] for spontaneous bleeds and 2.34 (3.54) [median 1.57] for traumatic bleeds.","Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370328/),,2.34,272957,DB00025,Antihemophilic Factor
